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Abstract 
Haemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory condition in 
which absent or markedly reduced T cell and natural killer (NK) cell cytotoxicity results 
in uncontrolled proliferation of T cells, activation of macrophages, hypercytokinaemia, 
pancytopaenia, and hepatosplenomegaly. Familial HLH (FHL), an autosomal recessive 
disorder affecting young infants and children, is fatal unless treated with chemotherapy 
and allogeneic haemopoietic stem cell transplantation. Mutations in the gene encoding 
perforin, a lytic protein involved in cell cytotoxicity, account for 30% of cases of FHL 
(FHL II). Mutations in genes encoding hMunc 13-4, syntaxin 11, and syntaxin binding 
protein 2, all essential for perforin release and T/NK cell cytotoxicity, have also been 
identified in FHL (FHL III IV and V respectively). A previous report form our group 
showed that in the UK, in consanguineous families of Pakistani descent, FHL (designated 
FHL I) maps to 9q21.3-22 in an area spanning 5Mb and containing 14 genes. The aim of 
my project was to identify the gene responsible for FHL I and to study the function of the 
corresponding protein. Based on the premise that similar to other types of FHL, the 
protein product of FHL I candidate gene would function in the perforin-dependent 
cytotoxic pathway, 4 out of the 14 genes emerged as strong functional candidates: KIF27, 
RASEF, UBQLN1 and FRMD3. 
My mutation screening strategy aimed at amplifying and sequencing all exons and intron-
exon boundaries of the candidate genes, followed by screening the remaining genes of the 
FHL I locus. The material used was either genomic DNA extracted from 4 parental and 1 
patient B cell line, or cDNA from the latter. In 2 newly identified patients, genomic DNA 
from granulocytes was used. PCR amplification of genomic DNA and direct sequencing 
or cloning and sequencing of individual clones or in some cases direct sequencing of the 
full length cDNA from the patient B cell line did not reveal any mutations in any of the 
known genes in the FHL I locus. For KIF27, mutations were excluded in gene regulatory 
areas by amplification and direct sequencing of the whole promoter region, up to 1kb 
upstream of the transcription start site. KIF27 protein expression was also studied by 
immunoblotting and immunostaining followed by confocal microscopy but no 
abnormality was identified at protein level. Promoter area mutation was also excluded in 
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UBQLN1, the other strong candidate. The gene responsible for FHL I remains 
unidentified. Further refinement of the locus with high-density SNP arrays in newly 
diagnosed patients demonstrating linkage to the FHL I locus might help identify the gene 
responsible for FHL I. 
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1.1 Haemophagocytic Lymphohistiocytosis  
 
Haemophagocytic lympohistiocytosis (HLH) is a severe hyper-inflammatory condition 
characterized by fever, hepatosplenomegaly, pancytopenia, hypertriglyceridaemia, 
hypofibrinogenaemia [1] and reduced or absent granule-mediated cytotoxic activity of 
lymphocytes [2] [3]. Uncontrolled proliferation and activation of T cells and natural killer 
(NK) cells as well as activation of macrophages (histiocytes) that phagocytose blood cells 
(haemophagocytosis) are hallmarks of this syndrome [1]. The clinical presentation of 
HLH usually consists of unexplained prolonged fever with hepatosplenomegaly, 
coagulopathy and neurological symptoms [4] [5]. Laboratory features include anaemia, 
thrombocytopenia, liver dysfunction, hypertriglyceridaemia, hypofibrinogenaemia and 
elevated serum ferritin. The activated histiocytes infiltrate multiple organs, including 
bone marrow, lymph nodes, spleen and liver. The primary autosomal recessive familial 
form of HLH, Familial Haemophagocytic Lymphohistiocytosis (FHL), has a reported 
incidence of 1 in 50,000 live births [6] and typically has its onset in infancy or early 
childhood.  FHL is a fatal disease with a median survival of less than 2 months after 
diagnosis if untreated [1]. 
1.1.1 Overview of the Histiocytoses 
 
The mononuclear phagocytic system consists of monocytes and macrophages derived 
from committed myeloid progenitors of the bone marrow [7], and are historically referred 
to as histiocytes. Normal functions of histiocytes, which are a major component of the 
innate immune system, include phagocytosis, antigen presentation and activation of the 
adaptive immune system through direct contact and cytokine signaling [8]. Histiocytes 
normally participate in wound and tissue repair and have key roles in initiation as well as 
regulation of inflammation [9]. HLH is regarded as a subset of a wide variety of 
individually rare and diverse diseases of the histiocyte that affect both children and 
adults, and range from benign skin lesions to rapidly life-threatening systemic disorders, 
collectively termed ‘histiocytoses’ [10]. The other best-known histiocytosis is 
Langerhans cell histiocytosis (LCH), with an annual incidence in the UK of 4 per million 
in children aged less than 15 years [11]. LCH occurs as a result of non- malignant 
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proliferation and occasionally multi- organ infiltration of epidermal macrophages 
(Langerhans cells), giving rise to either localized or widely disseminated granulomata, 
skin lesions, hepatosplenomegaly, lymphadenopathy, pituitary tumours, etc [12]. Prior to 
the structured classification of the histiocytoses by clinicians and basic scientists with 
interest in the histiocyte and its disorders who met in 1985 at an historic international 
workshop in Philadelphia leading to the foundation of the Histiocyte Society [13], 
histiocytic disorders were variably considered malignant, reactive or autoimmune in 
nature and no systematic large- scale therapeutic or diagnostic trials existed. International 
collaborative efforts by the Histiocyte Society has led to classification of the histiocytic 
disorders, on the basis of their cell of origin and widely histological criteria (Table 1.1). 
These, along with other clinical and laboratory criteria provide the basis for the modern 
classification of the histiocytic disorders, including the familial and acquired forms of 
HLH [10]. The Histiocyte Society has also helped consolidate international registries of 
these rare histiocytic disorders paving the way to evolve international clinical trials [14] 
[15] [16]. 
 
Table 1.1. Classification of benign and malignant histiocytic disorders adapted from 
the contemporary classification of histiocytic disorders* 
 
Benign disorders of varying biologic behavior 
 a. Dendritic cell related 
      i) Langerhans cell histiocytosis 
      ii) Juvenile xanthogranuloma and related disorders including: 
        - Erdheim-Chester disease 
        - Solitary histiocytomas with juvenile xanthogranuloma phenotype 
        - Secondary dendritic cell disorders 
b. Monocyte/macrophage related 
      i) Haemophagocytic lymphohistiocytosis 
         -Familial and sporadic 
      ii) Secondary haemophagocytic syndromes: 
          - Infection associated 
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          - Malignancy associated 
          - Autoimmune associated (Macrophage Activation Syndrome) 
          - Other 
      iii) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) 
      iv) Solitary histiocytoma of macrophage phenotype 
  
Malignant disorders 
a. Monocyte related 
Leukaemias 
i) Monocytic leukaemia 
ii) Acute myelomonocytic leukaemia 
iii) Chronic myelomonocytic leukaemia 
              Extramedullary Monocytic tumour 
b. Dendritic cell-related histiocytic sarcoma 
c. Macrophage-related histiocytic sarcoma 
*The WHO committee on Hystiocytic/Reticulum Cell Proliferations. Reclassification 
working group of the Histiocyte Society [17] 
 
 
1.1.2 Clinical features of Haemophagocytic Lymphohistiocytosis 
 
1.1.2.1 Historical notes and classification 
 
In 1952, Farquhar and Claireaux reported the case of a pair of Scottish siblings with a 
fatal infantile disease that they termed Familial Haemophagocytic Reticulosis [18]. Both 
infants developed fever, diarrhoea, hepatosplenomegaly, vomiting, and irritability at the 
age of 9 weeks. Laboratory features included normochromic anemia, granulocytopaenia 
and thrombocytopaenia, in the absence of infection. The first baby, a male, died at the age 
of 10 weeks with hepatosplenomegaly, progressive pancytopaenia, jaundice and skin 
bruising. The second infant, a female, was treated with adrenocorticotrophic hormone 
(ACTH) with transient improvement followed by a terminal relapse of the disease 3 
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months after the onset of symptoms. Autopsy showed histiocytic proliferation and 
haemophagocytosis in lymph nodes, spleen, liver and kidney. The third child of the 
family developed normally, but the fourth child, reported by Farquhar et al in 1958 [19] 
presented at the age of 14 weeks with a clinical picture identical to his siblings. Farquhar 
and Claireaux [18] emphasized that the disease differed from Letterer-Siwe-disease 
(currently termed Langerhans cell histiocytosis) in its familial occurrence, prominent 
erythrophagocytosis, lack of granuloma formation and absence of bone defects. The term 
‘Familial Haemophagocytic Reticulosis’ was subsequently replaced by ‘Familial 
Haemophagocytic Lymphohistiocytosis’ (FHL) [20] due to better understanding of the 
pathophysiology of this disease.  
The HLH syndrome described in the original report by Farquhar and Claireaux indicated 
an autosomal recessive inheritance, and provided the first description of FHL, which we 
now know is a monogenic disease with genetic heterogeneity. FHL tends to occur in 
infants and young children, although, increasingly, older children and adults are also 
being diagnosed with inherited forms of the disease [21].  Secondary or acquired HLH 
can occur due to a plethora of causes, including malignancies [22], viral infections such 
as HIV (Human Immunodeficiency Virus) [23], EBV (Epstein Barr Virus) [24]; 
tuberculosis [25]; helminth infection [26] and autoimmune disorders [27]. Recently, more 
and more older patients and patients presumed to have secondary HLH or EBV-HLH are 
being found to harbour the known familial HLH mutations and distinctions between 
familial and secondary or acquired forms of HLH are becoming increasingly blurred [28] 
[29] [30]. 
Clinical presentation of primary childhood HLH is also largely indistinguishable from the 
so-called secondary ones and it still remains difficult to distinguish between the familial 
and secondary forms of HLH despite recent advances in molecular diagnosis, as 
described in Section 1.1.8. Although occasionally associated with increased mortality, 
infection-associated forms of HLH may also resolve spontaneously [31]. Furthermore, 
proving an acute infection at onset of symptoms is not of major diagnostic or therapeutic 
benefit, since not only secondary HLH but also primary HLH often feature a triggering 
infectious agent [32].  
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1.1.2.2 Clinical hallmarks of HLH 
 
The clinical course of HLH is typically characterized by prolonged fevers and 
hepatosplenomegaly [20]. The first report from an international registry established by 
the Histiocyte Society of 122 children with HLH in 1996 reported a rate of parental 
consanguinity in a quarter of all cases and a positive family history in about half. The 
median age at disease onset was 2.9 months, with no difference between familial and 
sporadic cases. An associated infection (usually by common viral pathogens) was 
reported in 41% cases. NK cell activity was impaired in 36 of 37 patients studied and 
estimated 5 year survival was 21% [4]. Neurological symptoms often dominate the initial 
clinical course in HLH with seizures and/or ataxia [33]. A report from the HLH study 
group in 2008 of 193 patients followed up for a median of 5.3 years indicated that very 
high proportion (63%) of patients with HLH have neurological symptoms and/or 
abnormal cerebrospinal fluid (CSF) findings at the time of diagnosis, with seizures, 
meningism and irritability being the three most common symptoms. Neurodevelopmental 
delay and epilepsy were the two commonest sequelae reported by long-term survivors, 
and were present in about 15% of cases [34].  
Laboratory parameters of HLH include cytopaenias—especially anaemia and 
thrombocytopaenia, liver dysfunction, hypofibrinogenaemia, hypertriglyceridaemia, 
hypoalbuminaemia, hyponatraemia and a hypercytokinaemia, in particular elevated 
soluble interleukin 2 receptor (sIL-2r or sCD25) levels in serum and in the CSF [35]. 
Histopathological findings include a widespread accumulation of lymphocytes and 
mature macrophages, often with haemophagocytosis, affecting especially the spleen, 
lymph nodes (if enlarged), the bone marrow, the liver, and CSF (Figure 1.1). In the liver, 
a histological picture similar to chronic persistent hepatitis is commonly found [36] [37]. 
Symptoms may improve spontaneously in the early days to months after initial 
presentation, followed by clinical exacerbations. Furthermore, bone marrow biopsy 
examination early in the course of the disease may not reveal any obvious 
haemophagocytosis. 
Due to the diversity of clinical presentation and the clinical need for establishing rapid 
diagnosis, the Histiocyte Society has now broadened their diagnostic criteria to no longer 
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differentiate primary and secondary HLH and has established updated diagnostic 
guidelines based on clinical as well as laboratory parameters (Table 1.2). 
 
 
Figure 1.1. Haemophagocytosis in the bone marrow. 
Bone marrow aspirate from a patient with haemophagocytosis showing a single central 
macrophage with phagocytosed red cells within its cytoplasm. 
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Table 1.2. Updated (2004) diagnostic guidelines for HLH from the Histiocyte Society  
 
The diagnosis HLH can be established if one of either 1 or 2 below is fulfilled: 
(1) A molecular diagnosis consistent with HLH 
(2) Diagnostic criteria for HLH fulfilled (five out of the eight criteria below) 
                i) Fever 
                ii) Splenomegaly 
               iii) Cytopaenias (affecting ≥2 of 3 lineages in the peripheral blood): 
                       Hemoglobin <9 g/dL (in infants <4 weeks: hemoglobin <10 g/dL) 
                       Platelets < 100 x109/L 
                       Neutrophils <1.0 x109/L 
             iv) Hypertriglyceridaemia and/or hypofibrinogenaemia: 
                       Fasting triglycerides >3.0 mmol/L (i.e., >265 mg/dl) 
                       Fibrinogen <1.5 g/L 
                       Haemophagocytosis in bone marrow or spleen or lymph nodes 
             v) No evidence of malignancy 
             vi) Low or absent NK cell activity (according to local laboratory reference) 
             vii) Ferritin >500 mg/L 
             viii) Soluble CD25 (i.e., soluble Interleukin-2 receptor) >2,400 U/ml 
 
1.1.2.3 Differential diagnosis of HLH 
 
A large number of conditions may mimic HLH at the time of presentation, such as 
malignancies (leukaemia, lymphoma and solid tumours), sepsis (bacterial, viral and 
parasitic) and rheumatic disorders and a proportion of these patients will turn out to have 
secondary HLH [38]. The true incidence of secondary HLH is not known and despite 
attempts to differentiate primary from secondary or reactive forms of HLH, the 
symptomatic presentations are highly overlapping, and a significant proportion of patients 
diagnosed with secondary HLH are at risk of dying from the disease. Furthermore, 
patients with certain genetic disorders such as X- linked lymphoproliferative syndrome 
(XLP) [39] [40, 41], Chediak-Higashi syndrome (CHS) [42], Hermansky-
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syndrome Type 2 (HPS2) [43] and Griscelli syndrome (GS) [44] may develop HLH as 
part of their clinical course. Certain immune-deficiency disorders such as Wiskott-
Aldrich syndrome [45] and del (22q11) / Di George Syndrome [46] may also rarely 
present with secondary HLH. Other differential diagnoses are Langerhans cell 
histiocytosis (that may be complicated by HLH), lysinuric protein intolerance, [47] and 
severe combined immunodeficiency disease (SCID) [48]. Viral infections, especially 
EBV may trigger primary as well as secondary forms of HLH [49]. Macrophage 
activation syndrome (MAS), a serious complication of systemic rheumatoid arthritis and 
other childhood systemic inflammatory disorders, presents as an HLH-like syndrome and 
is caused by excessive activation and proliferation of T lymphocytes and macrophages. 
Both EBV-driven secondary HLH and MAS respond to systemic HLH- like therapies 
[50] [51]. Seriously ill children suffering from septic shock, multi-organ dysfunction 
syndrome and systemic inflammatory response syndrome [52] share some of the clinical 
and laboratory parameters described above and are included in the list of differential 
diagnoses of HLH. Some of these conditions warrant different therapeutic strategies and 
have different clinical outcomes. Hence some authors have suggested that cautious and 
meticulous application of the diagnostic guidelines is vital [53]. 
 
 
1.1.3 Treatment of FHL and related disorders 
 
Due to the aggressive and rapidly fatal nature of the disease, childhood HLH / FHL has 
been treated with chemotherapeutic agents such as the topoisomerase II inhibitor 
etoposide and vinca alkaloid vinblastine and methotrexate since the early 1980’s [20] 
[54] but sustained remission or cure  following chemotherapy alone was never achieved 
in familial cases [55]. Subsequently, because of the concern regarding the risk of 
etoposide-induced acute myeloid leukemia (AML), immunosuppression with 
glucocorticoids and cyclosporine A as maintenance therapy for patients with FHL was 
used [56]. In 1986, Fischer et al first reported successful outcome of patients with FHL 
treated with allogeneic bone marrow transplant [57] which was later confirmed by others 
[58]. Prompted by earlier disappointing therapeutic results, in 1994, the Histiocyte 
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Society developed a consensus study protocol: the HLH-94 protocol, comprising of an 
induction/continuation phase, which aimed to induce a remission in these often extremely 
ill patients, followed by haemopoietic stem cell transplantation (HSCT) from the best 
available donor to induce a definitive cure, in patients with familial, persistent and 
recurrent disease [59]. This seminal study reported an overall 3 -year probability of 
survival of 51% and none of the children with familial disease (i.e. with an affected 
sibling) survived without a HSCT. The estimated overall 3-year probability of survival 
after HSCT recruited during the period 1995–2000 was 64% (CI=±10%; n=86); 71±18% 
with matched related donors (MRD; n=24), 70±16% with matched unrelated donors 
(MUD; n=33), 50±24% with family haploidentical donors (n=16), and 54±27% with 
mismatched unrelated donors (MMUD; n=13). The study therefore demonstrated that 
survival for MUD transplant recipients was not significantly lower than that for MRD 
transplant recipients, and although the use of haploidentical donors and MMUD 
transplant gave less favourable survival, the outcome was still acceptable, supporting the 
use of alternative donors where matched donors were unavailable. Besides, persistent 
disease activity at 2 months after the start of HLH treatment suggested a worse long-term 
prognosis. Furthermore, a number of patients achieved long -term remission with 
induction chemotherapy alone and none of those patients were with known familial 
disease and were likely to have had secondary HLH, implying that secondary HLH could 
also be successfully treated with this protocol [15]. A single-centre retrospective study in 
2006 reported a 59% overall survival in a series of 48 patients with FHL including 60% 
of haploidentical HSCT, and indicated a high transplant related mortality (TRM) due to 
veno-occlusive disease (VOD) associated with young age [60]. Another recent report 
highlighting the Japanese experience of treating childhood HLH where incidence of 
EBV-related secondary HLH (EBV- HLH) is extremely high, a 10-year overall survival 
rate using chemoimmunotherapy and HSCT was 65% in FHL and 85% in EBV-HLH. 
Unrelated donor cord blood transplantation was used in half of the patients and TRM was 
significantly higher in FHL compared with EBV-HLH [61]. In the HLH94 study, TRM 
was 30% and was mainly due to myeloablative conditioning related toxicities such as 
non-infectious pulmonary toxicity and VOD, rather than the disease itself. Efforts have 
therefore been directed towards performing non-myeloablative reduced intensity 
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conditioning (RIC) HSCT with an aim to reduce TRM. In a recent single-centre report of 
25 children with HLH treated with RIC HSCT, 21 patients (84%) were alive and well 
with remission at a median of 36 months from HSCT. Six of twenty-one survivors had 
mixed chimerism but remained disease-free, suggesting that RIC compared favourably 
with conventional HSCT with long-term disease control in surviving patients with HLH 
despite a significant incidence of mixed chimerism [62]. The HLH 94 protocol was also 
used to treat patients with HLH as a result of genetic syndromes such as CHS, GS2 and 
XLP. A total of 10 patients were studied and 7 proceeded to HSCT, 6 of whom survived 
at a mean follow up of 6 years post transplant.  Results indicated that in patients with 
GS2, XLP and CHS that have developed a haemophagocytic syndrome, HLH treatment 
could be an effective first line treatment to induce remission [63]. 
The Histiocyte Society designed a new study that followed HLH94, called HLH 2004 
with updated diagnostic criteria (Table 1.2) and therapeutic strategy, and is currently 
recruiting. This study aims to enroll children with HLH regardless of primary or 
secondary disease. The treatment protocol is similar to that of HLH94 with minor 
modifications only, and comprises of a triphasic therapeutic strategy of induction along 
with CNS-directed therapy and maintenance, followed by HSCT [64].  
 
1.1.4 Pathophysiology of HLH 
 
1.1.4.1 Cellular defect in HLH 
 
In response to infection, the innate and adaptive arms of the immune system act together 
to clear the invading pathogen. In addition, the adaptive immune response has evolved to 
generate memory (B- and T cell) immune responses which will ensure a fast, efficient 
and specific response in future infections by the same pathogen [65]. For example, in 
response to a viral infection, antigen-specific CD8+T-cells can proliferate and efficiently 
kill infected target cells hence the term cytotoxic T cells (CTL). In addition, cytokines 
such as interferon gamma (IFNγ) that are released by activated CTL help to control viral 
replication by a direct anti-viral effect as well as indirectly through activation of the 
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cellular arm of the innate immunity, namely macrophages and NK cells [66]. Successful 
elimination of the virally infected host cells leads to the termination of the immune 
response, characterised by the apoptotic death of the vast majority of the effector cells 
and the persistence of a few long-lived antigen-specific memory T- and B-cells [67]. 
Failure of the effectors, especially CTL and NK cells to eliminate the pathogen leads to 
their perpetual activation and to the clinical syndrome of HLH [21]. Persistence of 
antigen and its incessant presentation via binding to major histocompatibility complex 
(MHC) Class I molecules by antigen presenting cells (APC) such as myeloid dendritic 
cells (DC) leads to persistent activation of CTL, secretion of IFNγ and continuous 
activation of macrophages and NK cells. These as well as the ability to secrete a host of 
TH1 cytokines and chemokines compound the immune homeostatic break-down in HLH 
[68] [69] [70] (Figure 1.2). 
 
 
 a)      b) 
Figure 1.2. Lymphocyte cytotoxic responses and their homeostatic control 
a) Normal CTL response following CTL-target cell interaction. The activating synapse 
formed between the T cell and a target cell bearing peptide-MHC Class I complex 
causes clonal expansion of T Cells and cellular cytotoxicity with production of IFNγ and 
activation of macrophages. Following successful elimination of infected target cells, 
CTLs undergo clonal contraction and generation of memory cells. This normal 
homeostasis is disrupted in HLH (b) where ineffective cellular cytotoxicity results in 
protracted antigen presentation and clonal expansion of CTLs leading to persistent 
macrophage activation and cytokine secretion.  
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1.1.4.2 Cytokine storm in HLH 
 
Several studies have documented an excessive production of interleukin (IL-) 1, IL-6, IL-
12, INFγ), and tumour necrosis factor alpha (TNFα) [68], monocyte chemo-attractant 
protein (MCP)1, macrophage inflammatory protein (MIP) beta, and IL-8 [70], all of  
which contribute to the high fever, hyperlipidaemia [through the inhibition of lipoprotein 
lipase] [71] and coagulopathy in HLH.  
In a series of 74 patients with HLH in Japan, 71 were shown to have elevated levels of 
soluble IL2 receptor (IL2R), and elevated IL2R levels corresponded to high INFγ levels, 
both of which inversely correlated to clinical outcome [72].  Early studies also showed an 
inverse correlation of clinical outcome with serum TNFα levels in children with HLH 
[73]. Furthermore, IL-18, a pro-inflammatory cytokine mainly produced by activated 
macrophages that strongly induces IFNγ production by T and NK cells [74], has been 
shown to be increased in HLH and also correlate with disease severity [75]. In contrast, 
IL-18BP (Interleukin-18 Binding Protein), its natural antagonist, is only moderately 
elevated in HLH, leading to high levels of free IL-18, a finding that led researchers to 
postulate that an imbalance between IL18/IL-18BP might be responsible for lymphocyte 
activation and Th1 cytokine production in HLH [76] [77].  It has recently been shown 
that IFNγ- induced expression of IL-18BP, a negative-feedback loop employed to reduce 
IFN activity and the subsequent Th1 responses [75] was severely impaired in a patient 
with HLH, further substantiating the role played by this cytokine in the pathophysiology 
of HLH [78]. A similar cytokine dysregulation has been observed in the pathogenesis of 
influenza in H5N1 (Avian flu) infection, where the H5 haemagglutinin from the virus has 
been shown to suppress perforin expression in CD8+ T cells and cause reduction of T cell 
cytotoxicity and increased production of cytokines [79]. 
 
1.1.4.3 Animal models of HLH 
 
Our understanding of the pathophysiology of HLH has been greatly increased by the 
study of knockout mice lacking a functional gene for perforin, the pore forming protein 
present in cytotoxic lymphocytes. Whilst these animals were relatively well when raised 
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in a pathogen free environment, introduction of lymphocytic choriomeningitic virus 
(LCMV) infection induced a fatal syndrome of fever, splenomegaly, pancytopaenia, 
hypertriglyceridaemia, hypofibrinogenaemia, elevation of multiple serum cytokine levels, 
and haemophagocytosis; demonstrating striking similarities to the HLH syndrome in 
humans. The researchers also showed that the HLH syndrome in perforin deficient mice 
was dependent on the presence CD8+ cytotoxic T lymphocytes and the production of 
IFNγ [80]. Furthermore, administering anti-IFNγ antibody to these mice resulted in 
termination of haemophagocytosis [81]. In another in vivo model using engraftment of 
Herpesvirus saimiri immortalized T-lymphocyte lines established from four FHL patients 
into SCID mice demonstrated that activated polyclonal T lymphocytes (mainly CD8+ 
HLADR+) infiltrated the lung, liver, kidney, lymph node and brain in association with 
haemophagocytosis. In this model, most T lymphocytes expressed a high level of 
apoptotic signals, suggesting that the accumulation of T-cells was a consequence of a 
defective triggering of apoptosis [82]. Another mouse model that developed an HLH 
phenotype with fever, cytopaenia, hepatosplenomegaly, and haemophagocytosis, reduced 
NK cell cytotoxicity and extramedullary haemopoiesis was those that were deficient in a 
protein involved in endosomal and lysosomal degradation called Asparagynil 
endopeptidase (AEP), although the precise role of AEP in generating this phenotype is 
currently unclear and human disease with AEP gene mutations has not been described 
[83]. Mice that are engineered to develop an increased susceptibility to cytomegalovirus 
infection (Jinx phenotype) develop a HLH syndrome following infection with LCMV, 
exhibiting hyperactivation of CTLs and APCs. Jinx was mapped to mouse chromosome 
11 and the phenotype was ascribed to the creation of a novel donor splice site in Unc13d, 
the mouse ortholog of hMunC13-4, mutations of which causes a genetic subtype of FHL 
in humans, known as FHL III (see below) [84]. 
1.1.4.4 Role of NK Cells in pathogenesis of HLH 
 
The role of NK cells in the pathogenesis of HLH has also been extensively studied. NK 
cells (using their cytotoxic and cytokine-mediated mechanisms) form a front line of 
defense against intracellular pathogens, such as viruses [85]. NK cells can also modify 
the initial APC responses to pathogens (likely through cytokine signaling), reducing the 
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signals subsequently communicated to antigen-specific T cells [86]. NK cells also play a 
role in eliminating T cells and histiocytes in later stages of antigen-driven activation, 
contributing to the natural contraction of immune responses [10]. Also critical to the 
contraction process of active T cell populations is the mechanism of restimulation-
induced cell death (RICD), recently shown to be defective in X-Linked 
Lymphoproliferative syndrome type1 (XLP1) [87].  
Children with FHL have consistently been found to have reduced or abolished NK cell 
cytotoxicity despite usually having normal NK cell numbers [88] [89] and in some 
studies, parents or siblings of children with FHL have also been found to have impaired 
NK cell cytotoxicity [3]. Similarly, other genetic mutations causing HLH syndromes such 
as Griscelli Syndrome (GS) or Hermansky- Pudlak Syndrome Type 2 (HPS2), have been 
found to be associated with impaired or absent NK activity [90] [91]. Conversely, in 
EBV-associated HLH, both NK numbers and cytotoxicity were reduced; suggesting that 
an acquired NK cell deficiency may be responsible for this clinical syndrome [92]. 
Similarly, in Systemic Onset Juvenile Rheumatoid Arthritis (SOJRA)-associated MAS, 
which is a clinical HLH- like syndrome, reports have shown defects in NK cell numbers 
and NK cytotoxicity [93].  
Taken together, these data suggest a model where antigen presentation to cytotoxic 
lymphocytes results in their activation; but a defective cytotoxic response prevents the 
destruction of the target cell, and therefore presentation and activation are never 
terminated. The final outcome is cytotoxic lymphocyte and APC hyperactivation, 
excessive cytokine production, and overwhelming systemic inflammation leading to the 
fulminant clinical presentation [94]. Although macrophages are classically regarded as 
the APC of interest in HLH due to the prominent appearance of the activated 
haemophagocytes in the bone marrow, recent evidence suggests that macrophages may 
actually play an anti-inflammatory role in HLH. CD163, the haptoglobin scavenger 
receptor, is highly expressed on hemophagocytosing macrophages [95] and patients with 
HLH have elevated serum levels of soluble CD163 [96]. CD163+ hemophagocytosing 
macrophages found in patients with HLH secondary to sepsis were shown to be a major 
source of the anti-inflammatory molecule heme oxygenase 1 (HO-1) in these patients 
[97] suggesting that the process of haemophagocytosis was a macrophage reaction to 
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systemic inflammation rather than a cause; large amounts of heme required for the 
production of HO-1 is facilitated by the process of haemophagocytosis, which in turn is 
protective in sepsis and other causes of systemic inflammation [94].  
 
1.1.5 Molecular basis of HLH 
 
The pivotal cellular feature in HLH is the reduced ability of cytotoxic lymphocytes, i.e., 
CTL and NK cells to kill their targets. The molecular basis of this defect is the reduced 
production, function or release of perforin in the immunological synapse, which is the 
area where cytotoxic lymphocytes are in physical contact with their targets cells. Below I 
discuss in some detail the cellular and molecular mechanisms of lymphocyte cytotoxicity. 
 
1.1.5.1 The Immunological Synapse and Mechanisms of Lymphocyte Cytotoxicity  
 
Cytotoxic lymphocytes have evolved into a highly efficient cell system whereby they can 
find and discriminate between wide varieties of antigenic stimuli and determine the 
context of these interactions by picking up on numerous external cues [98]. Antigen 
recognition by T cells can either be fleeting or sustained, resulting in the formation of a 
‘kinapse’ in the former and an immunological synapse (IS) in the latter. 
There are two types of IS, one that is required for activation of T-helper cells by APC 
such as DC  (T cell-APC IS) and another that is formed between activated cytotoxic 
effectors and their targets (effector-target cell IS). The majority of our knowledge of the 
IS has been derived from work on the T cell-APC IS, and some of that insight has been 
extrapolated to demonstrate the function of the cytotoxic effector- target cell IS. 
I will briefly outline the structure and function of the T cell-APC IS before I discuss in 
some detail the anatomy of the cytotoxic effector-target cell IS. The latter is required for 
the exocytosis of perforin, a molecule required for the delivery of granzymes, the 
cytotoxic effectors to the target cell. 
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1.1.5.2 The Immunological Synapse 
 
1.1.5.2.1 Ultrastructure of the Immunological Synapse 
 
The IS was first described by Grakoui et al in CD4 lymphocytes [99]. Additionally, 
Kipper and colleagues identified micrometer-scale molecular structures on the CD4-APC 
IS and referred to them as supramolecular activation clusters (SMAC). They observed 
that upon contact with an APC, the receptors that were involved in adhesion and those 
that were involved with antigen recognition segregated spatially within the contact site; 
thus the TCR and associated proteins focused in a central SMAC (cSMAC), and the 
integrins, comprising of ring of LFA-1-ICAM-1 interactions and talin surrounded this 
central cluster, defined as the peripheral SMAC (pSMAC) [100] (Figure 1.3a). 
Additionally, in the CD8+ cytotoxic cell synapse, a unique domain called the ‘secretory 
domain’ exists within the cSMAC, where the polarised secretary granules are exocytosed 
[101] (Figure 1.3b).  
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Figure 1.3. Molecular segregation within the immunological synapse.  
 (a) The stable T cell- APC synapse has an inner cSMAC and an outer pSMAC, which 
leads to T cell priming, TCR down regulation and sustained signaling.  
(b)The cytotoxic T cell-target cell IS has a specialised secretory domain where polarised 
cytotoxic granules are exocytosed. Adapted from Friedl et al Nature Reviews 
Immunology 2005[102] 
TCR; T cell receptor, LFA1; lymphocyte function associated antigen 1, ICAM1; 
intracellular adhesion molecule 1. 
 
 
Further refinement of the IS ultrastucture was highlighted by the observation that the IS is 
in fact an assembly of hundreds of tiny clusters called ‘TCR microclusters’ [103], which 
are continuously generated at the periphery of the cSMAC [104]. Upon reaching the 
cSMAC, signaling molecules such as the CD3 complex, the tyrosine kinas Zap70 (zeta-
chain-associated protein kinase 70) and the adaptor molecule SLP-76  (SH2 domain 
containing leukocyte protein of 76kDa) dissociate from the TCR in CD4+ T cells and the 
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processes of signal termination and TCR ubiquitination and degradation begins [105].  
1.1.5.2.2 Co-stimulatory and adhesion molecules of the Immunological Synapse and TCR 
activation 
 
The critical co-stimulatory receptor of the TCR microclusters in the IS is CD28, when 
engaged by its ligand CD80 [106]. The CD28-CD80 complexes are transported in TCR 
microclusters to the cSMAC, at which point they array in an annular cluster around the 
cSMAC, segregated from TCRs [107]. In the CD4 T cell-APC IS, ligation of the TCR by 
antigen and peptide-MHC recruits CD4 and CD28, which engage their respective ligands 
and cause activation of tyrosine kinases such as Lck (Lymphocyte-specific protein 
tyrosine kinase). Activated Lck then phosphorylates the ζ chain of the TCR, which in 
turn recruits ZAP-70, the latter being phosphorylated by Lck and in turn phosphorylates 
other downstream substrates including MAP-kinase, PI3 kinase, phospholipase Cγ 
(PLCγ) and other signaling molecules [108] (Figure 1.4). This ultimately leads to the 
release of cytoplasmic transcription factor NF-κB (nuclear factor κ-light-chain enhancer 
of activated B cells), allowing it to enter the nucleus and activate target gene transcription 
[109].  
LFA-1 engagement of ICAM-1 is also vital to the formation of the IS both in vivo and in 
vitro. Initially, these molecules serve as adhesion molecules, tethering opposing T cell 
and APC membranes within tens of nanometers, facilitating TCR-pMHC interactions and 
in vitro enhancing T cell sensitivity to antigen 100-fold [98].  
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Figure 1.4. Series of events leading to T cell activation following CD4 T cell-APC 
interaction.  
Resting T cells express TCR and CD3 complexes (a), which upon engagement with 
peptide-MHC engages co-stimulatory molecules such as CD28-CD80 (b), which in turn 
activates Lck, which leads to phosphorylation of ZAP70 and numerous other 
downstream signaling molecules such as MAP kinase, PI3K (c), leading ultimately to 
release of cytoplasmic transcription factor NF-κB, allowing it to enter the nucleus and 
activate target gene transcription. 
Adapted from Firestein 2004, Nature Reviews Immunology[108] 
LAT; Linker for activation of T Cells, Lck; Lymphocyte-specific protein tyrosine kinase, 
ZAP70; Zeta-chain-associated protein kinase 70, PI3K; Phosphoinositide 3 kinase, 
MAPK; mitogen activated protein kinase, PLCγ; phospholipase Cγ. 
 
1.1.5.2.3 Role of the actin cytoskeleton in T Cell activation 
  
In the steady state, actin polymerisation at the leading edge and cytoskeletal contraction 
at the uropod mediate rapid T Cell movement [110]. Upon T cell engagement of an APC-
bearing agonist peptide-MHC (pMHC), the T cell stops crawling, changes shape and 
forms an IS [111]. Alongside these shape changes, there is reorientation of the 
microtubule organising centre (MTOC) to lie just beneath the plasma membrane, near the 
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centre of the APC contact site. This reorientation is pivotal to effective T cell engagement 
and essential for downstream function [112]. 
Following TCR ligation with pMHC a signaling cascade is initiated, which ultimately 
causes formation of actin filaments, which effectively stops further T cell movement. 
This is induced by interactions between a large number of molecules such as tyrosine 
kinases (Lck and ZAP70), adaptor proteins (Slp76 and LAT) and actin regulatory 
proteins (VAV1, cdc42 and RAC1). The latter activates certain actin nucleation –
promoting factors such as Wiskott–Aldrich syndrome protein (WASp) and WAVE2 
(Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2), which in 
association with the ARP2/3 (actin-related protein 2/3) complex, generate a ‘seed’, from 
which actin filaments can elongate [112] (Figure 1.5). 
TCR signaling also inactivates ERM (ezrin, radixin and moesin) family proteins, which 
detaches the cortical actin cytoskeleton from the plasma membrane and reduces T cellular 
rigidity, leading to more efficient T cell-antigen-presenting cell conjugate formation 
[113]. The ERM-proteins also causes exclusion of CD43 and CD45 from the T Cell- APC 
interface, facilitating molecular interactions at the IS [114] [115].  
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Figure 1.5. Regulation of f-actin polymerisation during T cell-APC interaction 
Following TCR activation, LCK and ZAP70 are activated, causing phosphorylation of 
LAT and recruitment of SLP76, which serve as a scaffold for actin-regulatory proteins 
such as VAV1, CDC42 and RAC1. CDC42 activates Wiskott–Aldrich syndrome protein 
(WASP) and RAC1 interacts with the WASP-family verprolin-homologous protein-2 
(WAVE2) complex to polymerize F-actin through their association with the ARP2/3 
(actin-related protein 2/3) complex.  Hematopoietic-cell-specific protein-1 (HS1) 
stabilizes newly generated actin filaments. Cofilin causes f-actin severing and 
depolymerization, creating new barbed ends as substrates for filament growth. PP2A is a 
serine phosphatase that activates Cofilin upon TCR ligation. 
Adapted from Burkhardt et al, Annual Review of Immunology 2008 [112] 
  
1.1.5.2.4 Cytotoxic T Cell Immunological Synapse 
 
The classical view of a CTL is as a serial killer cell that forms a short-lived, well 
organised IS with a life span of 20–30 min. The mechanisms involved in the initial 
recognition of MHC Class I molecule bound to peptide on a target cell by a CTL and 
finally ending with directed killing of the target cell comprises of a highly orchestrated, 
step-wise process and has striking similarities with that of an IS between a CD4+ T cell 
and an APC. An overview of the processes involved are as follows: TCR recognition of 
antigen leads to a rapid polarisation of the MTOC towards the IS and the secretory 
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lysosomes of the CTLs, termed the lytic granules, move along microtubules towards the 
MTOC. The MTOC briefly contacts the plasma membrane at the cSMAC and directly 
delivers the lytic granules to the synapse [116]. Once lytic granules are delivered to the 
site of secretion, a void of cortical actin opens up just below the polarised cSMAC, which 
allows for lytic granule delivery to the target. Lytic granules dock at the plasma 
membrane and release their contents into a small secretory cleft, i.e., the IS that is formed 
between areas of tight membrane apposition between the two cells [101] (Figure 1.6). 
The cSMAC therefore plays a pivotal role in the directed secretion of the CTL upon 
encountering a target.  
The pSMAC also contributes to CTL cytolytic function in several ways. Blocking LFA-1 
and ICAM-1 interactions leads to decreased sensitivity and ability of CTL to lyse target 
cells [117]. Both actin and microtubules play a key role in cytolytic function as is evident 
by the rapid polarisation of the MTOC upon antigen recognition on the target cell 
towards the IS. TCR signaling contributes to MTOC polarisation through Lck and Fyn 
[118] [119]. The actin cytoskeleton rearrangements upon CTL IS formation may be 
linked to MTOC polarisation through the interaction of Cdc42 with IQGAP1 [120], a 
cytoskeletal regulator, which interacts with both actin and the plus-ends of microtubules, 
connecting actin reorganisation at the IS with MTOC polarisation in a single mechanism 
[98]. 
Finally, through the IS, the lytic granule contents, including the pore- forming protein 
perforin and the serine proteases reach the APC or target cell and triggers an apoptotic 
cascade that ultimately leads to the destruction of the pMHC-bearing cell. This post- 
synaptic cell killing is described in details in Section 1.1.7.2.1. 
Following the formation of the IS and delivery of the ‘lethal hit’, the CTL cytoskeletal 
network reorients, the MTOC retracts from the cSMAC, the TCR receptor is 
ubiquitinated [121] and internalized [122] and the same CTL moves on to engage with 
other APCs, defining a ‘serial killing’ ability of activated T Cells. The vesicles that 
remain polarised around the MTOC continue to remain accumulated around the MTOC 
for some time after disengagement, and can be used to rapidly deliver lytic proteins to the 
next APC [123]. 
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Figure 1.6. Ultrastructure of the CTL immunological synapse 
The peripheral supramolecular activation complex (pSMAC) forms an adhesion ring at 
the interface between a CTL and its target cell. This is formed by engagement of 
leukocyte function associated antigen 1 (LFA-1) on the CTL and intercellular adhesion 
molecule (ICAM) on the target cell. Within the pSMAC is the central SMAC, where TCR 
accumulates, and beside it the secretion domain where lytic granules fuse to release 
their content. The centrioles of the centrosome dock beside the cSMAC, which acts as a 
focal point for minus end microtubule mediated delivery of lytic granules. Actin 
accumulation occurs in a distal SMAC (dSMAC). 
Adapted from Jenkins and Griffiths, Current Opinion in Immunology, 2010 [124] 
 
1.1.5.2.5 The NK Cell Lytic Synapse 
 
NK cells play a very important role in host defense against viral infections and 
tumorigenesis [125]. They directly contribute to the removal of pathogens through their 
cytotoxic activity. Though primarily considered as an integral part of the innate immune 
response, they also contribute to generation of adaptive immune responses through 
production of chemokines and cytokines, such as IFNγ or TNFα, by activating dendritic 
cells [126] and have also been recently shown to proliferate following a repeat interaction 
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with the same pathogen [127]. 
The activity of NK cells is regulated by a balance between a variety of germline-encoded 
inhibitory or activating cell surface receptors [128] (Figure 1.7). Inhibitory receptors are 
characterized by the presence of cytoplasmic immunoreceptor tyrosine-based inhibition 
motifs (ITIM) and can be generally divided into two groups of molecules: 
immunoglobulin superfamily (e.g. KIR, LIR, etc) and C-type lectin domain family 
(e.g.NKG2A/CD94) proteins. Activating receptors can also be divided into two groups: 
receptors that interact with immunoreceptor tyrosine-based activating motif (ITAM)- 
bearing polypeptides including CD16, NKG2C/CD94 or natural cytotoxicity receptors 
(NCR) NKp30, NKp44, and NKp46, and receptors interacting with non-ITAM-bearing 
proteins, for example NKG2D, 2B4, or CD2 [129] [130]. 
Much of the biological processes that are involved in NK cell lytic synapse formation and 
subsequent vesicular exocytosis, cytokine release and target cell lysis are similar to those 
observed in CTL lytic synapses, although several key differences remain [131]. Unlike 
those in CTLs, lytic granules are pre-formed in resting NK cells. This calls for a well-
regulated cytolytic process in NK cells, involving additional mechanisms for controlling 
the secretion of lytic-granule contents in NK cells [131]. Unlike CTLs, the NK cell 
cytoskeletal polarisation process contains a series of checkpoints during cell killing and 
compared to CTLs, majority of NK cells establish slow or incomplete cytoskeletal 
polarity and minor cytoskeletal changes can significantly alter NK cell killing [132]. 
Additionally, inhibitory synapses in T cell have not been described, and the localisation 
of several essential proteins (LAT, ezrin, CD43, CD45, and CD2) differs significantly 
between NK and T cell synapses [128]. 
The formation of the activating NK IS is a sequential process [133], requiring several 
steps: contact and adhesion, receptor ligation, actin cytoskeletal restructuring, receptor 
clustering and signal amplification, MTOC and granule polarisation, degranulation, cell 
killing and finally, IS disassembly [131]. 
The encounter between NK cell and MHC Class I positive (i.e. normal and healthy) target 
cell results in generation of the immunological synapse that is dominated by inhibitory 
interactions and hence, is termed an inhibitory NK IS. Inhibitory NK IS is mediated by 
inhibitory NK receptors with ITIM motifs in their cytoplasmic tails that can activate 
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phosphatases such as SRC-homology-2-domain containing protein tyrosine phosphatase 
1(SHP1). It is distinct from the activating NK IS and lacks large cytoskeletal 
rearrangements characteristic of the activating NK IS, and its role is to prevent NK cell 
activation and killing of the target cell. Contrary to the activating NK IS, formation of the 
inhibitory NK IS is independent of ATP, lipid rafts and actin cytoskeleton. [134] [135, 
136]. 
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Figure 1.7. Activating and inhibitory NK synapses 
NK cell activity is regulated by a balance of activating and inhibitory signals.  
Upper panel: SMIC (Supramolecular inhibitory cluster): Upon encounter with a MHC 
class 1 molecule such as HLA-Cw4 (cognate KIR2DL1 ligand) KIR2-DL1 receptors 
cluster at the NK-cell inhibitory synapse, f-actin does not accumulate and MTOC does 
not polarise. 
Lower panel: SMAC (Supramolecular activating cluster): Absence of any cognate ligand 
for KIR2DL1 causes activation signaling, f-actin reorganization, MTOC polarisation and 
other downstream events, ultimately leading to lytic granule release at the synapse and 
target cell killing. 
Adapted from Orange J, Nature Reviews Immunology, 2008 [131] 
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1.1.6 The Microtubule Network and the role of the MTOC in T cell- target cell 
interactions 
 
At the steady state, the microtubule network is a dynamic polarised structure. The fast 
growing plus ends of microtubules extend towards the cell periphery, and the stable 
minus ends are localized in the MTOC [137]. γ-Tubulin is a member of the tubulin family 
of proteins involved in microtubule nucleation, and specifically localizes at the MTOC 
[138]. The MTOC is also thought to act as a signaling complex, due to its association 
with Lck and Proline-rich tyrosine kinase-2 (Pyk2), the latter interacting with adapter 
proteins such as Fyn, which has been shown to modulate the TCR-mediated production 
of IL2 [139].    
Within minutes of T cell-target cell interaction, there is cytoskeletal restructuring, (which 
involves f-actin polymerisation) [111] [140], MTOC reorientation towards the IS [141] 
and formation of the Distal Pole Complex on the opposite side of the cell [142]. The 
MTOC reorientation occurs rapidly and is accompanied by other components or 
organelles, such as the Golgi apparatus [143]. 
In CTLs, two principal movements have been described in cytolytic granule polarisation, 
namely, granule recruitment to the MTOC (where the lytic granules switch from a 
bidirectional mode of movement along the microtubules and move in a minus-end 
direction toward the MTOC [123]) and MTOC polarisation to the CTL –target cell 
interface. Both movements require productive TCR engagement [116] [144]. MTOC 
polarisation is also associated with f-actin remodeling and segregation [123]. Upon 
segregation, f-actin pulls the attached microtubules to the periphery of the IS. Consistent 
with this, the adhesion and degranulation adaptor protein (ADAP)-associated minus end 
directed dynein motors that are located at the periphery of the pSMAC also ‘winch in’ the 
attached microtubules in a distinctive sliding motion, forcing the MTOC to polarise to the 
IS [145] (Figure 1.8). 
Using CTLs that were transfected with over-expressing Rab-interacting lysosomal protein 
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(RILP), that recruits dynein through interaction with Rab7 on late endosomes/lysosomes, 
Stinchcombe et al demonstrated that CTLs do not require actin or plus-end microtubule 
motors for secretion, but instead the MTOC itself moves to and contacts the plasma 
membrane at the cSMAC to deliver the lytic granules at the site of exocytosis [116]. 
Regardless of the mechanism of granule delivery to the synapse, granule release always 
occurs within the cSMAC of a CTL, within a specialised ‘secretory domain’ as 
mentioned previously [101]. The cSMAC membrane lacks an underlying actin 
cytoskeletal network and appears to be suitable for efficient membrane fusion, mediating 
rapid endocytosis and exocytosis. Vesicle docking, priming, and membrane fusion, 
molecular events that are required for granule release, are mediated by specialized 
proteins that can operate only in a particular membrane environment termed ‘‘active 
zones’’, [146] and it is likely that the actin- depleted cSMAC provides such an 
environment [147]. 
Recent work has demonstrated that although MTOC polarization is critical for delivery of 
cytotoxic granule to the IS, it is the latter that is the crucial step in determining 
cytotoxicity.  By using both high and low avidity TCR interactions, Jenkins et al have 
demonstrated that although MTOC polarization occurred in response to both high and 
low-avidity interactions, recruitment of cytotoxic granules to the IS was possible in the 
presence of high avidity interactions only [148]. This indicates that centrosome and 
granule polarization were differentially regulated, although the exact mechanism for that 
remains unexplained [148].  
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Figure 1.8. MTOC polarisation upon T cell-target cell interaction 
Following proximal signaling events after TCR engagement with peptide-MHC complex 
of the target cell, the MTOC of the cytotoxic T cell polarises towards the synapse and 
docks at the plasma membrane. Cytotoxic granules migrate towards the MTOC, and are 
delivered directly to the cSMAC, where they dock and fuse at the plasma membrane, 
releasing their contents into the synaptic cleft, causing target cell destruction. 
Adapted from de Saint Basile et al, Nature Reviews Immunology, 2010 [149] 
 
1.1.7 Secretory Lysosomes  
 
Lysosomes are membrane-bound organelles that contain hydrolytic enzymes necessary 
for intracellular degradation. They represent the main cellular degradation compartment 
within the vacuolar system of the eukaryotic cell [150]. After endocytosis, protein and 
lipids from the products of cellular degradation are either recycled back to the plasma 
membrane following their sorting into early endosomes or proceed to late endosomes and 
eventually to lysosomes to be degraded [151]. More than 60 human disorders have been 
described, arising from deficiencies in lysosomal enzymes and proteins; resulting in 
accumulation of the corresponding substrate and giving rise to lysosomal storage 
disorders [152].  
The vast majority of the lysosomes' constituent enzymes are soluble, residing in the 
luminal compartment and are synthesized, N-glycosylated and folded in the endoplasmic 
reticulum (ER) [153]. Following transfer to the Golgi, they are recognized and tagged 
with mannose-6-phosphate moieties, which allows their capture by mannose-6-phosphate 
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receptors (MPR) in the trans-Golgi network (TGN). Granzymes, which are serine 
proteases and important constituents of secretory lysosomes, (see Section 1.1.7.2.1) are 
processed via this mechanism [154]. TGN vesicles release MPR-bound lysosomal cargo 
upon fusion with endosomal vesicles due to the acidic pH of the late endocytic 
compartment. MPR are then recycled back to the Golgi for additional rounds of vesicular 
transport (Figure 1.9). Proteins of the lysosomal integral membrane such as LAMPs are 
sorted to lysosomes either directly via the TGN vesicle to endosomes and then on to late 
endosomes and lysosomes, or indirectly to endosomes via the plasma membrane (Figure 
1.9).  
Members of the Rab GTPase family also regulate several discrete steps in exocytic and 
endocytic vesicle trafficking pathways. Almost 70 different Rab proteins have been 
identified in humans [155]. Each Rab protein has a characteristic vesicular distribution, 
which determines their membrane organization and specific vesicular identity 
[156] For instance, Rab4 and Rab5 localize on early endosomes, Rab11 on pericentriolar 
endosomal recycling compartment and Rab7 on late endosomes [157]. 
Some cell types, the majority of which are haemopoietic in origin, have a specialised dual 
function lysosomal compartment that not only contain lysosomal hydrolases which 
function at acidic pH, but also contain proteins active in neutral pH that can be secreted 
into the extracellular environment in response to an external stimulus. Such granules have 
secretory lysosome characteristics, including an electron-dense core found in secretory 
organelles and a vesicular surrounding region typical of lysosomes [158]. This is in 
contrast with conventional secretory cells (e.g., exocrine and endocrine cells), which use 
a separate organelle for the storage and release of their secretory products and separate 
vesicles for cellular degradation. These organelles are referred to as ‘secretory 
lysosomes’ and include lytic (cytotoxic) granules in NK cells and CTLs [158], histamine 
–containing granules in mast cells, peroxidase containing granules in eosinophils, platelet 
dense granules, melanosomes, Major Histocompatibility Class II compartment (MIIC) etc 
[159].  
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Figure 1.9. Sorting pathways to the secretory lysosome.  
Membrane proteins utilise two main routes to reach the secretory lysosomes- the indirect 
route, which involves travelling to the plasma membrane from where proteins reach the 
secretory lysosomes after being internalised into clathrin-coated pits and the direct route 
(showed here in dashed lines), involving attachment of a mannose phosphate moiety 
within the trans-golgi network, followed by binding to mannose phosphate receptor and 
release into the late endosomal compartment, where the MPR are recycled back to the 
TGN for additional rounds of transport. Lysosomal proteins such as granzyme A take the 
second, direct route. 
Adapted from Blott and Griffiths, Nature Reviews Molecular Cell Biology 2002 [160]. 
 
1.1.7.1 Lysosome biogenesis and biogenesis disorders 
 
Lysosome biogenesis is best understood by studying human diseases termed ‘lysosome 
biogenesis disorders’. These include Chediak-Higashi syndrome (CHS), Hermansky-
Pudlak syndrome (HPS), and Griscelli syndrome, among others.  CHS and HPS (8 known 
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variants in humans) are characterized by variegated pigmentation, variable immune 
deficiencies, and platelet dysfunction.  Despite being one of the first lysosomal diseases 
in which the defective gene was identified, CHS still remains one of the least well 
understood, and the gene function largely remains speculative. CHS (and the beige mouse 
homolog) is caused by mutations in the LYST gene [161] [162] encoding a lysosomal 
targeting regulator protein, and is characterized by the presence of greatly enlarged 
lysosomes within every cell of the body. Despite this, only the immune cells and other 
cell types with secretory lysosomes are defective, suggesting that LYST may play a role 
in the release of secretory lysosomes [123]. The mutated proteins known to give rise to 
the HPS variants occur in one or more of the cytosolic BLOC complexes, each being 
composed of different proteins, including the adaptor proteins 1-4 (AP1-4) [163]. In order 
to explain the ‘giant organelle’ phenotype in CHS, Zhang and co- workers [164] 
compared the composition of beige and normal lysosomal membrane proteins and found 
that the lysosomal membrane in the beige mouse ( as well as CHS patients) contain a 
large number of  ER proteins not found in the WT mouse counterparts. This results in 
disruption of lysosomal homeostasis, as predicted by the significantly altered ER-protein 
composition of the ‘giant’ lysosome membrane. As a result of this study, it was 
postulated that LYST protein serves to either spatially separate endosomal/lysosomal and 
ER membranes and prevent their unproductive (pathological) fusion; or remove 
unproductive endosomal/lysosomal and ER membrane fusions; or act as a template for 
organizing trafficking complexes (such as AP3 or BLOC) prior to their association with 
TGN vesicles. 
The adapter protein (AP) complexes 1-4 are all involved in sorting of proteins from the 
TGN or the endosomes to different compartments in the cell.  AP1 and AP2 bind to 
clathrin and assist in the formation of vesicles [150] [163]. Studies in HPS2 indicate that 
AP3 deficiency results in increased cell surface expression of the lysosomal membrane 
proteins CD63, LAMP-1, and LAMP-2, but not of non-lysosomal proteins, suggesting 
that AP3 functions in protein sorting to lysosomes [43]. Also, since mutations in the 
ADTB3A gene encoding the β subunit of the AP3 complex cause the only HPS subtype 
which is associated with an immune disorder along with other lysosomal abnormalities 
[165] [166], this indicates that AP3 is important for lysosome function within the immune 
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system. In the absence of AP3, CTL- mediated killing is severely impaired and the lytic 
granules are unable to move along the microtubules towards the MTOC when the CTL 
recognizes the target [167].  
1.1.7.2 Lytic granule- specific proteins of the secretory lysosomes in cytotoxic 
lymphocytes 
Apart from the usual array of lysosomal proteins, cytotoxic granules of T and NK cells 
also contain the pore- forming protein perforin and a family of serine proteases known as 
granzymes (Table 1.3). Granzymes are processed either en route to or in the granules 
from inactive pro-enzymes to active enzymes by cathepsin C [168] and are inactive in the 
acidic pH of the granules. Granzymes act as the principal mediators of induction of cell 
death /apoptosis in the target cell upon its encounter with a CTL or NK cell and are 
described in detail below. Lytic granules also contain cathepsin B, a protein that protects 
the CTL from destruction by its own granule enzymes released into the synapse by 
proteolytic cleavage and inactivation of perforin [169]. Lytic granules contain granulysin, 
a membrane- damaging protein homologous to bacterial defensins, which has anti 
bacterial and anti-tumour properties. Granulysin induces partial release of cathepsin B 
from lysosomes of target tumour cells, triggering an alternative form of programmed cell 
death termed necroptosis [170]. Another protein present in the lytic granule is calreticulin 
[171], which inhibits perforin-mediated autolysis, possibly by stabilizing the cell 
membrane [172].  
1.1.7.2.1 Granzymes  
 
Granzyme A and B are the most abundant granzymes in mice and humans. Granzyme B 
activates the caspase dependent pathway of apoptosis and like caspases, cleaves after an 
aspartate residue, thereby acting as an aspase [173]. CTLs from granzyme B knockout 
mice have a profound defect in their ability to induce rapid DNA fragmentation in 
allogeneic target cells [174]. Humans and mice encode different homologous duplications 
of the granzyme genes in three linked chromosomal clusters. The granzyme B cluster in 
humans also encodes granzyme H and mast cell chymase and is expanded in mice to 
encode granzymes C, D E, F and G [168]. Granzyme B transcriptional activation occurs 
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in a lineage- specific manner, with specific expression being predominantly activated in 
CD8+ T cells. It has recently been shown that chromatin remodeling and specific histone 
post –translational modifications are required for lineage- specific transcription of 
granzyme B [175].  
In many apoptosis pathways, apoptotic signals converge on mitochondria where they 
promote the oligomerisation of the BCL2 family members BAX (BCL2 associated X 
Protein) and/or BAK (BCL2 agonist/killer) in the outer mitochondrial membrane as a 
result of inhibiting the anti-apoptotic proteins BCL2 and BCL-XL [176] [177] [178]. 
BAX/BAK oligomerisation causes disruption of the mitochondrial membrane, resulting 
in the escape of cytochrome c and other pro-apoptotic molecules into the cytosol [179]. 
Cytochrome c release into the cytosol facilitates the formation of a complex, known as 
the apoptosome, between APAF-1 (Apoptosis protease activating factor 1) and caspase-9. 
This causes activation of caspase-9, which in turn activates a downstream caspase 
cascade, leading to rapid cell death [180]. Several caspases have been proposed to be 
granzyme B substrates, including caspase 3, 6,7,8,9 and 10 [181]  [182] [183]. However, 
cell death induced by CTLs also occur in the presence of complete caspase blockade 
[184] and over-expression of  BCL2 in target cells fails to abrogate their lysis by CTLs 
[185], indicating that CTLs also activate caspase- independent cell death. Granzyme A 
and B have both been implicated in inducing target cell death in caspase- independent 
pathways [184] [186]. 
The mechanisms of granzyme B and A- induced cell death have been studied extensively. 
Granzyme B can directly cleave BID to form tBID (truncated BID), which in turn causes 
disruption of the mitochondrial membrane [179], causing the release of pro apoptotic 
molecules and triggering of the caspase cascade, causing DNA damage and cell death. 
Granzyme B can directly activate caspase 3 by cleaving the inactive pro-caspase 3, [187] 
which in turn then disrupts the mitochondrial membrane. Granzyme B can also directly 
disrupt the mitochondrial membrane in a BID and caspase- independent pathway. [188] 
In addition to this, granzyme B can also directly cleave ICAD (Inhibitor of Caspase- 
activated deoxyribonuclease) to free CAD (Caspase activated deoxyribonuclease), to 
cause DNA fragmentation [189] (Figure 1.10). 
DNA damage inflicted by granzyme A causes single stranded DNA nicks as opposed to 
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granzyme B and caspase-mediated DNA damage by CAD, where double stranded 
oligonucleosomal DNA cuts of ∼200bp occurs [186]. Granzyme A acts in a caspase-
independent pathway and targets an ER- associated complex known as the SET complex, 
inhibition of which triggers the single stranded DNA damage process. Granzyme A 
cleaves SET and in turn activates NM23-H1, a tumour suppressor protein associated with 
the SET complex, which causes the DNA single stranded nicks [190].  
Other members of the granzyme family, often known as the ‘orphan granzymes’ also play 
a role in granule mediated cellular cytotoxicity, albeit to a much lesser extent than 
granzymes A and B [191] [192]. More recently, other non- apoptotic roles of granzymes 
have been identified, which suggests that granzymes may have a broader role in the 
immune system [193] [194]. 
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Figure 1.10. Granzyme B activates both caspase dependent and caspase independent 
nuclear cell death pathways 
After entering the target cell cytosol, granzyme B cleaves BID to form truncated BID 
(tBID), which disrupts the outer mitochondrial membrane, causing the release of 
cytochrome c (which activates pro-caspase 9), HtrA2/OMI (which blocks inhibitors of 
apoptosis) and endonuclease G, which causes DNA damage. Cytochrome c, along with 
APAF 1 and pro-caspase 9 forms the apoptosome, which activates caspase 3, which in 
turn cleaves inhibitor of CAD (ICAD) to release CAD (caspase- activated DNAse) to 
cause DNA fragmentation. Granzyme B can also directly cleave ICAD through an 
unknown mechanism. 
Adapted from Lieberman Nature Reviews Immunology 2003 [168] 
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Table 1.3. Content of lytic granules implicated in cellular cytotoxicity 
Membrane perturbing proteins Perforin and granulysin 
Granule serine proteases Granzyme A, B, C, D, E, F, G, H, K, and M 
Proteoglycan matrix Serglycin 
Perforin inhibitor Calreticulin 
Cathepsins B and C 
Stored T cell effector molecules FAS ligand and possibly β-chemokines 
Adapted from Lieberman J, Nat Rev Immunol 2003 [168] 
1.1.7.2.2 Perforin  
 
The other vital component of the cytotoxic secretory lysosome is the Ca++ dependent, 
67kDa pore forming protein perforin, the only molecule that can deliver granzymes to the 
target cell and together with granzymes mediate target cell death [195]. The mechanism 
of perforin sorting to secretory lysosome is not understood [154]. Perforin is primarily 
expressed in NK cells [196], antigen-experienced CD8+ T cells, and γδT cells [197], but 
it can also be expressed in subpopulations of CD4+ T [198] cells and NKT [199] cells. 
NK cells constitutively express perforin and are naturally lytic [196] , but perforin 
expression in CTLs require gene activation [200]. Percentage of perforin- expressing NK 
cells by flow-cytometric analysis is constant throughout life at about 95% but perforin-
containing CD8+ T cells increases with age, and young children, especially infants, have 
very low perforin+ CD8 T cells. Perforin-containing CD56+ T cells also increases with 
age [92].  
Until recently, the exact nature of regulation of perforin expression in cytotoxic 
lymphocytes was unknown. Although transcription factors such as Sp1, AP-1, MEF, 
MITF, T-bet and Eomesodermin have each been implicated to function at the PRF1 
promoter [201] the PRF1 promoter itself was shown to be  insufficient for physiological 
regulatory function in transgenic mice [202]. Later, two enhancers, 15kb and 1kb 
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upstream of the perforin promoter were shown to be responsive to TCR signals but 
transgene experiments using large genomic perforin clones that contained both enhancers 
and the promoter were only able to induce 5% of that expressed from the endogenous 
PRF1 gene [200], suggesting that the regulatory areas might lie further upstream. In a 
recent study involving microcellular chromosome transfer experiments, it was 
demonstrated that de novo activation of a silent PRF1 locus was controlled by a 150kb 
domain 35-50Kb upstream of exon 1 and comprised of 16 DNase I hypersensitive sites 
(DHS 1-16). These cis-acting sequences included a locus control region (LCR) (between 
DHS 4-8, only found in cytotoxic lymphocytes), the function of which was central for 
regulating the developmental and activation-specific PRF1 promoter activity 
characteristic of NK cells and CTL [203]. 
Perforin is a multi-domain protein (Figure 1.11). The precursor of human perforin is a 
555 amino acid protein that is synthesized with a 21 amino acid leader sequence. 
Cleavage of this leader peptide causes it to be recruited into the secretory pathway 
presumably by exposing a positively charged N-terminal peptide, which has some lytic 
activity in its synthetic form [204] [205]. The perforin precursor also contains two 
glycosylation sites, and the glycosylated carboxy-terminal peptide is removed to produce 
the mature active protein [206]. The central part of perforin comprises a putative 
amphipathic α-helical region similar to a region within the complement membrane attack 
complex (MAC) like proteins in many species [207]. As no other proteins were initially 
found to have structural homology to this domain [208], it was called the Membrane 
Attack Complex Perforin (MACPF) domain. However, it has recently been demonstrated 
that the MACPF domain is widely distributed in nature, with the MACPF fold being 
evolutionarily conserved extending back to the pore-forming toxins of bacteria [209]. 
Two long regions that are N- terminal and C-terminal to this amphipathic α-helical region 
are regions of low homology and are conserved throughout evolution but their function is 
unknown. The C2 domain is homologous to other calcium responsive proteins [210] and 
is pivotal for calcium-dependent membrane binding of perforin [211]. 
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Figure 1.11. Schematic representation of the putative functional domains of perforin 
Adapted from Voskoboinik I et al Nature Reviews, Immunology 2006 [212] 
 
Perforin is synthesized and stored in cytotoxic lymphocytes in a manner that is designed 
to protect them from being destroyed by the lytic effects of the protein. Upon synthesis in 
the endoplasmic reticulum, perforin binds to its inhibitor calreticulin [172] and is then 
transported to the cytotoxic granules. Although, after its entry into the granule, a cysteine 
protease removes a carboxy-terminal glycosylated peptide of perforin [206], it remains 
inactive there due to the acidic pH and the absence of free Ca++. Within the granule, 
perforin is also unable to multimerise to an active conformation as it is complexed with 
serglycin.  
The exact mechanism of perforin-mediated delivery of granzymes into the target cells is 
still unclear and is the subject of debate. It was first proposed that perforin polymerises 
on the target cell membrane forming pores that were large enough to allow granzymes to 
pass through to the target cytosol, triggering apoptosis. This theory was based on the 
ability of purified perforin to lyse red cells in vitro in a manner similar to complement 
MAC and with EM studies showing the formation of pore like structures in both cases; 
and also due to the sequence homology of the amphipathic α helical domain of perforin 
with that of complement MAC [213] [214]. However, this theory was questioned when it 
was found that granzyme B can enter the cytosol in the absence of perforin [215] [216] 
[217] and that when internalized by a target cell, granzyme B trafficks to an intracellular 
compartment and accumulates until its release is stimulated by the addition of perforin. It 
was demonstrated that granzyme B passed through rab5-positive vesicles and then 
accumulated within a novel compartment [216]. Based on these findings, Froelich and 
co-workers [217] proposed that perforin did not act at the target cell plasma membrane, 
but at the endosomal membrane in the cytosol of the APC to release granzymes from 
endosomes, presumably by forming pores in the endosomal membrane. Subsequently, 
researchers questioned the endosomolysis model of granzyme delivery based on the 
observation that when granzyme B-pre-incubated cells were washed to remove all cell 
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surface granzyme B, subsequent addition of perforin did not trigger apoptosis, suggesting 
that perforin and granzymes needed to be co-endocytosed to trigger granzyme delivery 
for apoptosis [215]. Furthermore, it was found that perforin, at physiologically relevant 
concentrations, created pores in the target-cell membrane, transiently allowing Ca++ and 
small dyes into the cell. The Ca++ flux triggered a so- called ‘wounded membrane repair 
response’, in which internal vesicles, including lysosomes and endosomes, donated their 
membranes to reseal the damaged membrane. In the target cell, perforin also triggered the 
rapid endocytosis of granzymes into large EEA-1 (Early Endosomal Antigen-1) staining 
vesicles. Upon restoring membrane integrity by triggering the repair response, target cells 
are proposed to avoid necrosis and undergo apoptosis instead, thereby actively 
determining its own fate during cell-mediated death [218]. Furthermore, the large EEA-1 
staining vesicles containing perforin and granzyme in the target cell cytosol did not stain 
for LAMP-1, which was found on the repaired membrane patches, indicating that the 
granzyme vesicles were not formed as part of membrane repair process [195]. This led 
Pipkin et al [195] in 2007 to propose a third, ‘hybrid’ model in which perforin forms 
small pores in the cell membrane that trigger a Ca++ influx, which in turn activates a 
membrane repair response in which internal vesicles donate their membranes to patch the 
holes. They proposed that the next step involves rapid co-endocytosis of granzymes and 
perforin into giant endosomes, followed by perforin-mediated release of granzymes to the 
cytosol (Figure 1.12). 
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Figure 1.12. Proposed mechanisms of target cell membrane disruption by perforin to 
deliver granzymes into the target cell cytosol. 
 (a) Pore-forming model: Perforin multimers formed pores in the APC membrane to let 
granzymes pass through- this were the first model proposed for perforin- mediated 
granzyme delivery 
(b) Endosomolysis model: Granzymes endocytosed into the APC independently of 
perforin and perforin then lysed the endosomal membrane to release granzymes into the 
cytosol of the APC. 
 (c) Hybrid model: Ca++ influx is triggered by making small pores in the APC membrane 
by perforin, activating a membrane repair response and causing internal vesicles to 
donate their membranes to patch the holes. This is followed by co-endocytosis of 
granzymes and perforin into giant endosomes, followed by perforin-mediated release of 
granzymes to the cytosol.  
Adapted from Pipkin et al Current Opinion in Immunology, 2007 [195]. 
 
 
 Recent publication of the crystal structures of MACPF proteins human C8α and C8α 
complexed to C8γ [219] [220]  and bacterial Plu-MACPF (a putative toxin synthesized by 
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Photorhabdus luminescens) [209] has provided the breakthrough required for researchers 
to predict structure-function relationships for perforin [221]. The structural data predicted 
that the folding mechanism was identical to that of the cholesterol-dependent cytolysins 
(CDCs) in bacteria such as Clostridium, Streptococcus and Chlamydia. Ironically, these 
bacteria secrete pore-forming toxins that fold through a similar molecular mechanism as 
the very proteins engaged by the immune system to eliminate them [222]. 
On the basis of the structural studies mentioned above, it was shown that the long- held 
dogma that the function of the highly conserved MACPF region of perforin was to do 
with target membrane insertion, might be incorrect [221]. This hypothesis was tested 
using site-directed mutagenesis and structural- functional analysis techniques targeting 
specific amino acid residues of the MACPF domain by Baran et al who recently 
demonstrated that the role of certain residues in this region was instead to mediate 
perforin oligomerisation, and no evidence of this region’s involvement in membrane 
spanning was found by them. They postulated that perforin oligomerisation occurred 
following membrane binding and prior to membrane insertion and pore formation. Their 
data provided a broader insight into pore formation by lytic MACPF proteins by 
demonstrating a model where these proteins assemble into pores via a common 
mechanism; namely oligomerisation via the large flat faces of the MACPF domain [222]. 
It is still unclear whether granzymes enter the cell membrane through those pores and 
what exactly triggers the rapid endocytosis of granzymes and perforin into giant 
endosomes. It is also not clear what mechanism causes perforin to mediate escape of 
granzymes from the endosome to the target cell cytosol. Further work is needed for a 
clearer model to emerge. 
 
1.1.8 Genetic basis of HLH  
1.1.8.1 Familial Haemophagocytic Lymphohistiocytosis 
 
Almost 50 years after the first cases of Familial HLH were reported by Farquhar and 
Claireaux [18], two separate loci mapping to regions in chromosome 9 (9q21.3-22) (FHL 
I, OMIM 603552) and chromosome 10 (10q21–22) (FHL II, OMIM 603553) were shown 
to be associated with the disease by two separate research groups by homozygosity 
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mapping and linkage analysis [223] [224]. Prior to this, genetic markers of FHL had been 
unsuccessfully investigated for many years, and occasional reports of chromosomal 
aberrations had not been confirmed in larger studies [225] [226]. Both groups 
demonstrated evidence of genetic heterogeneity in FHL, as there was no linkage 
demonstrated in some of the families that they had studied.  
Soon afterwards, Stepp et al demonstrated that sequencing of the coding regions of the 
perforin gene (PRF1) of eight unrelated 10q21-22-linked FHL patients revealed 
homozygous nonsense mutations in four patients and missense mutations in the other four 
patients. Cultured lymphocytes from patients had defective cytotoxic activity, and 
immunostaining revealed little or no perforin in the granules, demonstrating that defects 
in perforin were responsible for 10q21-22-linked FHL [227]. 
 
Using linkage analysis three further disease loci have since been identified- 17q25.1 
(FHL III, OMIM 608898) caused by mutations in the UNC13D gene encoding hMunc13-
4 protein [228], 6q24 (FHL IV, OMIM 603552) caused by mutation in the STX11 gene 
[229] and 19p (FHL V, OMIM 613101) caused by mutations in the STXBP2 gene 
encoding Munc18-2 protein [230] [231]. The discovery of several disparate disease loci 
in FHL underpins the theory of genetic heterogeneity of this condition despite remarkable 
clinical homogeneity of patients presenting with FHL.  
 
In summary, genes implicated in FHL so far are all involved in the molecular processes 
involved in cellular cytotoxicity- PRF1 encoding the protein perforin is vital for the 
delivery of granzymes into the target cell in order to mediate cell killing and is mutated in 
FHL II, UNC13D encoding hMUNC13-4 is involved in secretory vesicle priming and is 
mutated in FHL III, STX11 encoding syntaxin11 is involved in vesicle membrane fusion 
and is mutated in FHL IV and STXBP2 gene encoding Munc18-2 protein, which acts in 
synergy with syntaxin11, is mutated in FHL V [227] [228] [232]. Other genetic diseases 
that present with a HLH- like clinical syndrome are also caused by abnormalities in 
proteins required for granule exocytosis, such as GS2 caused by mutations in Rab27a 
gene, the protein being required for vesicle docking, CHS-1 mutations causing abnormal 
granule maturation and HPS2 and XLP caused by loss or absence of proteins implicated 
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in granule polarisation (Figure 1.13).  
 
 
 
Figure 1.13. HLH disorders related to abnormalities in granule mediated exocytosis in 
cytotoxic lymphocytes 
The recently-described subtype of FHL (FHL V) occurs in individuals carrying mutations 
in the STXBP gene, encoding the munc18-2 protein, which is proposed to intermediate 
both docking and fusion steps by interacting with syntaxin 11 to form a docking complex 
in the former and help clasping a SNARE complex in the latter [149]. 
CHS, Chediak Higashi Syndrome; XLP, X-linked lymphoproliferative disease; HPS2, 
Hermansky Pudlak Syndrome Type 2; GS2, Griscelli Syndrome Type 2; FHL, Familial 
Haemophagocytic Lymphohistiocytosis. Adapted from Arceci R, Current Opinion in 
Haematology, 2008 [233]. 
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The disease gene in FHL I linked to 9q21.3-22 has not yet been identified and it is not 
known whether or not this genetic form of FHL is associated with defective cytotoxic 
activity of lymphocytes. Nonetheless, reduced or absent granule mediated cytotoxicity 
appears to be the hallmark of FHL and supports the disease model of HLH, where 
defective lymphocyte cytotoxicity causing abnormal apoptosis triggering [234] in the 
face of an overwhelming infection/inflammation is thought to be the underlying 
pathogenesis of FHL, as previously discussed. 
Some researchers have indicated that in about 10% of patients, the putative gene disorder 
still remains unidentified [231] and several reasonable candidate genes involved in 
cytotoxicity and apoptotic pathways, such as the GZMB gene encoding granzyme B, 
SRGN gene encoding Serglycin, [a glycoprotein that binds to granzyme B], the GNLY 
gene encoding Granulysin, [another membrane disrupting protein], the ARF6 gene [a 
member of the ADP-ribosylation factor (ARF) family and plays a crucial role for 
cytotoxic granule secretion] have already been excluded as disease –causing genes in 
FHL [235] [236].  
 
1.1.8.2 Genetic syndromes associated with Haemophagocytic Lymphohistiocytosis  
 
Unlike FHL, where HLH occurs in isolation and is caused by autosomal recessive 
mutations in genes involved in the lymphocyte cytotoxicity pathway, a number of 
congenital immune deficiency disorders can also give rise to clinical HLH as part of a 
wider syndromic disorder. Perhaps predictably, the mutated genes implicated in these 
disorders also play a role in granule trafficking and exocytosis, apoptosis or cellular 
cytotoxicity (Figure 1.13).  
Three distinct immunodeficiencies that are typically associated with pseudo-albinism 
because of defects in lysosomal trafficking in lymphocytes as well as melanosomes have 
been associated with life-threatening episodes of HLH. They are: Chediak Higashi 
syndrome (due to mutations in the LYST, or CHS1 gene) [42], Griscelli syndrome Type 
II (due to mutations in the Rab27A gene ) [44], and Hermansky-Pudlak syndrome type II 
(due to mutations in the AP3B1 gene ) [43].  CHS and GS2 are described in sections 
1.1.7.1 and 1.1.8.5.1 respectively). 
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1.1.8.2.1 X-linked Lymphoproliferative disease 
 
HLH following exposure to EBV and less commonly other viruses, termed fulminant 
infectious mononucleosis (FIM) is the most frequent life-threatening complication of 
XLP1.  XLP1 is caused by hemizygous mutations in the SH2D1A gene encoding SAP 
[Signaling Lymphocyte Associated Molecule (SLAM)- Associated Protein] [41] [40] 
[39], which lead to abnormal B, T NK cell responses to infection and NKT cell 
deficiency. FIM occurs in the setting of primary EBV infection and occurs in about 60% 
of patients with XLP. The signs and symptoms resemble those of infectious 
mononucleosis and include fever, fatigue, malaise, sore throat, lymphadenopathy, 
hepatosplenomegaly, atypical lymphocytosis, and variable serum immunoglobulin levels 
[237]. Histological examination of affected organs shows infiltration of EBV+ B cells as 
well as polyclonal CD8+ and CD4+ T cells [238]. In about a third of the patients with 
XLP1, the main clinical phenotypes are dysgammaglobulinaemia and B- 
lymphoproliferative disorders [239].  
 
SAP is a 15–17-kDa protein expressed in NK and T cells, including thymocytes and 
mature CD4+ and CD8+ cells and contains an amino-terminal Src Homology 2 (SH2) 
domain.  XLP is caused by a variety of SH2D1A mutations leading to the loss of SAP 
activity and loss of function of its SH2 domain [240]. SAP binds to the SLAM receptor 
as well as other members of the CD2 receptor family such as 2B4 and also to the tyrosine 
kinase Fyn, enhancing the latter’s kinase activity [241]. SAP acts as an adaptor that is 
required for the generation of SLAM-receptor associated signaling complexes [242]. 
Although patients lacking the SAP protein have normal NK cell numbers, cytotoxicity of 
SAP deficient NK cells is not increased when cells are activated through SAP- 
associating receptors such as 2B4. Furthermore, SAP deficient NK cells have reduced 
cytotoxicity against EBV- infected B cells [243]. Thus, the inability of SAP-deficient NK 
cells to be activated through 2B4 or to kill EBV-transformed B cells causes these cells to 
persist during FIM, driving an abnormal T-cell response and a HLH- like syndrome 
[241]. Recent research also suggests that lymphocytes from patients with XLP1 
demonstrate decreased activation-induced cell death (AICD) [244]. The absence of SAP 
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impairs AICD- related T cell homeostasis, leading to uncontrolled proliferation of T cells 
in FIM. Thus, the adaptor molecule SAP regulates critical aspects of immune cell 
activation, including NK cell and CD8+ T cell killing, CD4+ T cell cytokine production, 
and CD4+ T cell help for antibody production as well as immune cell contraction by its 
pro-apoptotic properties, all of which is disrupted in XLP1 and gives rise to the clinical 
phenotype observed in XLP1. 
XLP2, caused by hemizygous mutations in XIAP, or BIRC4, has been described in males 
who develop sporadic as well as EBV-associated HLH [245]. Apoptosis of lymphocytes 
from XIAP-deficient patients is enhanced in response to various stimuli including the 
TCR–CD3 complex, the death receptor CD95 and the TNF-associated apoptosis-inducing 
ligand receptor (TRAIL-R) and appears to have a paradoxical effect in vivo by acquiring 
a lymphoproliferative phenotype [246] and the exact nature of processes underlying this 
phenotype is not clear.  
Children presenting with EBV driven – secondary HLH and XLP share common 
manifestations of dysregulated T-cell activation, enhanced Th1 cytokine secretion, and 
the subsequent development of fatal HLH. However, EBV-HLH is basically distinct from 
XLP in the lack of SAP/SH2D1A gene mutation and gender predilection [247]. The EBV 
latent membrane protein-1 (LMP1) has been reported to activate T cells, up-regulate 
TNFα and IFN [248] and inhibit the expression of SAP [249] and  lead to an enhanced 
cytokine storm and haemophagocytosis in the EBV-HLH setting. 
1.1.8.3 Perforin deficiency and FHL  
 
In 1968, Rosenau [250] reported that upon contact with lymphocytes, target cells swell 
before rupturing. Subsequent work by other investigators [251] [252]  in the 70’s 
indicated that the plasma membrane of the target cell may represent the primary site of 
lymphocyte attack from cell marker release experiments, in which radio- labeled markers 
taken up by target cells were shown to be rapidly released when exposed to attacking 
lymphocytes. This series of experiments raised the possibility that a lesion in the target 
membrane could be formed as a result of direct damage by lymphocytes [253]. In the 
early 80’s, electron micrographs of the membrane lesions formed on target surfaces by 
cloned CTLs and NK cells were shown to be ring-like structures with an internal 
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diameter of about 15 nm [208]. 
It was also noted at the time that cytotoxic lymphocytes cultured in vitro with IL2 
contained numerous azurophilic cytoplasmic granules, with electron-dense cores bounded 
by vesicular material. A role for these cytoplasmic granules in cell-mediated killing was 
suggested by morphologic studies demonstrating accumulation of granules at the site of 
contact with target cells [254]. The cytolytic function of perforin was first demonstrated 
in 1984 by its identification in CTL cytoplasmic dense granules that were shown to 
polymerise in a Ca ++ dependent reaction and cause cytolysis by membrane insertion and 
transmembrane channel formation [255]. Membrane lesions caused by perforin were 
thought at the time to resemble those caused by complement mediate cell lysis, as they 
were both large, ion- nonspecific and caused by aggregation of proteins [253]. Perforin 
was reported to be expressed in NK cells and IL2 treated CTLs [253] and also in murine 
CD8+ T cells following acute viral infection in vivo [256]. Prior to the early 1990’s some 
debate existed about the mechanism of cytolysis by CTL and NK cells, and in 1994, 
perforin- deficient mice were generated by homologous recombination in embryonic stem 
cells [257]. These mice were viable and fertile and had normal numbers of CD8+ T cells 
and NK cells, which did not lyse virus-infected or allogeneic fibroblasts, or NK target 
cells in vitro. The mice also failed to clear LCMV and eliminated fibrosarcoma cells with 
reduced efficiency, thereby proving perforin’s role as a key effector molecule for T cell 
and NK Cell-mediated cytolysis [257]. In the same year, the same group also established 
that both Fas- mediated apoptosis and granule- mediated cytolysis were involved in cell 
killing by cytotoxic lymphocytes [258]. Further investigation of the perforin mediated 
cytolysis pathway showed that perforin-dependent nuclear entry of granzymes preceded 
the nuclear events of apoptosis, such as DNA fragmentation and nuclear envelope 
breakdown; prevention of granzyme nuclear translocation through Bcl2 overexpression or 
treatment of target cells with inhibitors of caspase activation blocked these events. The 
critical factor for the induction of nuclear changes that are associated with granule-
mediated apoptosis is the nuclear localization of granzymes [259]. Furthermore, chronic 
LCMV- infected, perforin- deficient mice were shown to have enhanced virus-specific T-
cell response and the mice died as a consequence of immune damage mediated by CTLs, 
macrophages, IFNγ and TNFα [260]. 
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In 1999, Stepp et al demonstrated that perforin gene (PRF1) mutations were responsible 
for FHL in a subgroup of children (FHL II) [227] and the immune dysregulation observed 
in FHL II as well as in perforin-deficient mice following viral infection underpinned the 
role of  perforin as a regulatory molecule in the maintenance of human immune 
homeostasis [261]. 
PRF1 mutations cause a wide variety of clinical phenotypes, ranging from severe immune 
dysregulation in childhood to abnormal tumor surveillance in children and adults [262]. 
To date, over 65 different perforin mutations causing FHL II have been described in the 
literature, leading to partial or complete loss of function of the encoded protein [263] 
[264]. 
Most of the perforin mutations in patients with FHL II do not lead to severe protein 
truncation. Western blot of lysates from patients with PRF1 missense mutations have 
ranged from absent to normal [265] [266] [267]. About a fifth of the PRF missense 
mutations are termed ‘post-synaptic’ mutations and lead to abnormal perforin function at 
the level of the target cell and the rest are pre-synaptic defects leading to protein 
degradation due to misfolding or abnormal trafficking [222]. 
In order to investigate the effect of perforin missense mutations leading to loss of protein 
function, an ex-vivo system was devised by Risma et al, using transiently transfected rat 
basophilic leukaemia (RBL) cells with an internal ribosome entry site-based plasmid 
vector (pIRES2) encoding perforin (wild-type or mutant forms) and enhanced green 
fluorescent protein (EGFP) [262]. Using this cell system, the investigators identified three 
classes of perforin missense mutations: class one mutations led to partial maturation of 
perforin with identifiable protein in lysates and a variable degree of residual cytolytic 
activity of cells; class three mutation led to complete absence of protein and severely 
reduced activity and class two with an intermediate phenotype [262]. The researchers 
concluded that individuals with Class 1 mutations had a milder clinical phenotype with 
residual protein activity and older age onset of disease whereas individuals harbouring 
Class 3 missense mutations presented with a more severe clinical phenotype and an early 
onset of disease [262]. 
In a study of 124 patients with perforin –deficient FHL conducted by the Histiocyte 
Society in 2008 (Figure 1.14), it was revealed that the most common single mutation was 
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the nonsense mutation 1122G→A, resulting in W374X premature stop codon, as 
identified in 32 patients. These patients usually presented in early infancy and had typical 
clinical and laboratory parameters of FHL [263]. In this study, it was demonstrated that 
age at onset of FHL II depended on the functional impact of the PRF1 mutations. Patients 
with two null mutations had a significantly younger age at diagnosis than patients with a 
combination of one null and one missense mutation or patients with two missense 
mutations. Another conclusion drawn from this study was that certain mutations were 
predominant in certain ethnic groups, such as 91delCT mutation, resulting in L364 in 
Japanese patients and 50delT(L12fsX) in patients with African ancestry implying that 
these were founder mutations in these ethnic groups [263]. 
 
The perforin gene variant A91V (272C>T) has received considerable attention in recent 
literature. This variant was first reported in two siblings who developed late-onset FHL in 
their early 20s. Both also carried a second disease-causing PRF1 mutation [268]. The  
A91V-PRF1 substitution has been variably reported as a non-pathogenic variant, [269] 
[270] [271] a genetic susceptibility factor [272] , and as a disease-causing mutation [273]. 
This variant is also prevalent in healthy individuals at a rate of about 8-9% in Caucasian 
subjects in population-based studies [273]. A91V has also been shown to predispose to 
several non- FHL diseases, such as  childhood acute lymphoblastic leukaemia and some 
B and T Cell lymphomas [273]. To study the effect of this variant in FHL when co-
inherited with both PRF and hMunc13-4 mutations, Zhang et al in 2007 investigated its 
prevalence in 150 unrelated FHL patients from a North American cohort [274]. They 
found that the heterozygous A91V-PRF1 genotype was significantly more common in 
patients with FHL compared to race-matched controls (16% vs. 3%, P < 0.01). They also 
observed that 42% patients with A91V-PRF1 genotype also carried additional 
mutation(s) in either PRF1 or hMunc13-4 and concluded that A91V-PRF1 was unable to 
cause a disease phenotype on its own but might represent a genetic susceptibility factor 
for immune dysregulation [274]. The functional effect of this variant has also been 
investigated. Using three different experimental approaches, (primary CTLs, RBL-2H4 
cells, and purified protein), Voskoboinik et al in 2007 demonstrated that the A91V 
substitution in perforin caused both pre-synaptic (reduced steady state levels of 
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expression) and post-synaptic (reduced lytic capacity and a mild dominant negative 
effect) defects [273]. Nonetheless, despite the major intrinsic dysfunction of A91V-PRF 
CTLs, there was a relatively mild impact on the function of primary 
CTLs. The authors postulated that the diminished lytic capacity of the variant perforin 
was probably partly compensated in CTLs by synergy with other pro-apoptotic 
components of secretory granules, such as granzymes, to destroy target cells. They 
proposed that inheritance of a homozygous A91V substitution could predispose to disease 
associated with partial immune deficiency only, whereas when inherited in compound 
heterozygosity with a second perforin allele with “null” activity, could be disease-causing 
[273].
 
 
Figure 1.14. Details of 63 PRF1 mutations noted in 124 patients from the FHL registry 
of the Histiocyte Society in 2008 
Letters in bold indicate novel mutations noted in the study [263]. 
 
Recently, the role of perforin in diseases other than FHL has been investigated. It had 
been previously reported that perforin knockout mice develop spontaneous 
haematological cancers [275] and in a series of 29 lymphoma patients, biallelic PRF1 
mutations was found in 4 individuals, highlighting a putative role of perforin in cancer 
immunosurveillance [276]. In 2009, Chia et al examined perforin function in every 
patient reported in the literature that lived to at least 10 years of age without developing 
FHL despite possessing bilallelic PRF1 mutations and found that 50% of these patients 
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developed at least one hematological malignancy in childhood or adolescence. They also 
identified that these patients had PRF1 alleles encoding temperature-sensitive missense 
mutations [277]. The authors demonstrated that these mutations led to protein misfolding 
that was rescued in lower temperatures. They postulated that a mutated protein may have 
an increased chance to acquire a native folded state upon reduction of temperature, 
causing symptoms to appear later in life, thereby unmasking a predisposition to 
hematological cancer by extending the patient’s lifespan owing to escape from FHL II 
symptoms in childhood [278]. Perforin has also been implicated in development of 
cerebral malaria [279] and Type 1 diabetes mellitus following study in perforin knockout 
mice [280]. 
1.1.8.4 Mechanism of vesicle transport in cytotoxic lymphocytes and associated human 
disease 
 
After killer cell recognition of a target, cytotoxic granules are transported along 
microtubules and cluster around the MTOC. Then, after the polarised MTOC and 
centrosomes contact the plasma membrane, cytotoxic granules are delivered to the IS, 
where fusion with the plasma membrane occurs [157]. So far, genes responsible for 
causing FHL other than perforin all encode proteins that have been implicated in lytic 
vesicle exocytosis, thereby causing impaired delivery of cytotoxic molecules to the IS 
and inability of cytotoxic lymphocytes to mediate target cell lysis, leading to the clinical 
syndrome of HLH. Study of cells lacking these proteins have been vital in highlighting 
the mechanism of lytic vessel exocytosis and perforin delivery to the IS.  
1.8.4.1 the role of hMunc 13-4 in cytotoxic granule trafficking and FHL III 
 
Munc 13 proteins constitute a family of proteins expressed principally in brain tissue and 
Munc13-1 plays a central role in neuronal synaptic vesicle priming and exocytosis [281] 
[282]. Protein structure of hMunc13-4 is similar to that of other Munc proteins and 
contains two C2 domains, C2A and C2B, separated by long sequences containing 2 
regions called Munc homology domains, designated MHD1 and 2, respectively, see 
figure 1.15. The C2 domains are putative Ca++ binding domains and the C2A domain is 
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also thought to be involved in membrane binding. Additionally, the C2A domain might 
also serve to bind to other effector molecules based on structural homology with other 
Munc proteins [228]. Munc proteins have structurally variant N- terminal regions but 
similar C-termini. The N terminal region of Munc-13-1 has been shown to bind to RIM1, 
a rab3 effector with a putative role in vesicle tethering [282]. The conserved C terminal 
domain of Munc13-1 has interaction sites for several Munc 13 effector molecules such as 
Syntaxin and has been shown to be necessary and sufficient for vesicle priming in 
chromaffin cells [283]. Thus, Munc 13-1 acts as dual function molecules necessary for 
vesicle priming as well as tethering [228]. Unlike Munc 13-1,2 and 3, which are 
principally expressed in brain tissue, hMunc13-4 is almost absent in brain tissue but 
widely expressed in haemopoietic tissue as well as other tissues such as lung and 
placenta. 
 
 
Figure 1.15. hMunc13-4 domains and corresponding exons. 
hMunc13-4 contains two C2 domains, C2A and C2B, separated by long sequences 
containing 2 regions called Munc homology domains, designated MHD1 and 2, 
respectively. The C2 domains are putative Ca++ binding domains and the C2A domain is 
also thought to be involved in membrane binding.  
Adapted from Santoro et al J Med Genet 2006; 43:953–960 [284] 
 
Feldmann et al, in their first report linking hMunc13-4 mutations to FHL III indicated 
that hMunc13-4 was not required for vesicle polarisation or vesicle docking at the IS.  
Confocal and electron microscopy studies clearly demonstrated that Munc-13-4 deficient 
CTL lytic granules polarise normally towards the IS [228]. Furthermore, they also 
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demonstrated that only the lytic function of FHL III CTL was abrogated; the cells were 
able to secrete IFNγ normally. As an intact and functional IS is required for the secretion 
of IFNγ [101], this finding demonstrated that hMunc13-4 was not required for the 
formation of the IS and its secretory function. The lytic capacity of the hMunC13-4 
deficient CTLs were severely impaired, despite the observation that a number of lytic 
granules were seen to associate with the plasma membrane at the IS, in contrast to 
Griscelli Syndrome CTLs [44]. This led Feldmann et al to propose that hMunc13-4’s role 
in the granule exocytic pathway was downstream of Rab27a where it might be involved 
in vesicle priming, enabling the vesicles to attain a fusion- competent state, prior to 
vesicular membrane fusion [228].  hMunc13-4 has  subsequently been identified as one 
of the effectors of Rab27a, potentially  connecting granule movement to granule docking 
[285] [286]. The interaction of hMunC13-4 and Rab27a in the vesicular exocytic pathway 
was studied by Menager et al in 2007 by using CTLs that were transiently transfected 
with fluorescent protein tagged hMunC13-4 and Rab27a [157]. They demonstrated that 
hMunc13-4 has a dual function in cytotoxic cells. At an early step, hMunc13-4 mediated 
a Rab27- independent attachment of recycling and late endosome structures associated 
with Rab11, Rab27 and Rab7. The authors proposed that upon engagement of a target 
cell by a CTL, cytotoxic granules reached the IS as conventional lysosomal structures, 
whereas Rab27a and hMunc13-4 were transported towards the IS in the so called 
‘exocytic vesicles’, structures that were thought to be assembled by Munc13-4 and that 
these two distinct endosomal structures fused at a later stage of polarisation towards the 
IS by an unknown mechanism. Following docking of lysosomes at the IS, hMunC13-4, 
also caused them to achieve a Rab27a-dependent primed, fusion-competent state. [157]  
Patients with FHL III, caused by mutations in hMunc13-4, have a clinical syndrome that 
is indistinguishable from that of perforin-deficient FHL (FHL II) [2], with median age at 
diagnosis of 3-4 months [287]. In a recent study from Sweden where 74 children with 
FHL from Nordic, Middle Eastern and Turkish families were analysed for mutations in 
PRF, hMunc13-4 and STX-11 genes, 10% of children were noted to have hMunc13-4 
mutations [288]. 
 
Another study published earlier by the same group focussed mainly on the PRF and 
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STX11 negative FHL cases, and the researchers observed that hMunc13-4 mutations 
were responsible for 18% of such cases, the remainder had no mutation in all three genes 
studied. This was in accordance with an earlier report from a German cohort [289] but 
was lower than that reported by Japanese [290] and Italian groups [284], where 36% and 
50% of PRF1 mutation negative families respectively were found to have hMunc13-4 
mutations, highlighting the racial heterogeneity of hMunc13-4 mutations.  Three types of 
hMunc13-4 mutations have been described; nonsense, missense, and splice site 
mutations. Both of the novel nonsense mutations identified in the Swedish study [287] 
predicted to cause a truncation of the protein, resulting in a partial or complete loss of the 
region responsible for binding Rab27a. NK cell cytolytic activity of a child carrying such 
a mutation was very low at 4 hours as well as with prolonged incubation of 16 hours but 
cytolytic activity was increased following IL2 exposure [287]. Some patients with 
missense mutations have absent mature protein on immunoblotting. This has been 
explained by either decreased protein stability or disrupted splicing [284]. 
Although the median age at presentation is 3-4 months, some patients with FHL III 
present at a much older age, with the oldest age reported was 18 years by Santoro et al 
[284]. This individual had an 1874A>G splice mutation. In total, 4 patients in the Santoro 
cohort had the 1847A>G splice mutation- analysis of cDNA products from these patients 
showed that this mutation, which occurs in the U1 recognition site involved in splicing, 
lead to alternative splicing and loss of functional protein [284]. Although not 
experimentally validated, it has been postulated that a correlation exists between 
hMunc13-4 mutations with late onset disease that allow residual protein activity and a 
low residual cytolytic ability [287]. 
In order to aid rapid clinical diagnosis and identification of individual subtypes of FHL, 
e.g. FHL II (perforin deficient) and FHL III (hMunC13-4 deficient), researchers have 
devised and validated a flowcytometry based assay of secretory lysosome degranulation 
upon activation. Using the lysosomal marker CD107a (LAMP1) that transiently 
associates with the lymphocyte cell membrane when CTLs or NK cells are activated 
[291], researchers were able to differentiate FHL III (where impaired degranulation leads 
to significantly reduced CD107a staining) and FHL II where there is normal 
degranulation but defective cell killing due to perforin deficiency [292].  
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1.1.8.5 Role of Rab27a in cellular cytotoxicity and syndromes linking 
hypopigmentation and immunity 
Rab proteins regulate and control vesicle formation, organelle motility and the docking of 
vesicles to specific membranes and belong to a family of small Ras-like GTP binding 
proteins [150]. About 70 different Rab proteins have been described in humans and these 
proteins have significant structural homology. When active, Rab proteins are GTP bound; 
converting to their GDP-bound inactive state confers these proteins with a simple 
‘switch’ mechanism to terminate interactions [150].  
Organelle motility has been described as a four-step process that consists of: a) formation 
of a vesicle, b) movement of the vesicle towards its target compartment, c) tethering or 
docking with the acceptor membrane and d) fusion of the lipid bilayers. [155]. 
Rab-mediated attachment of a vesicle to the correct target organelle is the first specific 
event in organelle motility. The SNARE hypothesis predicts that all eukaryotic cells 
should have families of vesicle- (v) and target (t)-SNAREs whose members should form 
cognate pairs on the basis of membrane specificity and should be the central mechanism 
of membrane binding in vivo [293] (Figure 1.16). Specific pairing of cognate SNAREs in 
results in a specific fusion event [294] [295]. Rab proteins and their effectors regulate 
such specific pairing of SNARE complexes during membrane tethering and fusion [155]. 
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Figure 1.16. The SNARE hypothesis 
Each transport vesicle in the eukaryotic cell is proposed to have one or more unique v- 
SNARE that specifically pairs with its cognate t-SNARE, thereby docking the vesicle to 
its correct target. Only v-SNAREs and their corresponding cognate t-SNARES are 
shown with the same colour in the diagram. Adapted from Rothman J, Nature 1994, 
272(3) [294]. 
 
In order to attach to membranes, Rab proteins must be prenylated [150].This post-
translational modification occurs in association with the Rab Escort Protein (REP), which 
interacts with unmodified Rab, forming a complex which is then bound by Rab 
geranylgeranyl transferase (RGGT), the latter then serving to add two phenyl groups to 
the Rab at two C-terminal cysteine residues. REP transfers the prenylated Rab to its 
destination membrane [296]. 
Besides mediating membrane fusion events, Rab proteins can also regulate the movement 
of vesicles and organelles along the cellular cytoskeleton. Rab6 has been shown to 
interact with rabkinesin, an effector molecule involved in microtubule based movement 
[297]. Rab proteins have also been shown to interact with the actin and myosin 
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cytoskeletal elements. Such an interaction is absent in Griscelli Syndrome, a 
heterogeneous group of rare autosomal recessive disorders characterised by defective 
pigmentation of the skin and hair due to an abnormal accumulation of melanosomes in 
melanocytes and/or abnormal cellular cytotoxicity with an associated HLH syndrome due 
to ineffective lytic granule movement [150]. 
The study of melanosomes, specialized secretory vesicles involved in skin pigmentation, 
has provided insights into the mechanisms of Rab proteins and their effector molecules in 
controlling lysosomal movement [298]. One important difference between melanocytes 
and CTLs is that, in melanocytes, the MTOC remains perinuclear and melanosomes 
move in a plus-ended direction along microtubules to reach the plasma membrane before 
secretion, unlike in CTLs where the granules move towards a minus ended direction to 
reach the MTOC upon T Cell activation, see above [298]. The combination of immune 
deficiency and albinism in humans as their murine counterparts highlight the importance 
of a common vesicular secretory machinery. See table 1.4. 
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Table 1.4. Diseases of secretory lysosomes. Human diseases and their mouse models 
giving rise to defects in secretory lysosomes.  
Mouse 
mutant  
Defectiv
e gene 
Human 
Syndrome 
Defective 
Cells 
Associate
d HLH 
Complex 
Beige LYST Chediak 
Higashi 
Syndrome 
Immune 
cells and 
melanocyte
s 
Yes Unknown 
Ashen RAB27
A 
Griscelli 
syndrome 
Type 2 
Immune 
cells and 
melanocyte
s 
Yes Rab27a/MyoV/Melanophil
in complex 
Leaden MLPH Griscelli 
syndrome 
Type 3 
Melanocyte
s 
No Rab27a/MyoV/Melanophil
in complex 
Gunmeta
l 
Rabggta No 
equivalent 
human 
phenotype 
Immune 
cells, 
melanocytes
, platelets 
Not 
applicable 
Transient with Rabs 
Pearl HPS2 Hermansk
y Pudlak 
syndrome 
Immune 
cells, 
melanocytes
, platelets 
Yes AP-3 
Dilute MYO5A Griscelli 
syndrome 
Type 1 
melanocytes No Rab27a/MyoV/Melanophil
in complex 
 
1.1.8.5.1 GS arising as a result of Rab27a deficiency (GS2) 
 
Patients with GS2 often present with a HLH syndrome that is indistinguishable from that 
of FHL, although patients also suffer from hypopigmentation, which can be subtle and 
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easily missed in fair-haired populations [299]. GS2 was shown to occur as a result of 
mutations in the Rab27a gene [44] and its naturally-occurring mouse mutant counterpart 
has the ashen phenotype [300]. A recent study from Sweden reported that age at 
presentation of GS2 can vary form 2 months to 13 years and clinical course is 
complicated by neurological impairment in two-thirds of cases. The neurological 
sequelae are thought to be as a result of HLH and not directly as a result of Rab27a 
mutations [301]. Treatment of children presented with GS2 is similar to FHL and the 
resulting HLH syndrome requires chemoimmunotherapy and HSCT [301]. 
CTLs and NK cells in patients with GS2 have impaired cytotoxicity, resulting from the 
inability of these cells to release their lytic granule contents [44]. As with Munc13-4-
deficient lymphocytes, Rab27a deficient CTLs can normally form stable conjugates with 
target cells and polarise lytic granules but the polarised lytic granules are unable to dock 
at the plasma membrane at the IS [2]. 
Like many other Rab proteins, Rab27a is also a substrate for prenylation by RGGT. Two 
prenyl groups are anchored to mature melanosomes, which bind to two conserved 
cysteine residues located at the C-terminal end of Rab27a. This implies that like many 
other Rab proteins, Rab27a is also involved in targeting, docking, and fusion of transport 
vesicles [302]. Given that Rab27 was shown to associate with lytic granules, Menasche et 
al [2] proposed that following lymphocyte activation, the cytosolic inactive GDP-bound 
form of Rab27a switches to an active GTP-bound form targeted to the lytic granules. This 
active form of Rab27a then interacts with a specific effector complex in the cytotoxic 
cells, allowing the lytic granules to reach and dock at the plasma membrane.  
Several Rab27 effector proteins have been described, such as synaptotagmin like proteins 
(Slp), Slp homolog lacking C2 domain (Slac2), and Rab3-binding domain. The effector 
proteins possess a Rab27-binding domain at the N-terminus [303]. 
The Slac2 family of Rab27 effectors comprises of Slac2-a/melanophilin, Slac2-c/MyRIP 
and Slac2-b [304] [305]. Slac2-a and Slac2-c regulate actin-based transport of 
melanosomes by interacting with the molecular motors myosin-Va and myosin-VIIa, 
respectively, in the skin and retinal melanocytes [2]. In addition, a direct interaction 
between Rab27a and hMunc13-4 has also been demonstrated, suggesting that Rab27a 
also may be involved at the priming step of lytic granules [157]. Furthermore, it was 
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demonstrated that following TCR engagement with a target cell, Rab27a is assembled 
into a distinct endosomal compartment that polarises towards the IS independently of 
perforin-containing granules. This assembly was shown to be mediated by hMunc 13-4 
[157]. The same group also recently identified a novel synaptotagmin-like protein 2a 
(Slp2a) isoform specific to haemopoietic cells and brain tissue that is recruited by Rab27a 
to the same endosomal compartment upon TCR activation signaling and a complex 
consisting of this Slp2a isoform and Rab27a colocalises with perforin granules at the IS. 
The interaction between Slp2a and Rab27a is proposed to allow cytotoxic granules to 
dock at the plasma membrane [306]. 
 
1.1.8.5.2 GS in the absence of HLH 
 
Griscelli Syndrome Type1 (GS1) is characterized by hypopigmentation and severe 
neurological impairment such as hypotonia and severe developmental delay and has been 
shown to occur due to mutations in MYO5A. HLH-like symptoms are typically absent in 
GS1 [307]. MYO5A lies in the same 15q21 chromosomal region as RAB27a. MYO5A 
encodes the molecular motor protein myosin-Va, a 215-kDa protein, implicated in vesicle 
transport in cells and is abundant in neurons and melanocytes. Although expressed in 
hematopoietic cells, including cytotoxic cells, myosin-Va defect is not associated with 
defective cytotoxic activity [2]. MYO5A mutant mice, the dilute mice, also have 
hypopigmentation and neurological abnormalities such as opisthotonus and ataxia, and is 
fatal within 2-3 weeks after birth [308]. Slac2a/Melanophilin mutation has been reported 
to cause the typical hypopigmentation of GS in the absence of neurological or 
immunological abnormalities, defining GS type3. Melanophilin is a Rab27 effector in 
melanocytes only. Its murine counterpart is the leaden mouse, which harbours Mlph gene 
mutations [309]. 
Melanosome movement in melanocytes is dependent on interaction between the three 
proteins Rab27a, MyosinVa and melanophilin (Figure 1.17). Analyses in mouse models 
have demonstrated that Rab27a first associates with the membrane of melanosomes and 
then interacts with the Slp homology domain of melanophilin, which recruits myosin-Va 
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through its tail region. Binding of the head domain of Myo-Va to actin filaments links 
melanosomes with the peripheral actin network [2]. 
 
Figure 1.17. Mechanism of melanosome movement along microtubules in melanocytes 
Melanosomes can either be dispersed throughout the cell (a mechanism driven by the 
motor protein kinesin 2) or be aggregated in the cell centre, facilitated by cytoplasmic 
dynein. Kinesin 2 and dynein both compete for the same binding site of p150Glued on 
the dynactin complex and the dynein –mediated melanosome aggregation is augmented 
by the recruitment of myosin Va via the actin cytoskeleton. RAB27a recruits myosin Va 
to melanosomes through melanophilin in preparation for melanosome transfer to 
keratinocytes. Myosin Va and melanophilin track the microtubule plus end through an 
interaction with microtubule plus-end-binding protein-1.  
Adapted from Soldati et al, Nature Reviews Molecular Cell Biology 2006 [310] 
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The exact mechanism in which Rab27a affects cytotoxic granule exocytosis is still not 
clear. Further work will need to highlight the role of other, yet undefined effector 
molecules involved in vesicle transport. 
1.1.8.6 FHL IV, FHL V and role of Syntaxins in granule mediated exocytosis 
 
SNARE-mediated membrane fusion and Rab-mediated membrane docking and tethering 
are critical factors in vesicular transport. Upon successful tethering and priming, the 
SNAREs engage in trans-interactions between vesicle and target- SNAREs. This 
interaction leads to closely apposed membranes, resulting in fusion [155]. A SNARE 
complex contains a four-helix bundle including a v-SNARE (synaptobrevin/VAMP), a t-
SNARE (Syntaxin) and two molecules of either SNAP25 involved in neuronal complexes 
or SNAP23 in complexes associated with fusions in non-neuronal cell types [311] (Figure 
1.18).  
The third genetic mutation causing FHL, designated FHL IV, was identified in 2005 by 
genome-wide homozygosity mapping followed by positional candidate genes screening 
in a large consanguineous Kurdish kindred with five children affected with FHL. A 
homozygous deletion of 5 bp in the gene encoding a Syntaxin 11, a SNARE protein, was 
identified [229]. In addition to this family, homozygous mutations in STX11 gene were 
also found in five other consanguineous Turkish/Kurdish FHL kindred. Due to the 
putative role of Syntaxin 11 in the cytotoxic granule exocytic machinery, FHL IV was 
also proposed to occur as a result of the disruption of this machinery [229]. Although 
earlier reports indicated that STX11 mutations were only restricted to patients of Turkish 
Kurdish ethnicity [229] [288], a recent report has identified a novel STX11 mutation in 3 
unrelated, Argentinean patients with FHL, two of whom were from non-consanguineous 
families [312]. 
Patients with FHL IV have a clinical syndrome similar to other subtypes of FHL, but the 
median age at presentation is higher, reported at 14.4 months in one study. This was in 
contrast to 2.3 and 6.3 months in FHL II and FHL III, respectively [288]. 
Functional studies in cytotoxic lymphocytes form patients with FHL IV indicated that 
freshly isolated syntaxin11-deficient (FHL IV) NK cells failed to degranulate upon 
activation, but degranulation was partially restored by exposure to IL2 [232]. The authors 
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proposed that IL2 mediated restoration of NK cell lytic function could explain the later 
onset of FHL IV, and longer periods of remission without specific treatment that was 
often seen in FHL IV patients, unlike their FHL II and FHL III counterparts [232]. 
Syntaxin 11 is a member of the family of soluble t-SNARES [313] [311]. It is composed 
of 287 amino acids containing a Qa soluble SNARE motif from amino acids 201 to 277 
[314] [315] and is expressed in NK cells, CD8+T cells, and in the NK-cell line NK92 
[232]. 
Vesicular fusion normally requires the formation of a complex consisting of SNARE 
proteins, which combine to contribute alpha-helical Qa, Qb, Qc, and R-SNARE domains 
to a complex that drives membrane fusion [316] (Figure 1.18).  
Syntaxin11 contains a short cysteine-rich C-terminal tail instead of a hydrophobic 
membrane anchor that normally serves as a membrane-targeting palmitoylation site in 
other syntaxins [317] [318]. Despite the lack of this membrane anchor, C-terminal 
segment of syntaxin11 has been proposed to be required for degranulation, because 
lymphocytes from patients with the Q268X mutation, expressing a truncated syntaxin11 
protein lacking the 20 C-terminal amino acids failed to degranulate, indicating that this 
functional defect accounted for the prevalence of FHL in children homozygous for this 
mutation [287] [232]. Besides, syntaxin11 was retained in detergent-treated membrane 
protein fractions, [319] co-precipitates with SNAP23 in B cells [314] and SNAP23 was  
experimentally proven to be a binding partner of syntaxin11 in vivo [319]. The exact 
mechanism by which FHL occurs as a result of STX11 mutation is not entirely clear. 
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Figure 1.18. The SNARE conformation cycle during vesicle docking and fusion. 
Three target membrane SNAREs (Q-soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors) and a vesicular R-SNARE have been shown in this 
diagram. Q-SNAREs are organized in clusters and assemble into acceptor complexes 
and interact with the vesicular R-SNAREs, thereby nucleating the formation of a four-
helical transcomplex, the latter proceeding from a ‘loose’ to a ‘tight’ state, followed by the 
opening up of the fusion pore. In regulated exocytosis, this step is controlled by 
synaptotagmin. During fusion, the strained trans-complex relaxes into a cis-
configuration. Cis-complexes are disassembled by the cofactors NSF (N-ethylmaleimide-
sensitive factor) and SNAPs (soluble NSF attachment proteins).  
Adapted from John et al Nat Rev Mol Cell Biol 2006 7(9)641-643 [316] 
 
In 2009, a fifth FHL locus was assigned to a 1 Mb region on chromosome 19p by using 
high-resolution SNP genotyping of FHL patients by two groups independently [230, 
231]. Both groups identified either truncating or missense mutations in the gene encoding 
Syntaxin-binding protein 2 (also known as Munc18-2, official gene symbol STXBP2) 
and designated it FHL V. 
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Cote et al studied a cohort of 6 consanguineous families with known FHL, who did not 
harbour mutations in PRF1, hMunC13-4 and STX11 genes. They were of Saudi Arabian, 
Turkish and Iranian ethnicities [231]. They identified 2 different homozygous missense 
mutations in STXBP2- 1430C>T, giving rise to P477L and a homozygous splice 
mutation resulting in the use of cryptic acceptor and donor splice sites at intron 14 (1247-
1G>C ;IVS14-1G>C). A strong genotype/phenotype correlation was identified because 
all patients with P477L substitution had a very early onset of disease that rapidly led to 
death in most cases whereas FHL manifestations occurred several years later in all 
patients with the in-frame splice site mutation [231]. All patients with the P477L 
substitution were of Saudi Arabian origin, as was observed by both groups. Additionally, 
zur Stadt et al identified several other STXBP2 mutations; 260delT, 693_695delGAT, 
706delG, 626T>C, 875G>A, 1213C>T and 1214G>A and patients from Northern and 
Central European ethnicities were also represented in the cohort of FHL V patients. 
STXBP was found to express in cytotoxic lymphocytes and was shown to colocalise with 
STX11 in CTLs and NK Cells, which was confirmed by direct coimmunoprecipitation 
experiments [230]. Remarkably, FHL V patients who had absent expression of STXBP2 
on immunoblotting, such as those carrying the P477L substitution, also had absent 
STX11 expression but the reverse was not true of FHL IV patients lacking a functional 
Syntaxin11 protein, confirming the hypothesis that the expression of Syntaxin11 
depended entirely on that of Syntaxin Binding Protein 2. However, patients with in-frame 
splice site mutation of STXBP2 had normal expression of both proteins [231]. Functional 
assays by Cote et al revealed that FHL V NK cells showed normal polarisation of lytic 
granules upon target cell engagement but failed to degranulate in ADCC and natural 
cytotoxicity assays and like FHL IV, IL-2 treatment partially restored degranulation. In 
contrast, CTL degranulation was not remarkably impaired. 
STXBP2 is part of the Sec1/Munc18 family of fusion accessory proteins. These proteins 
clasp SNARE’s 4-helix bundle and the two play complementary roles in membrane 
fusion. [320] [321]. The role of Sec1/ Munc18 proteins in vesicle exocytosis has been 
studied in the STXBP1 knockout mouse model where neurotransmitter release is 
completely abrogated. [231]. STXBP2 has been conclusively shown to be required for 
stable expression of Syntaxin11, and FHL IV and FHL V appear to share clinical as well 
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and cellular functional phenotype. Although the exact role of Syntaxin11 in the cytotoxic 
granule exocytosis has not been experimentally proven, it is clear that the two proteins act 
in conjunction to help deliver the ‘lethal hit’.  
1.1.8.7 FHL I  
 
One of the outstanding issues in the molecular genetics of FHL is the identity and 
function of the gene mutated in FHL type 1. In fact, identification of the gene causing 
FHL I is the primary objective of my project. 
The FHL I locus was the first to be linked to FHL in 1999, by homozygosity mapping of 
4 consanguineous families of Pakistani origin where the proband presented with an HLH-
like syndrome in early infancy. It was mapped to 9q21.3-22 through a conventional 
genome-wide screen involving 342 microsatellite markers [223]. In total, 5 
consanguineous families were studied, but linkage was identified only in 4 families, all of 
whom were of Pakistani descent. The fifth family, of Arabic descent, failed to 
demonstrate linkage to the locus in chromosome 9q, highlighting the possibility that there 
was genetic heterogeneity in FHL; which was indeed proven to be the case, as 
subsequently other loci and genes causally linked to FHL were identified. 
Figure 1.19 illustrates the disease haplotypes of FHL I in the families investigated in the 
study of 1999 by Ohadi et al. The researchers initially selected 342 fluorescent- labelled 
PCR primer pairs to amplify highly informative microsatellite loci from the Genethon 
human linkage map [322] covering 22 autosomal chromosomes at an average distance of 
about 10cM. At initial screening, a single locus of homozygosity in the affected 
individuals of three Pakistani families and in none of the unaffected siblings was 
identified at D9S167. Further analysis revealed another homozygous locus in all affected 
individuals of the same families at D9S283, 12cM telomeric to D9S167, and a 
heterozygous marker at D9S175 14cM centromeric to D9S167, establishing linkage of 
the disease gene in these families to marker D9S167 and limiting the centromeric and 
telomeric boundaries to D9S175 and D9S283, respectively. 
The researchers then selected 9 microsatellite markers between D9S175 and D9S283 to 
confirm and narrow the disease gene interval. As indicated in Figure 1.19, homozygosity 
was observed in all the Pakistani families (kindred 1-4) between and excluding markers 
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D9S1867 and D9S1790, limiting the disease interval to about 7.8cM and yielding a 
highly significant maximum multipoint LOD score of 6.05. No linkage was observed in 
kindred 5, who were of Arabic descent. 
Further analysis of the haplotype data reveals that although a fraction of the disease- 
linked haplotypes is shared between families (for instance, kindred 1 and 2 share the 
haplotype 3-3-1 at D9S1877, D9S1865 and D9S1790), the majority of the haplotypes are 
disparate. Besides, D9S1877-3, D9S1865-3 and D9S1790-1 are the most frequently 
encountered haplotypes in Pakistani populations (unpublished data), hence their 
homozygosity in the affected individuals do not help narrow the disease interval. At a 
casual glance, this therefore excludes a founder mutation, although it must be borne in 
mind that the physical distance between markers D9S1877 and D9S1790 is considerable, 
and the possibility that investigating this area with finer mapping could potentially still 
reveal a founder effect cannot be ruled out.  
There has been no functional data available form the study of Ohadi et al [223], from 
which my project follows. It is therefore not known whether the affected individuals 
reported in that study harboured any defect in the activity of their cytotoxic lymphocytes. 
However, since the four genes that have subsequently been causally linked to FHL all 
share a common cellular phenotype of abnormal lymphocyte cytotoxicity, it is fair to 
assume that patients with FHL I would also be the same. 
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Figure 1.19. Allele segregation of linked and flanking markers in FHL I families 
Disease-linked haplotypes are boxed, see text. [223] 
 
In summary, the identification of the genes and their functions responsible for FHL as 
well as genetic disorders leading to a HLH phenotype has enormously helped in 
unravelling the mechanisms involved in granule mediated cytotoxicity and its role in 
immune haemostasis and immunosurveillance against malignancy. It is clear that a large 
number of molecular mechanisms in this highly regulated cellular machinery still remains 
to be identified.  
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1.1.9 Aim of my project  
The aim of my project was to identify the gene responsible for FHL I and study the 
function of the implicated gene in the context of cytotoxic lymphocyte function. 
Identification of the mutated gene and its function will help resolve some of the issues 
that are still outstanding in our understanding of the biology of lymphocyte cytotoxicity. 
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Chapter 2. Patients, Materials and Experimental Methods 
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2.1 Patient and parental cells 
 
2.1.1 B-Lymphoblastoid cell lines 
  
At the outset of this project I analysed EBV transformed B cell lines from individuals 1 
(PP0150), 10 (PP0180) and 13 (PP0225) of kindred 1, 2 and 3 respectively, as reported in 
the Ohadi study [223], from which my current study follows, (Figure 1.19). All three cell 
lines were established from cells obtained from parents of affected individuals and were 
therefore presumed to be heterozygous for the putative FHL I gene. Along with these, I 
also studied the parental cell line PP0277 from a family subsequently linked to the FHL I 
locus, but not included in the Ohadi study [223], (Figure 2.1a).  None of the probands 
described in the study had enough cells available for EBV transformation and 
immortalisation. The only cell line established from cells obtained from an affected 
individual linked to the FHL I locus was PP0231 (Figure 2.1b). This individual was also 
not included in the original study. Therefore, I initially worked with genomic DNA as 
well as cDNA from B cell lines from a total of five FHL I families. Due to constraints in 
available cellular material, none of these individuals were parental-proband trios, and 
were in fact all unrelated to one another.  
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a) B Cell line PP0277     b) B Cell line PP0231 
 
 
Figure 2.1. Family tree of FHL I locus- linked kindred not included in the Ohadi et al 
paper [223] 
B Cell line PP0277 corresponds to the father of the proband of the family depicted in 
Figure 2.1 a. 
PP0231, the B Cell line derived from an affected individual (female) is depicted in Figure 
2.1b.  
Disease-linked haplotype is boxed. Values correspond to microsatellite markers linked to 
the FHL I locus.  Further analysis of the haplotypes reveal the presence of two 
recombination events (marked with an ‘x’) on the maternal side in the family depicted in 
figure 2.1a and one recombination event in the maternal side in the family depicted in 
figure 2.1b. This data was obtained at the time of the publication of the Ohadi et al study 
[223] but was not included in the paper.  
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2.1.2 Patients recruited to the current study 
 
My study was approved by the National Research Ethics Service as a multi-centre 
prospective study, allowing for sample collection from patients, parents and siblings. Site 
-specific approval was obtained from individual hospital ethics committees. 
The entry criteria for my study were: 
1. Clinical and biochemical diagnosis of FHL in accordance to the current diagnostic 
guidelines of the Histiocyte Society (see table 1.2). 
2. Indian, Pakistani or Bangladeshi origin. 
3. Normal perforin expression on flow-cytometry and/or normal PRF1 genotype.  
Table 2.1 New patients recruited to my study 
 
Family Patient 
identifier 
Consanguineous Gender Age at 
diagnosis 
Father’s 
origin 
Mother’s 
origin 
1 RS No Female 5y Bangladeshi Pakistani 
2 AK No Female 9 months Pakistani Pakistani 
 
I had access to one parent-proband trio (family 1) and proband and maternal blood 
samples only in family 2. 
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2.1.3 Cryopreserved patient samples  
 
During the course of my study, there were no further new patients diagnosed with FHL in 
the UK who fulfilled all the recruitment entry criteria. However, I was kindly given 
access by Dr Andy Gennery of Royal Victoria Hospital, Newcastle, to cryopreserved 
PBMC’s from 2 patients who were diagnosed in the past and had either been treated 
successfully by haemopoietic stem cell transplantation or had succumbed to their disease. 
In both cases, written consent had been previously obtained by their clinicians for their 
samples to be used for research purposes. Demographic and clinical details of these two 
patients are detailed in Table 2.2. 
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Table 2.2. Patients from whom cryopreserved samples were obtained 
 
Patient identifier AM (male) NA (female) 
Ethnic origin  Pakistani Pakistani 
Consanguineous Yes Yes 
Age at first presentation 9 years (1995) 2 months (2001) 
Nature of first presentation Pneumonia & empyema 
Age 7 
Glomerulonephritis Age 8 
Clinical HLH age 9 and 10 
with EBV viraemia 
 
Unwell post first routine 
immunisation- febrile, 
lymphadenopathy, 
hepatosplenomegaly 
Other significant family 
history 
Nil Cousin had Omenn 
Syndrome 
Age at SCT 10y 3 months 
Cellular workup at 
presentation 
Normal CD3 and CD19 
count 
Normal NK count 
 
Low CD3 and CD19 
counts 
Normal NK count 
Normal TCR V beta 
distribution 
Molecular workup SAP gene –WT 
Perforin genotype WT 
RAG1 mutation not 
detected 
perforin/Munc genotype- 
not available 
Histology at diagnosis CNS haemophagocytosis LN biopsy showed 
depletion of B cell 
numbers and a large 
number of NK cells and a 
few T cells 
CNS: central nervous system, LN: lymph node WT: wildtype 
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2.1.4  Other patients and families studied in the course of my current project 
 
I also studied one consanguineous Pakistani family where the proband succumbed to 
HLH but the unaffected sibling (male, age 10 years at the time of recruitment to my 
study) was regularly followed up by a Paediatric Haematology centre. Peripheral blood in 
anticoagulant (EDTA) was available from both parents and unaffected sibling for study.  
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2.2 Molecular Techniques 
 
2.2.1 Nucleic Acid extraction 
 
2.2.1.1 DNA extraction 
 
Genomic DNA from B cell lines and from primary cells was extracted using the Qiamp 
DNA minikit (Qiagen) as per manufacturer’s instructions. The extraction process 
involved the use of enzymes and buffers that were optimised to lyse the samples, stabilise 
nucleic acids and improve DNA absorption to silica- gel membrane containing columns. 
Wash buffers were used to remove impurities and pure DNA was eluted out of the 
membrane by water or a low salt-containing buffer. The DNA thus obtained was 
quantified by the NanoDrop 2000 spectrophotometer (Thermo Scientific), which uses a 
patented sample retention system by utilising the inherent surface tension properties of 
the test sample, thereby obviating the need for the use of cuvettes. The concentration of 
DNA was automatically computed by measuring the absorbance at 260nm of UV light 
using the modified Beer- Lambert equation c=(A*E)/b, where c is the DNA concentration 
in ng/ µl, E is the wavelength- dependent extinction coefficient in ng-cm/µl, A is the 
absorbance in AU and b is the path length in cm. The extinction coefficient for double 
stranded DNA is 50. Measuring A260/A280 ratio, which should be between 1.8 to 2.0, 
assessed purity of the sample. Approximately 3µg of DNA was obtained per 1 million 
cells using this method. 
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2.2.1.2 RNA extraction 
 
The Qiagen RNeasy plus kit was used to extract RNA from EBV-transformed B Cell 
lines.  The process involved cell lysis and homogenisation in the presence of β-
mercaptoethanol and a guanidine isothiocyanate – containing buffer, followed by passing 
the lysate through a gDNA Eliminator spin column to remove genomic DNA and 
subsequent binding of RNA onto a specialised silica-gel membrane-containing column. 
This was followed by elution of RNA from the membrane with a low-salt buffer after 
washing the column twice with ethanol- based buffers. The RNA obtained by this method 
specifically enriched for mRNA by effectively removing RNA that was less than 200 
nucleotides long. Quantitation was made spectrophotometrically using the NanoDrop 
2000, as described above. In case of RNA, the extinction coefficient is considered to be 
40. Approximately 2µg of RNA was obtained per 1 million cells using this method. 
 
2.2.1.3 cDNA synthesis and reverse transcriptase polymerase chain reaction (RT-PCR) 
  
cDNA synthesis was performed by using the SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen). In this method, total mRNA was denatured at 65 0C for 
5 minutes followed by cooling and annealing with oligo(dT). cDNA was synthesized by 
using Superscript III reverse transcriptase enzyme at 50 0C  for 50 minutes. Superscript 
III reverse transcriptase is a version of the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) that has been engineered with the introduction of several 
point mutations to reduce RNase H activity and provide increased thermal stability. 
Following the termination of the reverse transcriptase reaction at 85 0C, the RNA 
template was removed by the addition of RNaseH at 37 0C for 20 minutes. cDNA 
obtained by this method was first amplified using cDNA- specific primers of the 
housekeeping gene β actin, in order to provide qualitative and semi-quantitative 
assessment of the cDNA. PCR was then performed in a separate tube using primers 
specific for the genes of interest.  
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2.2.2 Bioinformatics and primer design 
  
The DNA sequence of all the coding exons, intron- exon boundaries and in some 
instances, the promoter regions of all the genes within the FHL I locus (9q21.3-22) was 
obtained from the Ensembl (www.ensembl.org) and the National Centre for 
Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov) databases. Data generated 
from direct sequencing of test samples were aligned to the published genome sequence 
databases using either BLAST (The Basic Local Alignment Search Tool 
www.blast.ncbi.nlm.nih.gov) or the Clustal W multiple sequence alignment programme 
(www.clustal.org). Variation data was obtained from the International HapMap Project 
database (www.hapmap.org) and the Database of Genomic Variants 
(http://projects.tcag.ca/variation/). Published gene expression data was obtained from the 
BioGPS portal (biogps.gnf.org) and Aceview 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/).  
Primers for amplification of genomic DNA were designed to span entire exons as well as 
intron-exon boundaries. For exons that were greater than 600bp, internal sequencing 
primers were designed. Primers for real-time quantitative PCR (RQ-PCR) using the 
SYBR Green method were designed to span multiple exons in order to exclude 
amplification from genomic DNA contaminants. Amplicons for RQ-PCR were designed 
to be 100-150bp long. Primers were designed using the website Oligocalc 
(www.basic.northwestern.edu/biotools/oligocalc.html), were 21-24mer with annealing 
temperatures between 55-65 0C. Primers were designed after ensuring that there were no 
potential self- annealing sites, 3’ complementarity or potential for hairpin formation. 
Primers for amplification of microsatellite markers were obtained from the UniSTS 
database of NCBI (http://www.ncbi.nlm.nih.gov/genome/sts/sts.cgi).   
 The primers used and the expected amplicon sizes are detailed in the Appendix.  
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2.2.3 Polymerase chain reaction (PCR) 
2.2.3.1 Standard PCR reaction from genomic DNA 
 
PCR reactions for direct sequencing of template DNA up to amplicon lengths of 1.2Kb 
were made to a final volume of 40µl using 100ng of template genomic DNA, 1unit of 
native Taq DNA polymerase, 1x PCR buffer, 2mM MgCl2, 0.33 mM dNTP and 0.5 µM 
each of forward and reverse primers. PCR reaction conditions were first ascertained using 
genomic DNA from normal controls. The reaction consisted of an initial denaturation 
step of 95 0C for 5 minutes followed by 35 cycles of denaturation (94 0C for 45 seconds), 
annealing (55-65 0C for 45 seconds) and extension (72 0C for 1 minute), followed by a 
final extension time of 7 minutes at 72 0C. PCR products were stored at 4 0C until further 
use. All reagents were purchased from Invitrogen. Reactions were performed in the 
Verity 96-Well Thermal Cycler from Applied Biosystems.  
 
2.2.3.2 Long- template PCR 
 
PCR products greater than 1.5Kb were amplified using the Expand Long Template PCR 
System from Roche Applied Science. This system increases the fidelity of the PCR 
amplification by using a combination of polymerases, such as Pwo (Pyrococcus woesei) 
polymerase for efficient 3’-5’ exonuclease activity and Taq DNA polymerase for high 
processivity along with the use of specialised buffers that are optimised for generation of 
specific long- length products of up to 27Kb. I used reaction mixes containing 1xBuffer 2 
of the Expand kit, 0.3 µM each of forward and reverse primers, 0.5mM dNTP, 200ng of 
template genomic DNA or cDNA synthesised from 100ng of RNA and 2 units of 
polymerase to make up a 40µl final reaction volume. Cycling conditions included an 
initial short denaturation step of 950C for 2 minutes followed by 10 cycles of denaturation 
(940C for 20 seconds), annealing (55-650C for 30 seconds) and a long extension (680C for 
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4- 6 minutes). This was then followed by 25 cycles of further denaturation (940C for 20 
seconds) and annealing (55-65 0C for 30 seconds) and a specialised extension (68 0C for 
4-6 minutes, with increment of the extension time by 20 seconds per cycle). The reaction 
was completed by a final extension of 10 minutes.  
2.2.3.3 PCR for amplification of GC rich template 
 
Templates with GC content of >65% were amplified by adding 10% Dimethyl sulfoxide 
(DMSO)- a reagent that has been shown to facilitate DNA strand separation by disrupting 
base pairing and 2.5M betaine, a natural amino acid analogue that isostabilises DNA 
without inhibiting polymerases [323], to a standard PCR mix of a final volume of 25µl 
and containing 100ng of template genomic DNA, 1unit of native Taq DNA polymerase, 
1x PCR buffer, 2mM MgCl2, 0.33 mM dNTP and 0.5 µM each of forward and reverse 
primers. Cycling conditions were identical to that of a conventional PCR, as described in 
2.2.3.1. 
2.2.3.4 Touchdown PCR for amplification of microsatellite markers 
  
Microsatellite markers consist of short tandem repeats and amplification by conventional 
PCR programmes was difficult. Adding DMSO and betaine to a standard reaction mix, as 
described above, optimised reaction efficiency. A specialised cycling protocol was 
adopted which started with the highest stringency annealing conditions followed by 
stepwise lowering of annealing temperature, as illustrated in Figure 2.2. Using this 
programme enabled the simultaneous amplification of all the microsatellite markers 
studied, obviating the need for customisation of programme conditions for each marker. 
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Figure 2.2. Cycling conditions for microsatellite marker PCR amplification 
Reactions mix contained 10% DMSO and 2.5M Betaine along with 100ng of template 
genomic DNA, 1unit of native Taq DNA polymerase, 1x PCR buffer, 2mM MgCl2, 0.33 
mM dNTP and 0.5 µM each of forward and reverse primers. Reactions were run in the 
3132 thermal cycler from Applied Biosystems. 
2.2.3.5 Nucleic acid electrophoresis 
 
PCR products were visualised on agarose gels of appropriate concentration for the 
fragment size (0.8% to 2%, with lower concentrations for higher product sizes). Agarose 
gels were prepared by dissolving agarose (Invitrogen) in 0.5x Tris-borate buffer [TBE- 
containing 54g Tris, 28g boric acid and 10ml 1M ethylenediaminetetraacetic 
acid (EDTA) per litre of buffer], pH ∼8.3, by boiling and once cooled, adding SYBR Safe 
gel stain concentrate at 1:10000 dilution. The gel was then poured, allowed to set and 
placed in an electrophoresis tank containing 0.5x TBE buffer. PCR products were then 
mixed with loading buffer containing 25mg bromophenol blue (Sigma), 4g sucrose and 
H2O to 10mL at 1:3 dilution and loaded into wells in the gel alongside an appropriate 
DNA size marker (Invitrogen). DNA electrophoresis was then performed using 50-90 
volts across the gel. After electrophoresis, the stained DNA was visualised on the Gel –
doc system (Biorad) using an ultraviolet excitation of 302 nm. The Gel-doc system was 
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equipped with a photographic source for analysis and storage of the images. In certain 
circumstances, for instance in PCR reactions with multiple products that needed to be 
sequenced or cloned individually, DNA bands were excised while they were visualised 
on the Gel-doc system.  DNA from the excised fragments was then recovered using a gel 
extraction kit (Qiagen) containing a silica gel membrane-containing spin column.  
PCR products from microsatellite markers were analysed by capillary electrophoresis. 
Samples for capillary electrophoresis were prepared by diluting the PCR product to 1:50 
in water and adding 1µl of the diluted PCR product to 9µl of HiDiFormamide (Applied 
Biosystems) containing 15µl/ml of GeneScan 500 LIZ size standard (Applied 
Biosystems). Samples were run on an ABI 3700 DNA Analyser and the data was 
analysed using the GeneScan software (Applied Biosystems). The software facilitated the 
distinction between true peaks and stutter peaks produced during the PCR amplification 
of the microsatellite markers, thus allowing the true product size to be analysed for every 
individual studied.  
  
2.2.3.6 Direct sequencing of PCR products 
  
PCR products were first visualised on agarose gels, as described above. For those 
reactions where a single product was produced, dNTP’s and primers were removed prior 
to sequencing either using Microcon YM100 cellulose filter systems (Milipore) according 
to manufacturer’s instructions or diluting the PCR product in distilled water at the ratio of 
1:25 to 1:50. For PCR products with multiple bands, DNA was recovered by excision and 
gel extraction, as described above. The sequencing reaction was then performed using a 
BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems). The reaction mix 
was prepared by adding 1µl the purified PCR product (10 to 50ng DNA), 1µl of 8pmol/µl 
of template- specific primer, 0.5µl of BigDye Terminator ready reaction mix (containing 
the fluorescent dideoxy terminator nucleotides) and 2µl of 2.5x BigDye Terminator 
buffer to 5.5µl of distilled water in a 96-well plate. The cycle sequencing reaction was 
performed in an ABI 3130 thermal cycler (Applied Biosystems). The reaction consisted 
of an initial denaturation step of 94 0C for 1 minute followed by 25 cycles of 960C for 10 
 107 
seconds, 500Cfor 5 seconds and 600C for 4 minutes. Reactions were held at 160C until 
further use. DNA from the cycle sequencing reaction was precipitated by adding 50µl of 
ice-cold 100% ethanol, 2µl of 3M Sodium acetate and 2µl of 125mM EDTA to each well, 
followed by centrifugation at 3400rpm for 30 minutes. A further precipitation step was 
performed by the addition of 50µl of ice-cold 70% ethanol and centrifugation at 3400rpm 
for 15 minutes. The alcohol was then removed by brief centrifugation and the precipitated 
DNA was resuspended in 10µl Hi-Di Formamide, a highly deionised formamide used for 
electrokinetic injection on capillary electrophoresis systems. Capillary electrophoresis 
was then performed on an ABI3700 DNA Analyzer. 
 
2.2.3.7 Analysis of sequencing data  
  
The chromatograms resulting from the sequencing reactions were visualised with the 
4peaks software (mekentosj.com/4peaks) and sequences were aligned using the Clustal 
software package, as mentioned above. In the case of PCR products, every DNA 
sequence was analysed using template- specific forward and reverse primers. Products 
obtained from cloning were sequenced using either gene- specific or plasmid- specific 
primers. 
 
2.2.3.8 Real time quantitative PCR 
 
Relative expression of the genes within the FHL I locus were analysed using the 
QuantiTect SYBR Green Real-time PCR kit (Qiagen). The SYBR green RQ-PCR 
chemistry is based on the double-stranded DNA- biding and fluorescence- emitting 
properties of SYBR green, allowing for the quantification of the double stranded DNA 
produced during a PCR reaction.  
cDNA was synthesised from a fixed amount of RNA (1µg) extracted from the FHL I B 
lymphoblastoid cell lines PP0150, PP0277 and PP0231 as well as from the cell line 
PP0065 (a non- FHL I B- lymphoblastoid cell line, to act as control or calibrator) and 
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reverse transcribed using the SuperScriptTM III First-Strand Synthesis System for RT-
PCR, as described earlier. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene 
was used as an internal control gene to normalize the PCR reactions for the amount of 
RNA added to the reverse transcription reactions. Primers were designed to span 2 exons 
with annealing temperatures of 600C and PCR product lengths were 100-150bp. 
Relative expression of genes of the FHL I locus in the test cell lines compared to that in 
the control cell line was calculated using the ΔΔCT method [324], where relative gene 
expression is calculated as: 2 -ΔΔCT, where ΔCT is the difference in threshold cycles of 
amplification for test and reference (GAPDH) genes (allowing for normalization of the 
amount of cDNA applied to the experiment), and ΔΔCT is the difference in the ΔCT 
values between the calibrator cDNA (PP0065) and test cDNA (FHL I cell lines). 
In order to validate the 2 -ΔΔCT method and to ascertain PCR efficiencies of the primers, the 
ΔCT of the reaction in PP0065 cells in various template dilutions was measured.  A total 
of 3 dilutions were used, starting from neat, followed by two 10-fold dilutions to a 
maximum of 1:100. The ΔCT for each dilution was plotted against the log cDNA dilution 
and the absolute value of the slope was determined. Primers were designed to obtain a 
value of the slope close to zero, demonstrating that the amplification efficiencies of the 
target and reference genes were similar, thereby validating the 2 -ΔΔCT method to assess 
relative gene expression. 
Reactions were set up in 96-well plates and consisted of 12.5µl of 2x SYBRgreen PCR 
master mix, 0.3µM each of forward and reverse primers, 1 µl of cDNA (synthesized from 
1µg of mRNA) and RNAse-free distilled water to make a final volume of 25µl.  Cycling 
conditions included a 15-minute hot start step at 950C followed by 45 cycles of 
denaturation at 940C for 15 seconds, annealing at 600C for 30 seconds and extension at 
720C for 33 seconds. Reactions were run in the Applied Biosystems 7500 Real Time PCR 
Systems and data capture was performed in the extension step of each cycle. Sequence 
Detector Version 1.1 software (Applied Biosystems) was used to analyse raw data and 
Microsoft Excel was used to compute the standard curves and interpret the relative gene 
expression by the 2 -ΔΔCT method.  
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2.2.4 PCR cloning  
2.2.4.1 Plasmids 
 
pCR2.1 TOPO (Invitrogen) for TA cloning of taq polymerase- amplified PCR products 
and pJET 1.2 (CloneJET PCR cloning kit, Fermentas) for blunt ligation of large products 
were used for cloning and sequencing of PCR products. Maps of these vectors are shown 
in figure 2.3. 
 
 
Figure 2.3. Plasmids used in PCR cloning. Both plasmids contained an ampicillin 
resistance sequence for antibiotic selection 
a) pJET1.2 (Fermentas) was used for blunt end cloning of PCR products. In this plasmid, 
the 5’ end of the LacZ gene has been replaced by the gene coding for the Eco47I 
restriction endonuclease, which in the absence of cognate methylation, is lethal to the E 
Coli host cells. Insertion into the multi-cloning site (MCS) causes inactivation of the 
Eco471 gene and thereby acts as a positive selection mechanism. 
 b) pCR-TOPO (Invitrogen) was used in TA cloning. The multi-cloning site is flanked by 
phosphorylated thymidine residues (depicted here as ‘T’ overhangs) bound to 
topoisomerase 1, into which PCR products are ligated.  
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2.2.4.2 PCR amplification and purification of amplicon for cloning 
 
DNA was amplified using exon-specific primers and Taq DNA polymerase. PCR 
products were run on 1.5% agarose gel and the specific band of interest was either 
excised from the gel and purified by using QIAEX II Gel Extraction Kit (Qiagen) or 
centrifuged in Microcon YM100 cellulose filter systems (Milipore) according to 
manufacturer’s instructions.  
 
2.2.4.3 Bacterial transformation  
 
The purified product was ligated into a pCR2.1-TOPO vector by incubation in room 
temperature for 30 minutes in the presence of ligation buffer. In case of pJET plasmid, 
PCR products generated by taq polymerase were blunted prior to ligation by incubating 
the product with a DNA blunting enzyme and buffer provided in the kit. 
Chemically competent E coli cells (OneShot TOP10, Invitrogen) were thawed on ice and 
the ligation product was added to the cells. This was further incubated in ice for 30 
minutes and heat shocked at 420C for 30-45 seconds. 250µl of S.O.C. medium 
(Invitrogen) was added to the cells and shaken at 225rpm for 1 hour at 370C and plated 
onto LB agar plates smeared with 40ul of 20ug/ml Xgal (5-bromo-4-chloro-3-indolyl- 
beta-D-galactopyranoside) (Qiagen) in dimethylformamide. Xgal was not added to 
bacterial culture plates in case of pJET cloning. After ampicillin selection, at least 25 
white bacterial colonies for each PCR product were selected and expanded. Plasmid DNA 
was purified using Qiagen mini prep kit according to manufacturer’s instructions. After 
purification, the clones were screened for the presence of the specific insert of interest by 
EcoR1 restriction enzyme digestion (in case of TA cloning) or bglII digestion (in case of 
pJET cloning). DNA from positive minipreps was sequenced directly by using BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and run on ABI 3730 
Genetic Analyzer, as described earlier. 
  
 
 
 111 
   
 
2.3 Cell culture  
 
2.3.1 Preparation of mononuclear cells from whole blood and cellular 
cryopreservation 
 
Peripheral blood mononuclear cells (PBMC) were isolated using Lymphoprep (Axis-
Shield) density gradient medium. Freshly drawn, anticoagulant treated whole blood from 
healthy controls, patients and their parents were first diluted in phosphate buffered saline 
(PBS) at a ratio of 1:1 and then layered on to the density gradient medium. The samples 
were then centrifuged at 800g for 30 minutes in a Sorvall bench top centrifuge, followed 
by a slow deceleration without the application of brakes. PBMC’s form a distinct band at 
the sample/medium interface, which was then removed without disturbing the upper 
layer. Cells obtained my this method were washed with PBS, counted and then re-
suspended in fetal bovine serum (FBS) with 10% DMSO and frozen overnight at -80°C, 
after which they were transferred to liquid nitrogen. 
Genomic DNA was isolated from the neutrophils present in the precipitate using a DNA 
extraction kit, as described earlier. 
When necessary, cryopreserved PBMC’s were thawed at 370C and resuspended in 
medium warmed to 370C. The sample was then washed once to remove the DMSO 
contained in the cryopreservation medium and processed as necessary. 
 
2.3.2 Cell line culture 
 
Table 2.3 details the immortalised cells used. The B- lymphoblastoid cell lines were 
grown in R10 complete medium consisting of RPMI 1640 (GIBCO), 10% FBS 
(Invitrogen), 1 unit/ml penicillin (Sigma), 1µg/ml streptomycin (Sigma) and 2mM l-
glutamine (Sigma) and maintained at a density of 0.5- 1x106 /ml in a cell culture 
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incubator at 370C with high humidity and 5% CO2 flow. Culture medium was renewed 
every 3 days. 
293T cells were used as positive control for KIF27 gene expression. Cells were grown in 
75cm2 tissue culture flasks in Dulbecco's Modified Eagle Medium (DMEM) (GIBCO), 
supplemented by 10% FBS, 1 unit/ml penicillin and 1µg/ml streptomycin. Adherent cells 
such as 293T were maintained at 75% confluence. Adherent cells were detached by 
replacing the DMEM with PBS for an initial wash to remove the excess divalent cations 
and trypsin inhibitory proteins in the medium. This was followed by incubating the cells 
with 1x trypsin –EDTA solution at 370C for 10 minutes to completely detach the cells. 
Cells were then re-plated at desired concentration with DMEM. 
A number of adenocarcinoma cell lines were also used for analysing KIF27 gene 
expression, and are detailed in table 2.3. The chronic myeloid leukaemia cell line K562 
was used for the lack of MHC Class1 molecules and their susceptibility to cytotoxic lysis 
by NK cells. P815 cell line is a rat mastocytoma cell line and was used as target cells for 
CD8+ T cells in cytotoxicity experiments, including single cell imaging. All the above 
cell lines were grown and maintained in R10 complete medium and split every 3 days.  
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Table 2.3. Cell lines used in the study 
 
Cell line Species Tissue FHL I 
family 
member 
Cell 
culture 
medium 
Source Used for 
PP0150 Human EBV transformed 
lymphoblastoid  
Father of 
proband 
R10 
complete 
ECCAC 
 
 
Mutation 
screening 
PP0225 Human EBV transformed 
lymphoblastoid 
Father of 
proband 
R10 
complete 
ECCAC 
 
 
Mutation 
screening 
PP0180 Human EBV transformed 
lymphoblastoid 
Mother of 
proband 
R10 
complete 
ECCAC 
 
 
Mutation 
screening 
PP0231 Human EBV transformed 
lymphoblastoid 
Proband R10 
complete 
ECCAC 
 
 
Mutation 
screening 
PP0277 Human EBV transformed 
lymphoblastoid 
Father of 
proband 
R10 
complete 
ECCAC 
 
 
Mutation 
screening 
PP0065 Human EBV transformed 
lymphoblastoid 
N/A R10 
complete 
Departmental 
stock 
RQ-PCR 
calibration, 
Apoptosis 
assay 
control 
PP0091 Human EBV transformed 
lymphoblastoid 
N/A R10 
complete 
Departmental 
stock 
Positive 
control for 
gene 
expression, 
Apoptosis 
assay 
control 
PP0054 Human EBV transformed 
lymphoblastoid 
N/A R10 
complete 
Departmental 
stock 
Positive 
control for 
gene 
expression, 
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Apoptosis 
assay 
control 
K562 Human Chronic myeloid 
leukaemia, 
erythroleukaemia 
in blast crisis 
N/A R10 
complete 
Departmental 
stock 
Conjugation 
with NK 
cells 
P815 Rat Mastocytoma  N/A R10 
complete 
Departmental 
stock 
 
 
Conjugation 
with T cells 
MCF7 Human Breast 
adenocarcinoma 
N/A R10 
complete 
Dr J Sturge, 
Division of 
Oncology, 
Imperial 
College 
Positive 
control for 
gene 
expression 
MDA-
MB-231 
Human Breast 
adenocarcinoma 
N/A DMEM Dr J Sturge 
 
Positive 
control for 
gene 
expression 
PC3 Human Prostate 
adenocarcinoma 
N/A DMEM Dr J Sturge 
 
Positive 
control for 
gene 
expression 
293T Human Human embryonic 
kidney 
N/A DMEM Departmental 
stock 
 
 
Positive 
control for 
gene 
expression 
Jurkat Human T cell leukaemia N/A R10 
complete 
Departmental 
stock 
 
Positive 
control for 
gene 
expression, 
Apoptosis 
assay 
control 
N/A: Not applicable, ECCAC: European Collection of Cell Cultures 
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2.3.3 Generation of Phytohaemagglutinin- induced, allogeneically stimulated 
polyclonal T cell blasts  
2.3.3.1 Preparation of feeder cells 
 
Cryopreserved PBMC from normal donors were thawed in a water bath at 370C and 
washed with warm R10 complete medium by centrifugation at 1500rpm for 5 minutes. 
The cells were irradiated at 3000 rads, washed in PBS by spinning at 1500 rpm for 5 
minutes on a tabletop centrifuge and resuspended in human T Cell culture medium 
[RPMI 1640 supplemented with 1 unit/ml penicillin, 1µg/ml streptomycin, 2mM l-
glutamine, 5% heat- inactivated human AB serum (Invitrogen) and 100U/ml of 
recombinant human IL2 (Ebioscience)] at the concentration of 1x106/ml. 
 
2.3.3.2 Cloning of T Cells 
 
Freshly isolated or cryopreserved test PBMC from patients or normal donors were 
thawed and washed as described above. Cells were then resuspended in T cell culture 
medium at a concentration of 1x106/ml. Cells were plated at 1ml/well in 24-well culture 
plates to which 1ml of feeder cell mix was pre- added. PHA was then added to this cell 
suspension mix at a concentration of 1µg/ml. Cells were incubated in a humidified 
chamber at 370C with 5% CO2. PBMCs stimulated in this manner expand with a doubling 
time of 4-5 days, at which point they were split. No further allogeneic stimulation was 
provided during the course of the cultures that usually lasted 4-6 weeks. IL2 was added to 
the medium at the concentration of 100U/ml every 72 hours. Mitogenic stimulation by 
PHA was renewed every 3-4 weeks. After 2 weeks of culture, the expanded polyclonal T 
cell populations were conjugated with target cells and stained for immunofluorescence 
microscopy as detailed later.  
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2.3.3.3 CD8 selection from clonally expanded T Cells 
 
About 10 x106 T Cell clones that were cultured and expanded as described above were 
subjected to CD8+ selection at day 16 of culture. Cells were washed, counted and CD8+ 
cells were negatively selected by immunomagnetic beads (Easysep Negative Selection 
Human CD8+ T Cell enrichment kit, Stem Cell technologies). CD8+ cells were obtained 
at over 95% purity, as determined by flow-cytometry. About 5 million CD8+ cells were 
obtained by this method. These cells were then resuspended in human T cell medium, and 
cultured in a humidified chamber at 370C with 5% CO2 and IL2 was added to the medium 
at the concentration of 100U/ml every 72 hours.  
 
2.3.4 Generation of T and NK Cell clones by single cell culture 
 
Cryopreserved PBMC’s obtained from patients with HLH several years after they had 
undergone stem cell transplantation were clonally expanded by using a single cell culture 
system. The details of such patients are outlined in table 2.2. 
2.3.4.1 Preparation of feeder cells 
 
Feeder cells were prepared by using a mix of normal donor PBMC and B- 
lymphoblastoid cells in a 1:1 ratio. PBMCs for the feeder layer were prepared as outlined 
in section 2.3.3.1. B-lymphoblastoid cells (BLCL) were irradiated at 6000 rads and 
resuspended in T Cell medium at a concentration of 1x106/ml. Irradiated PBMC and 
BLCL were mixed at equal proportions to a final concentration of 1x106/ml in T Cell 
medium supplemented by 1µg/ml of PHA. 100µl of this cell mix (containing 100,000 
feeder cells) was added to 96-well U bottom plates. A total of 6 such plates were prepared 
for the sorting, 2 each for CD8+, CD4+ and CD56+ cells. T-Cell medium used in plates 
prepared for receiving CD56+ NK cells was supplemented by 500U/ml of IL2 rather than 
100U/ml of IL2. 
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2.3.4.2 Preparation of test cells 
 
Cells were initially thawed in a 370C water bath and washed in warm R10 medium by 
spinning in a tabletop centrifuge at 1500 rpm for 5 minutes. The resulting cell pellet was 
resuspended in warm PBS and counted in a haemocytometer. Cells were then spun and 
resuspended in FACS staining buffer (Robosep buffer, Stem Cell Technologies), divided 
into three aliquots and stained with antibodies conjugated to fluorochromes for single cell 
sorting by flow-cytometry. Each aliquot was stained for one cell type only. NK cells were 
labelled with anti-CD56 antibody conjugated to phycoerythrin (PE), CD8+ T cells were 
labelled with anti-CD8 antibody conjugated to allophycocyanin (APC) and CD4+ T cells 
were labelled with anti-CD4 antibody conjugated to peridinin-chlorophyll-protein 
complex (PerCP). All these antibodies were purchased from BD biosciences. Details of 
FACS staining are discussed in section 2.4. 
2.3.4.3 Single cell sorting 
 
Test cells stained for CD4, CD8 and CD56 cells were sorted by flow-cytometry on a BD 
FACSAria II (Becton Dickinson). Ninety-six well plates that were prepared with feeder 
cells, T cell medium, PHA and appropriate amount of IL2 were placed in the sort 
collection chamber of the FACSAria. A live cell lymphoid gate was obtained and three 
distinct cell populations were identified for CD4, CD8 and CD56 cells. Single cells were 
then plated into each well of 96-well plated according to their antigenic profile. Two 96- 
well plates were prepared for cloning each cell type. Both normal control PBMC and 
patient PBMC were plated for every experiment. 
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2.3.4.4 Single cell culture 
 
Ninety-six well plates containing cells obtained by single cell sorting were incubated in a 
humidified chamber at 370C with 5% CO2. Every 72 hours, a 25% medium change was 
performed and IL2 was added to the wells at a concentration of 100U/ml for T cells and 
500U/ml for NK cells. Allogeneic re-stimulation with PBMC irradiated at 3000 rads was 
repeated every 10 days. PHA was added every 2 weeks. Using this culture system, T Cell 
clones expanded from single cells were microscopically visible from around day14 of 
culture. Cells were split when the expanding clones occupied about 80% of the well. 
Between 10-40% cloning efficiencies were obtained. Generally speaking, CD4 clones 
grew more efficiently that CD8 and CD56 clones. Cell cultures were maintained for 4-6 
weeks, until sufficient cell numbers were obtained for further functional testing. 
2.3.4 T Cell activation and gene expression 
 
PBMC from a normal blood donor was subjected to T Cell negative selection by 
immunomagnetic beads (Easysep, Stem Cell Technologies) according to manufacturer’s 
instructions.  Ten million T cells of high purity (97%, as determined by flow-cytometry) 
were obtained from 40 million PBMC. T Cells obtained by this method were suspended 
in T Cell medium at a concentration of 1x106/ml and1 ml of this cell suspension was 
added per well into a 24-well tissue culture plate. T cells were then stimulated either by 
PHA (1µg/ml) or CD3/CD28 coated magnetic polymer beads (Dynabeads, Invitrogen) at 
1:1 of cell to bead ratio. Cells were stimulated for a total of 2.5 hours at 370C with 5% 
ambient CO2 and RNA was extracted from cells at baseline and at four further time 
points- 15 minutes, 30 minutes, 1 hour and 2.5 hours, both for PHA and for bead-
stimulated T cells. cDNA was synthesised as described earlier and KIF27 expression was 
studied by RQ-PCR using SYBRGreen. 
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2.4 Flow-cytometry 
 
2.4.1 Flow-cytometry for surface antigens 
 
 Up to a total of 4 fluorochromes were used for cellular staining in flow-cytometry 
experiments. In all cases, conjugated monoclonal antibodies were used.  
The general staining procedure for surface antigens was as follows: Cells were first 
washed in ice- cold PBS supplemented with 2% FBS (FACS buffer) and incubated with 
appropriate antibodies for 20-30 minutes on ice. After incubation, cells were washed 
twice at 1500rpm in a tabletop centrifuge for 5 minutes each and resuspended in 400µl of 
FACS buffer and were analysed in the BD FACSCalibur flowcytometer. In case of dual, 
triple or quadruple colour-stainings, settings of the appropriate compensation parameters 
were guided by single staining of cells with each of the fluorochrome- conjugated 
antibodies. Gates were set on live cells as defined by forward and side-scatter parameters. 
CellQuest software (Becton Dickinson) was used for data acquisition. Data was analysed 
by FlowJo version 8.7 (TreeStar corporation).  
The following purified mouse anti-human monoclonal antibodies were used- CD4- PE 
(clone RPA-T4), CD4- Fluorescin isothiocyanate (FITC) (clone 25723.11), CD8-APC 
(clone RPA-T8), CD56-PE (clone MY31) and CD3-APC (clone UCHT1)- all from BD 
Biosciences.  
2.4.2 Flow-cytometry for intracellular perforin 
 
For flow-cytometry for the intracellular protein perforin, 100µl of whole blood or 100µl 
of PBMC suspended in FACS buffer at a concentration of 106/ml was incubated in room 
temperature for 20 minutes with a mixture of membrane protein antibodies (CD56 PE, 
CD8 PerCP and CD3 APC) and washed in FACS buffer by spinning on a tabletop 
centrifuge for 5 minutes in 1500 rpm. Samples were processed alongside age- matched 
controls, where possible. Cells were then fixed and permeabilised in 250µl of 
Cytofix/Cytoperm solution (Becton Dickinson) for 20 minutes and washed twice in 1ml 
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of 1x Perm/Wash buffer (Becton Dickinson). Each sample was processed up to this stage 
in duplicate.  
Samples were then resuspended in the remaining volume of Perm/Wash buffer post- 
decant by gentle mixing and sample-pairs were then either stained with 5µl of anti-
Perforin-FITC (clone δG9, BD Biosciences) or FITC- Mouse IgG2b κ Isotype Control 
(BD Biosciences) and incubated in room temperature for 10 minutes. Cells were then 
washed twice with perm/wash buffer and resuspended in 250µl of Cell Fix (Dulbecco's 
Phosphate-Buffered Saline containing 4% w/v paraformaldehyde). 
A minimum of 100,000 events was acquired after selecting a lymphoid gate on live cells 
by forward and side scatter characteristics. Perforin expression in permeabilised CD56+ 
NK cells and CD8+ T cells were analysed by comparison with the isotype control. 
 
2.4.3 Granule release assay 
 
Cytotoxic T lymphocytes were assessed for their ability to degranulate upon activation by 
PHA or by TCR cross-linking by unconjugated anti-CD3 antibody. Degranulation was 
measured by the presence of CD107a on the cell surface of activated T cells [325]. 
CD107a is usually present in the membrane of cytotoxic granules and is briefly exposed 
to the cell surface as a result of degranulation.  
For this purpose, 1x106 clonally expanded CD8+ cells or freshly isolated PBMC and the 
same number of control cells was cultured overnight in human T cell medium in the 
presence of 100U/ml of recombinant human IL2. Following overnight cultures, cells were 
washed by centrifugation and resuspended in 1.5ml of human T Cell medium and divided 
into three tubes, each containing 500µl of cell suspension.  Five µl of CD107a-FITC 
(Clone H4A3, BD Biosciences) was added to all three tubes, one of which was 
supplemented by PHA at the concentration of 1µg/ml, one was supplemented by 
unconjugated anti-CD3 antibody (1µg/ml, Pelicluster, Mast) and the third tube was left 
unstimulated. Cells were further incubated at 370C with 5% ambient CO2 for 2 hours. 
After incubation, cells were washed by centrifugation and stained for surface markers 
with CD3-APC, CD8-PerCP and CD56-PE by incubation at room temperature for 20 
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minutes. Following staining, cells were washed twice in FACS buffer and resuspended in 
250µl of Cell Fix.   
Cells were then analysed by flow-cytometry in BD FACSCalibur. Data was acquired and 
analysed by CellQuest and FlowJo software, respectively.  
  
2.5 Immunofluorescent staining and confocal microscopy 
 
2.5.1 Cells used for immunofluorescence staining  
 
Cytotoxic T lymphocytes that were polyclonally expanded by allogeneic stimulation in 
the presence of PHA (henceforth referred to as PHA blasts) were conjugated with P815 
cells and stained for immunofluorescent confocal microscopy. T cell clones that were 
expanded by single cell cultures were also conjugated to P815 cells and stained for 
visualisation of the cytotoxic machinery. The FHL I B cell line PP0231, derived from a 
proband was also used for immunofluorescent staining. 
 
2.5.2 Primary and secondary antibodies  
 
T cell cytotoxic machinery was visualised by the use of the following unconjugated 
antibodies – rabbit anti-human Lamp1 antibody (clone AS120, kind gift from Professor 
Gillian Griffiths, Cambridge Institute for Medical Research, University of Cambridge), 
mouse anti-human β tubulin (clone TUB 2.1, Sigma Aldrich) and mouse anti-human γ 
tubulin antibody (clone GTU-88, Sigma Aldrich). Secondary antibodies used were: Alexa 
Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 546 goat anti-mouse IgG. A rabbit 
anti-human polyclonal, unconjugated anti-KIF27 antibody purchased from Atlas 
Antibodies, Sigma Aldrich, was used for immunofluorescence as well as western 
blotting. 
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2.5.3 Conjugation of P815 cells with PHA blasts or CD8+ cells expanded by single 
cell cultures  
 
PHA blasts or CD8+ T cell clones were conjugated with P815 cells in the presence of 
unconjugated anti-CD3 antibody or PHA. For this purpose, T cells were first washed in 
RPMI to remove serum and resuspended in serum- free medium at a concentration of 
1x106/ml. P815 cells were also washed in RPMI and resuspended at the same 
concentration. 250µl of each cell suspension were mixed together, to which either anti-
CD3 or PHA was added at a concentration of 1µg/ml. After 5 min in suspension at room 
temperature, cell samples were plated onto glass multi-well slides (50 µl/well) and 
transferred to a 370C incubator with 5% ambient CO2 where they were incubated for 25-
30 minutes.  
2.5.4 Fixing and staining of T cell- target cell conjugates 
 
After incubation, conjugates in glass multi-well slides were fixed on ice in -200C 
methanol for 5 minutes and washed thrice in PBS. Cells were then blocked in PBS and 
1% bovine serum albumin (blocking buffer) for 2 hours in room temperature or overnight 
at 40C. Following this, cells were incubated in the first primary antibody (anti Lamp-1, 
1:200 dilution) for 1 hour and washed several times. Cells were then incubated with the 
appropriate secondary antibody (1:200 dilution) for 45 minutes in the dark and washed 
several times afterwards. Next, the second primary antibody was added  (anti γ-tubulin or 
anti-β tubulin, 1:200 dilution) and incubated for 1 hour and washed several times after 
incubation, followed by a 45-minute incubation with the second secondary antibody. All 
incubation steps following the addition of the first secondary antibody was performed in 
the dark. All antibody dilutions were made in blocking buffer. All washes were 
performed in blocking buffer apart from the wash following the second secondary 
antibody, which was done in PBS. Finally, nuclear stain was prepared by adding 3µl of 
Hoechst 33342 trihydrochloride trihydrate (Invitrogen) in 10ml of distilled water and 
 123 
added to the multi-well slides for 15 minutes. After 3 final washes, Vectashield mounting 
medium was applied with a coverslip and the edges sealed by a transparent varnish. 
KIF27 staining of cells were performed in glass multi-well slides in a similar fashion.  
2.5.5 Confocal microscopy 
 
Samples were visualised using a Leica TCS SP5X laser scanning confocal microscope. 
Serial confocal z-sections were taken at either 0.3mm intervals for whole cell analysis of 
individual cells and conjugates, or across the region of the CTL-target cell contact at 
0.2µm intervals.  Leica LAS AF software or Volocity version 5.3 software 
(www.improvisions.com) was used for analysis of the images. The former was used for 
projection of serial z sections as .avi movie files and the latter was used for the projection 
of serial xz and yz images in order to produce 3D reconstructions of cell conjugates and 
contact sites.  
 
2.6 Apoptosis assay  
 
The FHL I cell lines were subjected to apoptosis by the addition of human anti-FAS 
antibody (Clone DX2, BD Biosciences) and the degree of apoptosis was compared to that 
of Jurkat cells and non-FHL I B Cell lines PP0065, PP0054 and PP0091. This assay is 
based on the principle that upon induction of apoptosis, phosphatidyl serine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane. Annexin V is a 
35kDa phospholipid-binding protein, which has a high affinity for PS and can be used to 
identify cells in which PS is externalised by conjugating it to a fluorophore and analysing 
it by flow-cytometry in order to quantitatively determine the percentage of cells 
undergoing apoptosis. Propidium iodide  (PI) is a vital dye that permeates the cell 
membrane of dead cells and can be used in conjunction with Annexin V to differentiate 
between dead (necrotic or apoptotic) and dying (apoptotic) cells. 
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2.6.1 Induction of apoptosis 
 
For this purpose, cell lines were renewed with fresh culture medium one day prior to the 
assay. On the day of the assay, a 96- well flat-bottomed plate was plated with 100µl of 
R10 complete medium containing reducing amounts (100-, 50-, 25-, 12.5-, 6.25- and 
0ng/µl) of anti-FAS antibody. Test and control cell lines were washed and resuspended in 
fresh medium at a concentration of 1x106/ml. 100µL of this cell suspension (containing 
105 cells) was added to each well. Cells were added in duplicate for every concentration 
of FAS antibody used. Cells were then incubated for 4 hours at 370C at 5% ambient CO2. 
(A time-course experiment for optimisation of incubation time at 370C between 30 
minutes and 24 hours was performed during the initial experimental setup. Optimum 
apoptosis was obtained at 4-hour incubation time).  
2.6.2 Annexin V staining and detection of apoptotic cells by flow-cytometry 
 
After incubation, cells were washed twice in cold PBS and resuspended in 1x Annexin V 
binding buffer (BD Biosciences) at a concentration of 1x106/ml. One hundred µl of this 
suspension was added to a 5ml FACS tube, to which 5µl of Annexin V-FITC (BD 
Biosciences) was added and incubated for 15 minutes in room temperature and protected 
from light. Cells were then washed and resuspended in 400µl of binding buffer. 
Immediately prior to analysis, 1µl of PI (Miltenyi Biotech) was added to each tube. Cells 
were analysed in a BD FACSCalibur flowcytometer. Data acquisition was performed by 
the CellQuest software and analysed using the Flowjo software, as before. Cells that 
stained positive for Annexin V alone or those that stained positive for both Annexin V 
and PI were considered as apoptotic cells. Cells staining for PI alone were not included 
among the apoptotic cells as they also included cells that had undergone cell death by 
necrosis. Apoptotic cells were expresses as a percentage of the total cells analysed for 
every cell type. A mean of the duplicate wells were taken for the readings and data was 
analysed on a Microsoft Excel spreadsheet. 
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2.8 Western Blotting  
 
Western blotting relies on the principle of separating denatured proteins in a 
polyacrylamide gel, causing proteins to migrate according to their molecular weights and 
allowing their detection in comparison to size standards. Proteins are denatured and a 
negative charge is added to them by exposing them to sodium dodecyl sulphate (SDS) 
and can then be separated by electrophoresis. 
2.8.1 Cell lysis 
 
KIF27 protein was analysed in normal PHA blasts and FHL B Cell lines PP0277 and 
PP0231. Cells were washed twice in PBS and 3x106 cells were pelleted. To this, 500µl of 
lysis buffer was added and the resulting mixture was heated to 980C for 5 minutes.  
2.8.2 Preparing the polyacrylamide gel for electrophoresis 
 
A 10% resolving gel was made for electrophoresis of KIF27 protein, which was reported 
to have a molecular weight of 130kDa.  A 15ml final gel volume was prepared by mixing 
3.75 ml of 40% acryl/bisacryl with 1.875ml of resolving buffer, 8.6ml of distilled water, 
100µl of 10% ammonium persulphate (APS) and 15µl of tetramethylethylenediamine 
(TEMED). APS and TEMED catalyse the polymerisation of the acrylamide, leading to 
cross-linking and setting of the gel. 
The resolving gel was poured into a western blotting gel chamber and allowed to set. 
Exposure to atmospheric oxygen was prevented by careful application of distilled water 
on top of the setting gel, thereby allowing the polymerisation of acrylamide to proceed. 
Next, a stacking gel was prepared by adding 1ml of 40% acryl/bisacryl to 2ml 4x 
stacking buffer, 5ml of distilled water along with 100µl of 10% APS and 15µl of 
TEMED. The stacking gel was poured over the set running gel in the chamber and a 
comb was inserted. When the stacking gel was set, the comb was removed and the 
chamber was inserted into the electrophoresis tank. Running buffer was added to the tank 
to submerge the gel and the protein lysate was loaded on to the wells in increasing 
volumes (10-40µl). Alongside the lysate, a protein standard was also loaded (See blue 
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plus 2, Invitrogen), which consists of 10 pre-stained protein bands in the range of 4-250 
kDa. Protein electrophoresis was then performed at 100 volts or 25 mAmp. 
2.8.3 Protein transfer 
 
After the gel has run, the separated proteins were transferred onto a nitrocellulose 
membrane by electrophoresis in order to proceed with immunoblotting. The electric 
current at 100 volts was now applied at 90 degrees to the gel in order to allow for the 
proteins to migrate out of the gel and onto the membrane.  
2.8.4 Blocking 
 
Once the proteins were transferred onto the nitrocellulose membrane, the membrane was 
blocked in order to reduce non-specific interactions with the antibodies. This was done by 
submerging the membrane in blocking buffer for 2 hours on a rocking platform in room 
temperature or overnight at 40C. 
 
2.8.5 Antibody staining 
 
The membrane was then cut into two halves along the 50kDA marker in order to stain for 
KIF27 (130kDa) and β actin (42kDa) in separate containers. Primary anti-KIF27 antibody 
was diluted to 1:125 dilution in blocking buffer and the membrane was stained for 1 hour 
on a rocking platform followed by three washes in TBST (Tris-base buffer with tween-
20) for 5 minutes each. The other half of the membrane was stained by immersing in 5ml 
of mouse anti-human β actin antibody at 1: 500 dilution, and washed similarly. 
Secondary antibodies of appropriate species specificities were then applied to the 
membranes at 1:500 dilutions – goat anti rabbit for KIF27 and goat anti-mouse for β 
actin, both conjugated to horseradish peroxidase to allow for detection by 
chemiluminescence.  This was followed by three further washes by in TBST for 5 
minutes each on a rocking platform.  
2.8.6 Developing 
 
Enhanced chemiluminescent (ECL) solutions 1 and 2 (Amersham Lifesciences) were 
mixed together at 1:1 ratio and applied to the membrane after placing the latter on a 
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plastic film. Excess solution was prised out from the plastic wrapping and placed in a 
film cassette, after ensuring that no bubbles remained.  In the dark, an x-ray sheet was 
applied onto the membrane within the cassette and exposed for various time points (30 
second to 20 minutes). The films were then developed to obtain the blots. 
2.8.7 Buffers used in Western blotting 
 
All buffers were prepared in house. 
1. 5X lysis buffer was prepared by mixing 10% SDS, 10mM β mercaptoethanol, 
20% glycerol, 0.2M Tris-hydrochloride and 0.05% bromophenol blue in distilled 
water.  
2. Running buffer was prepared by adding 25mM Tris-hydrochloride, 200mM 
glycine and 0.1% (w/v) of SDS. 
3. 10X transfer buffer stock was prepared by adding 30.3 g Tris base and 144.1 g 
glycine to 1 litre water and stored at 4° C.  
4. 1x transfer buffer was prepared by adding 100 ml 10X stock and 200 ml methanol 
to 700ml distilled water. 
5. 8x Resolving gel buffer was prepared by adding 36.3 g Tris base (3 M) and      
0.8g SDS to 100ml distilled water and adjust pH to 8.8 with concentrated HCl 
6. 4x Stacking gel buffer was prepared by adding 6.05 g Tris base (0.5 M) and   0.4g 
SDS to 100ml distilled water and pH adjusted to 6.8 by hydrochloric acid. 
7. 10X Tris base buffer (TBS) was prepared by adding 12.11 g Tris-base (100 mM), 
87.66 g NaCl (1500 mM) and 1litre distilled water, pH adjusted to 7.6.  
8. 1x TBST was prepared by adding 100 ml 10X TBS to 900 ml distilled water and 
1 ml Tween-20. 
9. Blocking buffer was prepared by dissolving 5 % skimmed milk powder in TBST  
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Chapter 3. Mutation Screening of the Functional Candidate 
Genes in FHL I 
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3.1 The FHL I locus in the physical map of the human genome 
 
My study follows from the study by Ohadi et al [223], where linkage to a 7.8 cM region 
on chromosome 9q21.3-22 between the markers D9S1867 and D9S1790 defined the 
novel FHL I locus. My project aims to identify the disease gene within this locus and 
define its role in the pathogenesis of HLH.  
In order to identify all known and potential novel genes mapping to the FHL I locus, a 
transcript map was constructed using the Ensembl genome server (http://www. 
ensembl.org) assembly GRCh37 February 2009, version 57.37b, which contains a 
complete assembly of the human genome. This identified a total of 13 characterised 
genes, one novel protein-coding gene, a number of processed pseudogenes, processed 
transcripts and small RNA genes. (See figure 3.1 and Table 3.1). 
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Figure 3.1. The FHL I locus showing all known and novel genes.  
Microsatellite markers and the corresponding genes within the region on the physical 
map spanning 5Mb are shown. Functional candidate genes are highlighted in red. 
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Table 3.1. Genes at the FHL I locus. 
  
Ensembl gene 
ID 
Known 
genes 
Novel genes Size of 
transcript 
(bp) 
Number 
of 
coding 
exons 
Chromosome 
9 position 
(Mb) 
196781 TLE1  3893 20 84.1 
214929  FLJ46321 4833 3 84.6 
204561 FAM75B  768 3 84.6 
165105 RASEF  5576 17 85.5 
172159 FRMD3  5297 20 85.8 
148057 C9orf103  1623 3 86.2 
135018 UBQLN1  4118 12 86.2 
165113 GKAP1  1778 10 86.3 
165115 KIF27  4653 18 86.4 
165118 C9orf64  2443 4 86.5 
165119 HNRNPK  2652 13 86.5 
178966 RMI1  3416 1 86.5 
197506 SLC28A3  4887 18 86.8 
148053 NTRK2  3708 17 87.2 
Each of the Ensembl gene ID is preceded by ENSG00000 
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3.2 Candidate gene approach to sequencing 
 
In the initial cohort of patients with FHL I, functional studies were not performed by 
Ohadi et al [223]. However, all types of FHL described so far bear mutations in genes 
that encode proteins involved in the vesicular exocytic pathway. It was therefore 
reasonable to assume that like the four other genes implicated in FHL, the putative, 
disease- causing gene in FHL I would also fundamentally perturb the function of perforin 
and will result in impaired lymphocyte cytotoxicity. Based on the structural and 
functional homology of genes within the candidate region to that of proteins implicated in 
the lymphocyte cytotoxic pathway, KIF27, RASEF, UBQLN1 and FRMD3 were 
considered as likely candidate genes and were selected for mutation screening in the first 
instance. All these candidate genes are described in detail, including the rationale to 
consider their candidacy as putative disease causing genes, in section 3.3. 
My initial strategy was to demonstrate the expression of the candidate genes in cytotoxic 
lymphocytes and amplify and sequence all coding exons and intron- exon junctions of the 
candidate genes from genomic DNA extracted from BLCL derived from parents and 
patients mapping to the FHL I locus from the original study cohort.  
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3.3 Candidate genes of the FHL I locus 
3.3.1 KIF27 
 
KIF27 covers 84kb on the reverse strand on chromosome 9q21.32, has 18 exons and a 
transcript length of 4653bp (Figure 3.2). KIF27 expression data available in the NCBI 
Aceview database (www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) indicated 
that KIF27 is moderately expressed (21% of average gene expression) in germ cell 
tumours, testis, breast and kidney cells.  
Data mining from Aceview (www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) 
revealed that KIF27 has 8 different mRNA splice variants, of which 1 is unspliced and 7 
are alternatively spliced. Three of these encode a kinesin motor domain, and are termed 
isoforms A (160.3 kDa), B (152.3 kDa) and C (149 kDa). Isoform A expression has been 
found in normal nasopharynx, normal breast tissue, colon, kidney and skeletal muscle.  
 
 
Figure 3.2. Scheme of the genomic structure of KIF27. 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are drawn to 
scale. 
 
 
KIF27, along with Kif7, KIF4A, KIF4B and KIF21A constitute the Kinesin 4 sub-family 
of mammalian Kinesin family proteins [326] (Figure 3.3). The kinesin superfamily 
proteins (KIFs) contain highly conserved amino acid sequences such as the microtubule 
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binding domain and the ATP binding domain and transport cellular organelles, protein 
complexes, and mRNAs to specific destinations in a microtubule- and ATP-dependent 
manner [327]. Members of the Kinesin 4 subfamily have been implicated in neuronal 
organelle transport and chromosome segregation during mitosis. The motor domain in 
KIF27 is found at the N-terminus [328] and it thereby constitutes an N-type kinesin. N- 
type kinesins are plus-end directed molecular motors. Kinesin motor domains use the 
energy derived from hydrolysis of ATP to achieve the required conformational changes 
to generate an ∼8nm ‘step’ to move along the microtubule at a speed of about 640 nm per 
second and create a force of several picoNewtons, in order to carry large cargo through a 
crowded cytoplasm. It has been shown that non- motor domains can also play important 
roles in the motor function of these proteins, such as cargo- binding domains and coiled- 
coil segments for dimerisation of motor domains [310].  
 
 
 
Figure 3.3 Phylogenetic analysis of kinesin family members 
Phylogenetic analysis reveals that KIF27, KIF7, KIF4B, KIF4A and KIF21A constitute the 
Kinesin 4 subfamily (marked with an oval). Adapted from Katoh et al, 2004 [326]. 
 135 
 
Another member of the Kinesin 4 subfamily, KIF4, has been shown to be required for 
activity- dependent neuronal survival by regulating apoptosis of juvenile neurons [329]. 
A further member of the Kinesin 4 subfamily, KIF21A, was found to be mutated in 
congenital fibrosis of the extraocular muscles type 1 (CFEOM1; OMIM #135700), an 
autosomal dominant strabismus disorder associated with defects of the oculomotor nerve 
[330]. It has been postulated that CFEOM1 resulted from the inability of the mutated 
KIF21A to deliver a cargo essential to the development of the extraocular neuromuscular 
system. The physiological role of KIF27 has not been experimentally demonstrated, but 
analysis of its domain structure as well as the function of its phylogenetic family 
members suggest that it may be implicated in the vesicular transport of cytotoxic 
lymphocytes, and KIF27 was therefore a strong candidate gene within the FHL I locus. 
3.3.2 RASEF 
RASEF, encoding Ras and EF hand domain containing protein, (synonym RAB45) is a 
17- exon gene encoded on the minus strand of chromosome 9q21.32 (coordinates 
85597315 to 85678043 of the NCBI 37, March 2009 human genome build). (See Figure 
3.4).  
 
 
Figure 3.4. . Scheme of the genomic structure of RASEF. 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
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Four spliced variants are predicted in RASEF. Splice variant A has a 5586bp mRNA and 
a predicted protein that is 830 amino acids long (92.3 kDa). (See figure 3.5). It contains 
one Ras domain, 3 Ca++ binding EF-hand domains, one Miro-like domain (mitochondrial 
Rho GTPase), a coiled coil stretch, and a leucine zipper domain. According to the 
Aceview database of NCBI (www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), 
this variant is expressed in lung, skin, melanoma and prostate tissues, apart from a wide 
variety of other tissues. Splice variant B mRNA is 1765bp long and encodes a protein 
containing 292 amino acids (31kDa). It has 2 Ca++ binding EF-hand domains and is 
expressed in muscle, rhabdomyosarcoma tissue, breast adenocarcinoma tissue and normal 
breast tissue. Variant C mRNA is 646bp long, encodes a 91 amino acid protein (6.1kDa). 
Expression of this variant has only been demonstrated in breast adenocarcinoma tissue 
and it contains a Ras domain. 
 
Figure 3.5 Crystal structure domains of human RASEF 
 
a) Rab domain in human RASEF complexed with GDP, demonstrated by X ray 
diffraction method (Zhu et al www.sgc.ox.ac.uk) b) EF hand domain of human RASEF 
adapted from Kyoto Database of Genes and Genomes (www.genome.jp/dbget-bin).  
 
RASEF has recently been proposed to be a tumour suppressor gene in the context of 
uveal melanomas. The proposed mechanism involves loss of heterozygosity in its 
genomic locus in combination with epigenetic silencing such as hypermethylation of its 
promoter [331]. 
The Ras superfamily of small GTPases comprises six subfamilies, namely Ras, Rho, Ran, 
Rab, Arf and Kir/Rem/Rad and includes over 150 small GTPases. Members of the Ras 
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superfamily have been implicated in a variety of cellular roles such as survival, growth 
and differentiation, production of cytokines, phagocytosis, chemotaxis and vesicle 
trafficking. Rab proteins play important roles in both endocytic and exocytic vesicular 
trafficking pathways [155]. As discussed in Section 1.1.7 and 1.1.8.5, about 70 different 
Rab proteins have been identified in humans and each Rab protein has a characteristic 
vesicular distribution and may function to determine specific vesicular membrane 
organization and serve to provide specific organelle identities. The role of another Rab 
protein, Rab27a, in vesicular trafficking in lymphocytes and melanocytes has already 
been clearly demonstrated, through the study of Rab27 in patients with Griscelli 
syndrome, characterised by pigmentary dilution and a HLH syndrome in humans and in 
mice with the ashen phenotype.  
Based on these data it was plausible to consider RASEF as one of the prime candidate 
genes in FHL I. 
3.3.3 UBQLN1 
UBQLN1 (synonym PLIC1) maps to 9q21.2-21.3 and covers 48.29Kb. It is encoded on 
the minus strand and lies between the coordinates 86274878 to 86323168 (NCBI 37, 
March 2009). (See Figure 3.6). 
 
Figure 3.6. Scheme of the transcript structure of UBQLN1 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
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UBQLN1 has nine alternatively spliced variants, of which 2 contain a Ubiquitin-like  
domain. The longest, variant A, has a predicted protein of 589 amino acids (62.5 kDa) 
and contains an N- terminal Ubiquitin-like domain and a C-terminal ubiquitin- interacting 
motif (UIM). This variant is expressed in a wide variety of normal tissues, including 
kidney, lung and brain. Splice variant B has a predicted protein of 561 amino acids (59.2 
kDa) and is reported to be expressed in normal and malignant B cells. Like variant A, 
variant B also contains an Ubiquitin-like domain and a UIM. The other variants do not 
appear to have any known protein domains or characteristic Psort motifs other than 
variant G, which comprises 120 amino acids (12kDa) and has a UIM. Expression data 
was obtained from the Aceview database of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html). 
The protein encoded by PLIC1 (protein linking integrin associated proteins and 
cytoskeleton) or UBQLN1 was shown to physically associate with proteasomes 
(specifically to the UIM of the proteasome subunit S5a [332]) as well as certain ubiquitin 
ligases, thereby serving as a functional link between the ubiquitination and the 
proteosomal degradation machinery of the cell [333]. More recently, Plic1 has been 
shown to promote stability of the inhibitory gamma amino butyric acid A (GABAA) 
receptors on the ER, increase the rate of their neuronal membrane insertion as well as 
increase the polyubiqutination of the receptor subunits, highlighting the role of Plic1 in 
rapid synaptic inhibition of neurotransmission [334]. Genetic variation in the UBQLN1 
gene has been shown to significantly increase the risk of developing Alzheimer’s disease 
possibly by influencing alternative splicing of this gene in the brain [335]. Expanding on 
the association of Plic1 with the UIM of the proteasome subunit S5a, a wider role of Plic1 
in associating with other proteins harbouring the UIM motif, such as UIM proteins ataxin 
3—a deubiquitinating enzyme, HSJ1a—a co-chaperone—and EPS15 (epidermal growth 
factor substrate 15)—an endocytic protein has been demonstrated [336]. Using a 
polyglutamine disease model, it was also demonstrated that Plic1 plays a role in the 
cellular stress response and regulates aggresome formation.  
Ubiquitination and subsequent degradation of the TCR and associated signaling proteins 
are important mechanisms of signal termination in T cells. For instance, abnormally 
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sustained signal transduction and T cell activation in response to antigen was noted in 
mice with double knockout of the ubiquitin ligases c-Cbl and Cbl-b [337]. Thus, 
disruption of this biological pathway could potentially be associated with abnormal 
cytotoxic lymphocyte response in FHL I. Given its role in the ubiquitination and 
proteasome- associated protein degradation machinery, UBQLN1 was a strong candidate 
as the putative FHL I-causing gene. 
 
3.3.4 FRMD3 
 
FRMD3 maps on chromosome 9q21.32, covers 295.61kb and spans the coordinates 
85862300 to 86153348 (NCBI 37, March 2009), on the reverse strand (Figure 3.7). 
 
 
 
Figure 3.7. Scheme of the genomic structure of FRMD3 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
 
FRMD3 is also known as 4.1O (Ovary type) or FERM domain containing 3. FRMD3 has 
20 exons and up to 9 alternatively spliced variants. The longest open reading frame 
(ORF) is 5302bp long, has a predicted protein of 667 amino acids (76kDa), which 
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contains a FERM domain and 2 leucine zipper domains and is widely expressed in 
normal tissues. Five other alternatively spliced variants also possess the FERM domain, 
of which variant b has 553 amino acids (63.7kDa) and was reported to be expressed in 
adult ovary only [338]. FRMD3 is a member of the 4.1 family of structural proteins that 
also include 4.1R (Red blood cell type, located at 1pter-p34), 4.1N (Neuron type, located 
at 20q11.2-q12), 4.1B (Brain type, located at 18p11.32) and 4.1G (General type, located 
in 6q23). All the 4.1 proteins characteristically possess the FERM (F, 4.1; E, Ezrin; R, 
radixin and M, moiesin) domain, which is a 30kDa membrane- binding domain and 
contain binding sites for membrane proteins such as band 3.1, glycophorin C or CD44 
[338].  
The function of the FRMD3 protein has not been well characterised so far. Following 
data obtained by microarray analysis of primary non-small cell lung carcinomas 
(NSCLC), Haase et al in 2007 reported that FRMD3 was expressed in normal lung tissue 
but expression was reduced in 54 out of 58 tumours studied. The researchers also 
demonstrated that FRMD3 over-expression in epithelial cell lines resulted in a reduction 
in their clonogenecity, presumably by increasing the rate of apoptosis. The authors 
concluded that FRMD3 was a tumour suppressor in NSCLC [339]. More recently, 
following genome- wide SNP arrays in patients suffering from diabetic nephropathy 
versus normal controls, Pezzolesi et al concluded that polymorphisms in the FRMD3 
locus rendered it the most significant disease susceptibility locus [340].  
Despite the paucity of data concerning FRMD3 per se, the role of ERM domain- 
containing proteins in the formation of the T cell immunological synapse has been well 
established. ERM proteins ezrin and moesin (Figure 3.8) help attach transmembrane and 
cytoplasmic molecules to the actin filaments at the cell cortex. They have also been 
implicated in a wide variety of T cell functions such as microvilli maintenance; FAS 
induced cell death and TCR induced-signaling leading to cytokine production [112]. At 
the steady state, T cells in humans contain an excess of phosphorylated moesin, which 
associates with CD43 in the cell membrane, whilst ezrin remains dephosphorylated and 
remains in the cytoplasm. Upon T cell stimulation, moesin is rapidly dephosphorylated, 
causing the membrane microvilli to collapse and cause release of CD43. Concomitantly, 
ezrin binds to ZAP70 and recruits it to the IS, from which moesin and CD43 are excluded 
 141 
[341] (Figure 3.9). It has been shown that rapid inactivation of ERM proteins following 
antigen recognition by the TCR is mediated via a Vav1-Rac1 pathway, leading to 
detachment of the actin cytoskeleton form the plasma membrane, reduction in cellular 
rigidity and more efficient cell conjugate formation [113].  
 
 
 
 
 
 
 
Figure 3.8. Domain structure of the FERM domain – containing proteins ezrin and 
moesin present in T cells 
ERM proteins are present in two conformations. In the inactive form, the N-terminal 
FERM domain (equivalent to the N-terminal ERM-association domain, NERMAD) 
interacts with a C-terminal region (C-ERMAD), which contains the actin binding domain 
(ABD). This interaction masks both the actin and cargo binding sites. PRD: Proline rich 
domain. CD43, RhoGDI bind to the FERM domain and F- actin binds to the ADB. Y 
indicates important phosphorylation sites. 
Adapted from Burkhardt et al, 2008 [112] 
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Figure 3.9. Role of ezrin and moesin, the two FERM domain-containing proteins in T 
cell immunological synapse in human.  
Upon T Cell activation, moesin is rapidly dephosphorylated, leading to release of CD43 
from the IS. Ezrin helps in the ZAP70 recruitment to the IS on initiation of T cell 
signaling. Adapted from Fehon et al, 2010 [341]. 
 
 
Thus, the presence of a FERM- domain containing protein within the FHL I locus makes 
FRMD3 a candidate FHL I gene, as there are clearly a number of important roles played 
by other members of this superfamily in T cell function. 
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3.4 Mutation screening of candidate genes: KIF27, RASEF, UBQLN1 and 
FRMD3 
 
3.4.1 Mutation screening of B Cell lines from FHL I families 
 
My mutation screening strategy initially focused on sequencing the exons and exon-
intron boundaries of KIF27, RASEF and FRMD3 from genomic DNA of an affected 
individual and several parents from kindred already known to be linked to 9q21.3-22 
[223]. In the case of UBQLN1, full-length cDNA from the same individuals was used. In 
order to screen for regulatory area mutations, I also studied gene expression by real time 
PCR of all the FHL I genes.  In selected occasions, I also amplified and sequenced the 
whole regulatory areas of certain genes, details of which I will discuss later. 
As discussed in section 2.1.1, the EBV transformed B cell lines PP0150, PP0180 and 
PP0225 were available for FHL I mutation screening. All three cell lines were established 
from parents of affected individuals from families demonstrating linkage to the FHL I 
locus and were therefore presumed to be heterozygous for the putative FHL I gene. Along 
with these cell lines, I also studied the parental cell line PP0277 and the patient cell line 
PP0231, the latter being the only proband material available to study. It should be noted 
that PP0277 and PP0231 were not part of the initial cohort of families reported by Ohadi 
et al [223]; instead they were studied at a later time and their linkage to FHL I was 
reported in an abstract form. (Family trees with microsatellite marker haplotypes of 
PP0277 and PP0231 are illustrated in Figure 2.1). 
Therefore, I initially worked with genomic DNA as well as cDNA from B cell lines from 
a total of five FHL I families. Due to constraints in available cellular material, none of 
these individuals were parental-proband trios, and were in fact all unrelated to one 
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another. PP0231, the sole proband whose genetic material was available for study was 
female and had been reported to carry the A91V polymorphism in its PRF1 gene, 
something that I confirmed by sequencing the PRF1 gene (see Figure 3.10).  Researchers 
from the Ohadi study [223] had identified the mother to be homozygous for this 
polymorphism, but I did not have any material to confirm this finding. Furthermore, 
using long-range PCR and internal sequencing primers I genotyped exon 2 (coding exon) 
of STX11 from genomic DNA of PP0231 and found it to be wild type, thus excluding 
STX11 as a disease gene in this patient. By amplifying and sequencing exons 5, 8, 9, 10, 
14 and 16 of STXBP2, the gene recently reported as the causative gene in FHLV [230, 
231] from genomic DNA from PP0150, PP0277 and PP0231 I found them to be wildtype, 
therefore excluding all the reported mutations in this gene. 
  
 
Figure 3.10. Chromatogram showing sequence of PRF1 Exon 2 from PP0231  
The chromatogram depicts a heterozygous C/T variation in position 272 in Exon 2, 
leading to the formation of the A91V polymorphism in heterozygosity.  
 
3.5.2 FHL I locus genotype analysis using microsatellite markers 
 
Using the same set of 7 microsatellite markers spanning the FHL I locus used in the study 
by Ohadi et al [223], I genotyped the FHL I cell lines PP0231, PP0277, PP0225 and 
PP0150. Primer sequences of the markers (consisting of dinucleotide repeats) were 
identified from the NCBI UniSTS database.  Fragment length analysis of individual 
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alleles was performed using the Genescan software by Applied Biosystems (See Figure 
3.11). Manual haplotype construction using the family trees shown in Fig 1.19 as 
reference confirmed the findings of Ohadi et al, with the exception of PP0150 and 
PP0277. In the case of PP0150, discrepancy pertains to markers D9S167 and D9S152, 
which were reported as heterozygous in the early study but were found homozygous in 
this study. Because alleles in the Ohadi study were assigned on the basis of migration on 
polyacrylamide gels, it is possible that alleles of similar size such as 8 and 7, or 5 and 6 
could be wrongly assigned; while the high resolution capacity of capillary electrophoresis 
used in my study allows accurate assignment of allele sizes. In the case of PP0277 there 
are discrepancies pertaining to several markers, for which no satisfactory explanation can 
be given. 
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Figure 3.11. Haplotypes from 4 kindred that demonstrated linkage to the FHL I locus 
Cell lines are derived from one member of each kindred, as indicated in brackets. 
Haplotypes from the original study by Ohadi et al [223] are depicted in black. The same 
individuals were subjected to repeat typing, depicted in blue, with individual alleles 
indicated by length of the amplified fragments. Putative disease- linked haplotypes are 
boxed. There appears to be a discrepancy between the Ohadi and this study in the 
genotyping of PP0277 and PP0150, see text. 
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3.5.3 Mutation screening of KIF27  
 
3.5.3.1 Expression pattern of KIF27 
 
In order to establish a positive control, cDNA was synthesised from non- haemopoietic 
cell-lines that have been reported in databases such as Aceview of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) to express KIF27, such as 
293T (human embryonic kidney cell line), PC-3  (prostatic adenocarcinoma cell line), 
MDA-MB231 and MCF7 (both breast adenocarcinoma cell lines) and LN405 (human 
glioma cell line) and cDNA- specific primers were used to amplify KIF27. I was able to 
demonstrate KIF27 expression in cells of haemopoietic origin as well as some cancer cell 
lines (See figure 3.12). In particular, KIF27 was expressed in B-lymphoblastoid cell lines 
derived from parent PP0150, and patient PP0231 with linkage to the FHL I locus as well 
as in resting T cells.  
 
 
Figure 3.12. RT-PCR to demonstrate KIF27 expression from various cell types.  
Agarose gel showing RT-PCR for KIF27 and beta-actin amplification control. Primer 
pairs were designed to span more than one exon in order to exclude genomic DNA 
template contamination; source of cDNA is indicated in the gel. PBMC: Peripheral blood 
mononuclear cells; PP0150, PP0231: B-lymphoblastoid cell lines derived from parent 
and patient respectively mapping to the FHL I locus; PC3: prostate cancer cell line, JKT: 
Jurkat cells, 293T: Human embryonic kidney cell line; MCF: breast adenocarcinoma cell 
line. H2O Ctl: Water control.  
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In order to determine whether KIF27 expression changes upon T cell activation, I studied 
KIF27 mRNA levels in stimulated T cells derived from normal blood donors. For this 
purpose, PBMC were separated from normal blood buffy coats followed by CD8 T cell 
negative selection using immunomagnetic beads (see example in Figure 3.13). 
 
 
 
Figure 3.13. FACS analysis showing high purity of CD8 + T cells obtained by negative 
selection from PBMC using immunomagnetic beads 
The red line represents isotype control and the blue line represents CD8-APC. 
 
The CD8 + T cells obtained by this method were then stimulated with the mitogen lectin 
phytohaemagglutinin (PHA) or with anti-CD3/CD28-coated Dynabeads for various time 
points. KIF27 expression of the activated T cells were analysed by RQ-PCR using the 
housekeeping gene GAPDH as an internal normalisation control and comparing the fold 
– change of KIF27 expression with the unstimulated T Cells as baseline (Figure 3.14).  
The RQ-PCR data demonstrated an increase in level of KIF27 expression at 15 minutes 
after stimulation, and levels were back to baseline between 30 minutes to an hour of 
stimulation.  
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Figure 3.14. KIF27 expression at various time points in normal CD8+ T Cells 
following stimulation by phytohaemagglutinin or CD3/CD28 – coated beads.  
Each bar represents an average of two separate RQ-PCR experiments. Individual RQ-
PCR readings were obtained from mean data from samples in triplicate. 
3.5.3.2 Direct sequencing of KIF27 from genomic DNA  
 
The strategy for mutation screening of KIF27 involved the PCR amplification of all 
exons and intron- exon junctions followed by direct sequencing of the PCR amplicon; or, 
in select cases (see below) PCR amplicons were first cloned into a TA cloning vector and 
subsequently individual clones were subjected to direct sequencing. Finally, direct 
sequencing of the full length KIF27 cDNA was also undertaken. 
For direct sequencing, genomic DNA was extracted from EBV B-cell lines from 4 
parents (PP0150, PP0225, PP0277 and PP0180; see family trees in Fig 1.19) and one 
affected patient (PP0231) (See Figure 2.1 for family tree) all belonging to different 
kindred, from the original study by Ohadi et al [223]. DNA from a total of 6 non-FHL 
controls was also used i.e., 4 from normal donor PBMCs and two from non- FHL EBV 
B-cell lines. 
Table 3.3 summarises the sequence analysis of KIF 27 from direct DNA sequencing. 
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Table 3.3. Summary of genomic DNA sequence analysis of KIF27 
 
KIF27 Cell line 
PP0150 
(Parent, 
Kindred 
1) 
Cell line 
PP0277 
(Parent, 
Kindred 
15) 
Cell line 
PP0225 
(Parent, 
Kindred 3) 
Cell line 
PP0231 
(Affected, 
Kindred 6) 
Cell line 
PP0180 
(Parent, 
Kindred 
2) 
 
Contr
ol 
DNA 
Exon 2 WT WT WT WT 63A>G 
non-
coding 
portion of 
Exon2, 
coding 
sequence 
begins in 
position 
145 
- 
Exon 3 WT WT WT WT WT - 
Exon 4 WT WT NA 782G>A het 
exonic 
WT - 
Exon 5 WT WT WT WT WT - 
Exon 6 2 het 
exonic 
changes- 
1851T>C
, 
1952A>
G 
3 het 
exonic 
changes- 
1851T>C, 
1952A>G 
1877G>A 
3 het 
exonic 
changes- 
1851T>C, 
1952A>G 
1877G>A 
3 het exonic 
changes- 
1851T>C, 
1952A>G 
1877G>A 
3 het 
exonic 
changes- 
1851T>C, 
1952A>G 
1877G>A 
- 
Exon 7 1 intronic 
and 6 
exonic 
‘a’ intronic 
insertion 
100 bp 
2 intronic 
changes 
and 5 
1 intronic 
and 5 exonic 
het changes 
1 intronic 
and 6 
exonic het 
- 
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het 
changes 
2012G>
A 
2030G>
A 
2035A>
G 
2045A>
G 
2050A>
G 
2117G>
A 
upstream of 
intron-exon 
junction 
and 1 het 
exonic 
change 
2117G>A 
exonic het 
changes 
2012G>A 
2030G>A 
2035A>G 
2045A>G 
2050A>G 
2012G>A 
2030G>A 
2035A>G 
2045A>G 
2050A>G 
changes 
2012G>A 
2030G>A 
2035A>G 
2045A>G 
2050A>G 
2117G>A 
Exon 8 Chromat
ogram 
shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatogra
m shows 
double 
peaks, See 
cloning data 
Chromato
gram 
shows 
double 
peaks 
 
Exon 9 Chromat
ogram 
shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatogra
m shows 
double 
peaks, See 
cloning data 
Chromato
gram 
shows 
double 
peaks 
Chro
matog
ram 
shows  
doubl
e 
peaks 
Exon 10 2563A>
G het in 
exonic 
sequence 
2563A>G 
het in 
exonic 
sequence 
2563A>G 
het in 
exonic 
sequence 
2563A>G 
het in exonic 
sequence 
2563A>G 
het in 
exonic 
sequence 
- 
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Exon 11 2 exonic 
changes 
2595G>
A het 
2664G>
A het 
3 exonic 
changes 
2595G>A 
het 
2664G>A 
het 
2723G>A 
het 
2 exonic 
changes 
2595G>A 
het 
2664G>A 
het 
2 exonic 
changes 
2595G>A 
het 
2664G>A 
het 
2 exonic 
changes 
2595G>A 
het 
2664G>A 
het 
- 
Exon 12 PCR 
condition 
not found 
PCR 
condition 
not found 
PCR 
condition 
not found 
WT in 
cDNA 
sequence 
analysis 
PCR 
condition 
not found 
- 
Exon 13 WT WT WT WT WT - 
 
Exon 14 WT Exonic 
change het 
3198A>G 
NA Exonic 
homozygous 
3250 
rs55654273 
A>G 
WT - 
Exon 15 3330 
rs295274 
T>A 
homozyg
ous 
3330 
rs295274 
T>A het 
3330 
rs295274 
T>A het 
3330 
rs295274 
T>A het 
3330 
rs295274 
T>A 
homozygo
us 
- 
Exon 16 3684A>
G het 
WT WT 3684A>G 
het 
3684A>G 
het 
- 
 
 
 
 
Exon 17 Chromat
ogram 
Chromatog
ram shows 
Chromatog
ram shows 
Chromatogra
m shows 
Chromato
gram 
Chro
matog
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shows 
double 
peaks 
double 
peaks 
double 
peaks 
double 
peaks; see 
cloning data 
shows 
double 
peaks 
ram 
shows 
doubl
e 
peaks 
Exon 18a Chromat
ogram 
shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatog
ram shows 
double 
peaks 
Chromatogra
m shows 
double peaks 
Chromato
gram 
shows 
double 
peaks 
Chro
matog
ram 
shows 
doubl
e 
peaks 
Exon 18b WT 
coding 
part 
NA WT coding 
part 
WT coding 
part 
WT 
coding 
part 
- 
WT: wild type, het: heterozygous, AA: Amino acid, N/A: Not available, A: Adenine T: 
Thymine C: Cytosine G: Guanine Single nucleotide polymorphisms that have been 
published in the hapmap database (http://www.hapmap.org) have been highlighted in 
bold with their corresponding variation number. Exon 1 is non- coding and was 
sequenced as part of the promoter sequence; see below. 
 
Direct sequencing showed multiple and complex changes in all exons with the exception 
of exons 3, 5 and 13. These changes were confirmed by sequencing of both the sense and 
anti-sense strands. Most findings comprised single nucleotide substitutions of which only 
two (3250 rs55654273 A/G, exon 14 and 3330 rs295274 T/A, exon 15) are recognised 
single nucleotide polymorphisms (SNP) in KIF27 gene published in the hapmap database 
(http://www.hapmap.org). Exon12 could not be amplified from genomic DNA despite 
attempts with 5 different primer pairs. Direct sequencing showed double- peaked 
chromatograms in exons 8, 9, 17 and 18 on all 5 test DNA as well as normal genomic 
DNA from 4 unaffected controls (A representative group of chromatograms from KIF27 
Exon 8 genomic DNA PCR sequencing is shown in Figure 3.15). 
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Figure 3.15. Chromatogram traces of KIF27 Exon 8 from various genomic DNA 
sources. 
Double peaks in chromatogram from sequencing of genomic DNA from: 
a- PP0150 (FHL I cell line from parent) 
b- PP0231 (FHL I cell line form proband) and  
c- Normal control DNA.  
Blue arrows indicate start of exon 8. Red arrows indicate start of abnormal 
chromatogram. The chromatograms appear identical in FHL I cell lines as well as 
normal control. See text. 
 
This finding implied the presence of variants of KIF27 either in the form of a 
pseudogene, duplicated gene or copy number variation (CNV). Therefore, it became 
necessary to proceed with sequencing at the single molecule level in order to exclude 
sequences arising from such genomic variants and also in order to identify any underlying 
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mutation in the KIF27 gene itself, which might be masked by the amplification of such 
variants. This was achieved by performing TA cloning of PCR products of the exons 
under investigation as described in detail in section 2.2.4. 
3.5.3.3 TA cloning of Exons 8,9, 17 and 18 
 
TA cloning data has been summarised in Table 3.4. Specifically, exons 8, 9, 17 and part 
of exon 18 (referred here as exon 18a) were cloned from both PP0231 (patient cell line) 
and one normal control DNA. Direct PCR and sequencing of all these exons had shown 
double peaks in their chromatogram traces in both FHL I cell lines and normal controls. 
Between 6 and 13 individual clones were examined for each exon under investigation, in 
test as well as control DNA. Direct sequencing of individual clones revealed that between 
40-90% of clones from PP0231 and normal control DNA completely aligned to the 
published wildtype sequence of KIF27 from the Ensembl and NCBI databases. Some of 
the remaining clones aligned to an area 2Mb upstream of KIF27 in chromosome 9 with 
95- 98 % homology. This area contains a known pseudogene RP11-213G2.2 (Ensembl 
Gene ID ENSG00000165121) with two transcripts ENST00000297820 and 
ENST00000431724, but no protein product. Indeed, further investigation of the aberrant 
finding in KIF27 genomic sequencing data revealed the presence of a 100.5-kb complex 
inverted segmental duplication, separated from the gene by 2Mb involving all but exons 
1, 2 and 3 of KIF27 and exon 1 of the neighbouring centromeric GKAP42 gene, with 
98% overall homology, as annotated in the Human Segmental Duplication database 
(http://projects.tcag.ca/humandup). 
 
 
 
 
 
 156 
 
 
 
Table 3.4 TA Cloning data from KIF27 
 
KIF27 
Exon 8 
cloning 
    
DNA 
source 
No of 
clones 
sequenced 
Exonic changes Intronic 
changes 
Remarks 
PP0231 13 4 (30%) clones had a 4- bp deletion 
(2164-2167 or 2163-2166) as well 
and 2216T>C changes. 2 out of the 
above 4 clones also had an A>G 
change, one had 2192A>G other had 
2211A>G. 
1 clone had no deletions but had 
2199A>G change  
None 8 clones 
(61%) were 
wildtype  
Normal 
control 
12 1 (8%) clone had 4bp deletion 2164-
2167 and 2211A>G change 
None 11 clones 
(92%) were 
wildtype 
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KIF27 
Exon 9 
cloning 
    
DNA 
source 
No of 
clones 
examined 
Exonic changes Intronic changes Remarks 
PP0231 9 4 clones (44%) had 
2310T>C change 
and 2335A>G 
change, another 
clone had 
2312A>G change 
4 clones that had 2310T>C 
and 2335A>G change also 
had an a>t change 24 bp 
downstream of intron- exon 
junction and a t deletion 42 
bp downstream of intron- 
exon junction 
4 clones 
(44%) 
were 
wildtype 
Normal 
control 
10 5 clones (50%) had 
2310T>C and 
2335A>G changes 
a>t 6 bp downstream of 
intron-exon junction, het in 1 
clone. This clone has WT 
coding sequence 
4 clones 
(40%) 
were 
wildtype  
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KIF27 
Exon 17 
cloning 
    
DNA 
source 
No of 
clones 
examined 
Exonic changes Intronic changes Remarks 
PP0231 6 1 clone (16%) had 
3799G>T, 4 
clones (67%) had 
3857C>T, 
rs1055358 known 
SNP in KIF27  
‘cg’ insertion 
and c>g change 
73bp upstream 
of start of exon 
17 in 4 clones 
2 clones had an 
‘a’ insertion 
rather than ‘cg’ 
insertion in 
same position 
‘cg’ and ‘a’ insertion 73 
bp upstream of start of 
exon17 is the likely 
cause for double peaks 
on direct sequencing of  
PCR-amplified genomic 
DNA 
Normal 
control 
6 3771T>C and  
3784A>G in 1 
clone and 
3778T>C in 1 
clone 
‘ac’ insertion in 
2 clones and ‘a’ 
insertion in 1 
clone -73 bp 
upstream of start 
of Exon 17 
4 clones have WT 
coding sequence. 
Double peaks on direct 
sequencing is likely due 
to intronic insertions, as 
in cloning data from 
PP0231 
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KIF27 Exon 
18a cloning 
    
DNA source No of clones 
examined 
Exonic 
changes 
Intronic 
changes 
Remarks 
PP0231 7 1 clone had 
complex 
changes- 
3870A>T, 
3871G>A, 
‘AGG’ del 
3906-9 
3971A>G, 
‘CA’ del 4146-
7 
None 6 out of 7 
clones were 
WT 
Normal control 8 3870A>T, 
3871G>A in 5 
clones (63%). 
CC-TT change 
in 1 out of 
these 5 clones 
in position 
3895 and 3896. 
1 clone had 
4015A>G 
change 
None 2 out of 8 
clones were 
WT 
 
In summary, the sequencing data from this set of cloning experiments did not identify 
changes specific to the parental or patient samples; in addition, it supports the presence of 
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a variant of the KIF27 gene in chromosome 9 in the form of segmental duplication and/or 
copy number variant. 
3.5.3.4 Amplification of KIF27 from cDNA of cell line PP0231 derived from FHL I 
patient 
 
In order to determine whether the genomic sequencing data changes were also present at 
mRNA level, RNA was extracted and cDNA synthesised from PP0231 cells. The entire 
coding sequence of KIF27 (4206 bp) was amplified using long-range RT-PCR and 
sequenced using sequencing primers covering overlapping segments of 300bp each. 
Sequencing of KIF27 in PP0231 cDNA did not show any of the numerous changes seen 
from the genomic sequencing data, except the two recognised SNP (3250 rs55654273 
A/G, exon 14 and 3330 rs295274 T/A, exon 15) found in the direct sequencing of 
genomic DNA extracted from PP0231. The rest of the sequence was normal as annotated 
in the NCBI database build 37, March 2009. Thus, these data combined with the genomic 
sequencing data discussed in 3.5.3.3 ensure that there are no pathogenic mutations in the 
coding region of KIF27 in the patient cell line PP0231. 
 
3.5.3.5 RQ-PCR of KIF27 from FHL I cell lines 
 
The various approaches to sequencing KIF27 excluded a coding region mutation in this 
gene in both patient and parental B cell lines. However, there was still the distinct 
possibility that either a regulatory (e.g., promoter) or intronic mutation being present, and 
if so, such mutations would be expected to result in reduced KIF27 mRNA levels. 
As a first step to addressing the possibility of a regulatory area or intronic mutation in the 
KIF27 gene, I quantified the KIF27 mRNA in the test cell lines. As I was able to 
demonstrate KIF27 expression in BLCL earlier, I proceeded to analyse the relative 
amount of gene expression of KIF27 in the FHL B cell lines using SYBR Green- based 
RQ-PCR (QuantiTect PCR system). I employed a ΔΔCT method to quantify expression 
of KIF27 in the test FHL I cell lines normalised to an internal control (housekeeping gene 
GAPDH) and compared that with the expression of KIF27 in a non- FHL BLCL, PP0065. 
My data showed that KIF27 was consistently and reproducibly reduced in the patient cell 
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line PP0231 compared to those from the parents but only slightly lower than the normal 
controls (Figure 3.16a) thus making the significance of the reduced mRNA levels in the 
patient in relation to parental lines uncertain. When I tested gene expression of the FHL I 
cell lines in relation to another non-FHL I B cell line PP0007, I found that gene 
expression in PP0231 was in fact higher than that of the parental cell lines PP0277 and 
PP0150 (Figure 3.16b), further confirming that KIF27 expression was not reduced in the 
proband cell line PP0231. 
 
 
 
Figure 3.16a. Relative expression of KIF27 in FHL I cell lines by RQ-PCR using cell 
line PP0065 as standard. 
Gene expression was normalised to an internal control housekeeping gene GAPDH and 
compared to the expression of KIF27 in a non- FHL I B Cell line PP0065 using the ΔΔCT 
method. The data is representative of 5 experiments (Mean ± s.d.). 
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Figure 3.16b. Relative expression of KIF27 in FHL I cell lines by RQ-PCR using cell 
line PP0007 as standard. 
Gene expression was normalised to an internal control housekeeping gene GAPDH and 
compared to the expression of KIF27 in a non- FHL I B Cell line PP0007 using the ΔΔCT 
method.  
 
 
 
3.5.3.6 Promoter sequencing of KIF27 including FHL I patients and controls 
 
In order to exclude a regulatory area mutation of the KIF27 gene in PP0231 as indicated 
by the reduction of KIF27 expression in PP0231 compared to that in the FHL I parental 
cell lines PP0150 and PP0277 in the RQ-PCR experiments using cell line PP0065 as 
standard, I obtained the regulatory sequence of KIF27 from the Regulatory build of the 
Ensembl database. The regulatory areas in the Ensembl database are built by identifying 
core regulatory regions using DNAse 1 hypersensitivity sites, which mark for accessible 
chromatin, histone H3 trimethylated at lysine 4 (H3K4me3), which is associated with 
active chromatin and gene expression and CTCF (CCCTC binding factor) binding sites 
that can act as transcription initiation sites 
(www.ensembl.org/info/docs/funcgen/index.html).  
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The KIF27 promoter region is 1.64Kb and is situated between the coordinates 86450932-
86452605 in chromosome 9 of the NCBI 37 database. I amplified and sequenced the 
promoter region of the patient cell line PP0231 as well as the parental cell lines PP0150 
and PP0277 along with 10 normal controls using a GC- rich PCR protocol. Sequencing 
was complicated by the presence of a 32bp sequence that was repeated three consecutive 
times, occasionally giving rise to the appearance of a 32bp ‘deletion’ on the sequence 
chromatogram, most likely due to a polymerase ‘slippage’ (Figure 3.17). This sequencing 
anomaly was observed in both normal and FHL I DNA, and variously present or absent 
when template DNA from all the test and control samples were re-amplified and 
sequenced in separate experiments, confirming the hypothesis that it was due to a 
sequencing artefact.  
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Figure 3.17. Alignment of KIF27 promoter sequences from FHL I parental cell line 
PP0277 showing a 32bp ‘deletion’ 
Alignment was performed using the Clustal 2 programme. Using genomic DNA from 
PP0277, 9 different PCR reactions were performed. In experiments 4 and 5, forward 
primer sequencing (F4, F5) shows complete alignment to the wiltdype sequence. 
Reverse primer sequencing from the same PCR product (R4, R5) shows presence of the 
32bp ‘deletion’. Wildtype sequence was also obtained from PCR 6. However, all other 
reactions demonstrate the presence of the same ‘deletion’. Similar sequences were also 
obtained from DNA from normal controls. This data indicates that the ‘deletion’ was in 
fact a sequencing artefact. See text.  
 
The remainder of the KIF27 promoter region sequencing of the FHL I cell lines revealed 
the presence of several known SNP’s. PP0231 had 2 homozygous SNP’s          
(rs11140295 and rs58903860) and one heterozygous SNP (rs12552069). PP0231 also had 
a heterozygous ‘G’ insertion 232bp upstream from the start of Exon 1, giving rise to 
double peaks on the chromatogram but confirmed on reverse primer sequencing. (Figure 
3.18). This area of the KIF27 promoter was PCR-amplified from genomic DNA from 
PP0231, cloned into a TA cloning vector, followed by sequencing of individual clones. 
Sixty per cent of the clones had the G insertion and 40% were normal, confirming the 
presence of this variation in heterozygosity. This change was not observed in any of the 
10 normal controls studied or FHL I parental cell lines PP0150 and PP0277. In principle, 
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this promoter insertion could be of functional significance; however within the 
consanguinity context it would be expected to be found in homozygosity. Thus, it is 
unlikely that the -232G insertion is pathogenic. 
 
Figure 3.18. Chromatogram showing a heterozygous G insertion in the promoter 
region of the patient cell line PP0231 
This change was not observed in ten normal controls examined and all the FHL I 
parental cell lines examined (PP0150 and PP0277). Sequencing reaction using the 
reverse primer confirms the presence of a ‘G’ insertion in heterozygosity. Arrow indicates 
the position of the insertion. 
 
Apart from the changes described above, the entire sequence of the promoter region of 
KIF27 in the FHL I patient as well as parental cell lines were similar to the wildtype 
sequence. 
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3.5.3.7 Confocal microscopy for cellular localisation of KIF27 
 
Due to the strong candidacy of KIF27 as an FHL I gene and the gene expression data 
suggesting the reduction of gene expression in the patient cell line, I then proceeded to 
study the gene at the protein level. I did this using two approaches. First, using a 
polyclonal rabbit anti- human KIF27 IgG antibody, I performed immunostaining and 
confocal microscopy of the patient cell line PP0231 and of the non- FHL I cell line 
PP0065 and compared expression of KIF27 in the two cell lines (Figure 3.19). I found 
that both cell lines expressed KIF27 at similar levels in the nucleus as well as the 
cytoplasm. Next, I proceeded to study KIF27 protein expression by western blotting. 
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Figure 3.19. KIF27 expression in patient and control B cell lines as assessed by 
immunostaining and confocal microscopy. 
The top panel shows a secondary- only control. The middle panel shows KIF27 staining 
of the FHL I patient cell line PP0231. The bottom panel shows KIF27 staining in non- 
FHL cell line PP0065, demonstrating cytoplasmic as well as nuclear localisation of the 
protein. 
 
3.5.3.8 Western blotting for KIF27 
 
As well as confocal microscopy I employed western blotting to assess expression levels 
of KIF27 in patient and parental B cell lines and compared them with normal donor PHA 
blasts. Again, I found very similar levels of KIF27 expression in parental and patient cell 
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lines as well as in PHA blasts from normal blood donors (Figure 3.20). In all cases, a 
clear band corresponding to 130kDa was obtained, which is the predicted molecular 
weight of KIF27 Isoform A. 
 
 
 
Figure 3.20 KIF27 immunoblotting of FHL I cell lines and normal PHA blasts. 
 
Immunoblotting of normal PHA blasts, FHL I cell lines PP0231 (patient) and PP0277 
(parent) shows presence of a band corresponding to 130kDa which is the predicted 
molecular weight of KIF27, Isoform A. Wedges indicate increasing amounts of protein 
lysate loaded in the blotting gel. 
 
 
3.5.3.9 Conclusion of mutation screening and protein expression studies of KIF27 
 
As discussed in section 3.3.1, KIF27 was the strongest candidate gene for FHL I due to 
the presence of its N-terminal kinesin motor domain. Initial mutation screening by PCR 
amplification and direct sequencing from genomic DNA from the FHL I cell lines was 
complicated by the presence of an area of genomic duplication and the presence of the 
pseudogene RP11-213G2.2 with over 95% homology with the genomic sequence of 
KIF27. I therefore cloned and sequenced individual clones of exons that demonstrated 
abnormal chromatograms on direct sequencing. In all cases, I was able to demonstrate a 
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large percentage of wildtype clones, indicating that the KIF27 gene was unmutated at 
genomic level. I also tested expression of KIF27 in the B cell lines by RQ-PCR, and 
although initial data suggested that expression of KIF27 in the patient cell line PP0231 
was lower than the parental cell lines PP0277 and PP0150 it was no different to controls. 
Nevertheless, I went on to search for promoter mutation but none was found except for 
the G insertion in heterozygosity in the patient cell line PP0231. I also studied the KIF27 
protein by western blotting and immunofluorescence staining and confocal microscopy 
and no abnormality in post translational modification of KIF27 could be inferred, as 
KIF27 protein expression in PP0231 was the same as in normal or parental controls. In 
summary, my findings argue that KIF27 is not the disease gene in FHL I. 
 
 
 
3.5.4 Mutation screening of RASEF  
3.5.4.1 Cellular expression of RASEF 
 
RASEF was strongly expressed at mRNA level in 293T cells and the breast 
adenocarcinoma cell line MCF7 but was only very weakly expressed in haemopoietic 
cells such as total PBMC and CD8+ T (Figure 3.21). No expression was found in B 
including the FHL cell lines, despite several attempts. This finding is in keeping with 
other reports of RASEF expression [342]. I then studied RASEF expression in T cells that 
were activated with PHA for various lengths of time (15 minutes to 2 hours) as well as in 
NK cells, but RASEF expression was not present in activated T cells and only very weak 
expression was present in NK cells. There was strong RASEF expression in normal cord 
blood (Figure 3.22). 
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Figure 3.21. RASEF expression in various cells and cell lines 
Agarose gel showing RT-PCR for RASEF and β actin amplification control. Primer pairs 
were designed to span more than one exon in order to exclude genomic DNA template 
contamination; source of cDNA is indicated on the gel. There was no expression of 
RASEF in cDNA synthesised from the HLH cell lines (parental or affected). 
PBMC: Peripheral blood mononuclear cells; PP0150, PP0231: B-lymphoblastoid cell 
lines derived from parent and patient respectively mapping to the FHL I locus; PC3: 
prostate cancer cell line, JKT: Jurkat cells, 293T: Human embryonic kidney cell line; 
MCF: breast adenocarcinoma cell line. LN405: Human glioma cell line, CB: cord blood, 
H2O Ctl: Water control.  
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Figure 3.22. RASEF expression in activated T cells and other cell types. 
There was no RASEF expression in resting T cells (T0), as well as T cells activated by 
PHA for various lengths of time: T15, T30, T60 and T120 (15, 30 60 and 120 minutes, 
respectively).  Very weak expression was noted in NK cells and strong expression was 
noted in cord blood. Amplification control by β actin is shown in the bottom gel. LN405: 
human glioma cell line, FB: Fetal brain, PP0065: Non-FHL B cell line. 
 
3.5.4.2 Direct sequencing of RASEF from genomic DNA 
 
As with KIF27, I amplified and directly sequenced all 17 exons and intron- exon 
junctions of RASEF using genomic DNA from the FHL I cell lines. Mutation analysis of 
RASEF was not associated with problems of CNV or duplications, as in KIF27.The 
majority of single nucleotide changes were in the intronic regions and were heterozygous. 
The entire coding sequence of RASEF in PP0231 cell line was normal except for a 
heterozygous intronic g/a change 115bp downstream of the end of exon 4. Table 3.5 
summarises the findings of RASEF mutation screen. 
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Table 3.5. Data from direct sequencing of RASEF 
 
RASEF Cell line 
PP0150 
(Parent, 
Kindred 1) 
Cell line PP0277 
(Parent, Kindred 
15) 
Cell line PP0231 
(Affected) 
Cell line 
PP0180 
(Parent, 
Kindred 2) 
Exon 1 WT  WT WT WT 
Exon 2 WT WT WT WT 
Exon 3 WT WT WT WT 
Exon 4 g/a intronic 
change (het) 
98bp 
downstream of 
end of exon 4 
WT g/a intronic 
change (het) 
115bp 
downstream of 
end of exon 4 
WT 
Exon 5  Exonic 
1046C>T  
Homozygous 
(rs4146960)  
Intronic 
sequence g>a 
(rs4146169) and 
t>g 
(rs10121395) 
both hom, 113 
and 126 bp 
upstream of start 
of exon 5  
 
Intronic sequence 
g>a (rs4146169) 
and t>g 
(rs10121395)       
(both het) 113 
and 126 bp 
upstream of start 
of exon 5 
Exonic sequence 
is WT 
WT Exonic 
1046C>T  
Intronic 
sequence g>a 
(rs4146169) and 
t>g 
(rs10121395) 
both  
Homozygous, 
113 and 126 bp 
upstream of start 
of exon 5  
 
Exon 6 WT WT WT N/A 
Exon 7 WT WT WT WT 
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Exon 8 WT WT WT WT 
Exon 9 WT Double peaks 
60bp downstream 
from exonic 
sequence, see 
text below 
WT WT 
Exon 10 WT WT WT WT 
Exon 11/12 WT WT WT WT 
Exon 13 WT WT WT WT 
Exon 14 WT WT WT WT 
Exon 15 WT G2197A het 
change in exonic 
sequence but no 
change in amino 
acid 
WT WT 
Exon 16 WT WT WT WT 
Exon 17 Abnormal 
sequence with 
double peak- 
most likely 
sequencing 
artefact due to 
multiple CT 
repeats in 
intronic 
sequence  
Abnormal 
sequence with 
double peak- 
most likely 
sequencing 
artefact due to 
multiple CT 
repeats in 
intronic sequence 
WT coding 
sequence (Both 
on high 
efficiency 
polymerase 
amplification as 
well as TA 
cloning) 
Abnormal 
sequence with 
double peak- 
most likely 
sequencing 
artefact due to 
multiple CT 
repeats in 
intronic 
sequence  
WT: wildtype, het: heterozygous, bp: base pair. SNP’s that are published in public 
databases such as hapmap have their unique identifying numbers with a prefix ‘rs’ as 
indicated above, wherever applicable. 
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Exon 9 in the parental FHL I cell line PP0277 showed double peaks on chromatogram 
60bp downstream from the 5’ end of the exon. Further analysis of DNA from the new 
patient RS (see later) showed that the abnormality is likely due to a 5bp insertion and 
12bp deletion in the intronic sequence about 54bp downstream form the end of exon 9. 
Chromatogram from exon 15 was abnormal on forward primer sequencing for all 4 FHL I 
cell lines but normal on reverse primer sequencing for PP0231, the patient cell line. This 
was due to the presence of multiple T repeats 8 bp upstream of the beginning of exon 15 
likely causing taq ‘slippage’ and thus a sequencing artefact. I also cloned the PCR 
amplification product of exon 15 from PP0231 into a TA cloning vector and sequenced 
individual clones, which confirmed that exon 15 from PP0231 was of normal sequence. 
Sequencing of Exon 17 showed abnormal double peaks, which were resolved by 
revealing normal sequence when higher efficiency platinum taq instead of native taq 
polymerase was used. This PCR artefact was likely due to Taq polymerase ‘slippage’ 
created by a large number of CT repeats 26 bp upstream of exon17. I also confirmed this 
by TA cloning (see later). 
 
3.5.4.3 TA cloning and sequencing of RASEF Exons 15 and 17 
 
I cloned the PCR products of exons 15 and 17 into a TA cloning vector and sequenced 
individual clones in order to follow up abnormal chromatograms on direct sequencing of 
these exons. I used genomic DNA from PP0231 and from a normal blood donor as 
control. Putting together the data from direct sequencing and cloning of RASEF Exons 15 
and 17, I was able to conclude that no mutations existed in either exon for PP0231. See 
Table 3.6 for details. 
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Table 3.6. TA Cloning data from RASEF 
 
RASEF Exon 
15 cloning 
    
DNA source No of clones 
examined 
Exonic 
changes 
Intronic 
changes 
Remarks 
PP0231 13 3 clones had 
unique A>G 
changes, likely 
due to artefacts 
‘t’ deletion 8bp 
upstream of 
start of Exon 
15 in 4  clones 
Abnormal 
chromatograms 
was likely due 
to intronic t 
deletion in 
heterozygosity 
Normal control 14 Wildtype ‘t’ del in 2 out 
of 14 clones 
 
RASEF Exon 
17 cloning 
    
DNA source No of clones 
examined 
Exonic 
changes 
Intronic 
changes 
Remarks 
PP0231 5 Wildtype Wildtype  
Normal control 6 Wildtype 4 out of 6 
clones had 4bp 
CTCT deletion 
Likely 
heterozygous 
variation in CT 
repeat 
 
3.5.4.4 Conclusions of RASEF sequencing 
 
Due to the presence of a Rab domain in its predicted protein structure, RASEF was a 
strong candidate as the putative FHL I gene (see section 3.3.2). However, PCR 
amplification and direct sequencing of all the exons and intron-exon boundaries as well 
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as cloning and sequencing when required did not reveal any mutations. As RASEF is not 
expressed in B cell lines, I was unable to quantify RASEF expression in the FHL I cell 
lines by RQ-PCR. In summary, RASEF does not appear to be the disease gene in FHL I. 
 
3.5.5 Mutation screening of UBQLN1 
3.5.5.1 Cellular expression of UBQLN1 
 
UBQLN1 was expressed in foetal brain as well as in T, B and NK cells, see Figure 3.23. 
 
 
 
Figure 3.23. UBQLN1 expression in various cells and cell lines 
Agarose gel showing RT-PCR amplification of UBQLN1. Source of cDNA is indicated 
below. Amplification control by β actin is shown in the bottom gel PP0065: Non-FHL B 
cell line, FB: Fetal brain. 
3.5.5.2 Sequencing of UBQLN1 cDNA 
 
As I was able to demonstrate UBQLN1 expression in B cell lines, I initially amplified the 
full-length cDNA (1.7 kb) of UBQLN1 from the FHL I cell lines PP0150, PP0277 and 
PP0231 by a long template PCR protocol and then directly sequenced the cDNA using 
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several internal sequencing primers designed to anneal along the entire coding sequence. 
By this method, I demonstrated that the cDNA sequence was normal in all FHL I 
samples, apart from the presence of the rs1044175 1170G/T SNP in heterozygosity in all 
three cell lines. To complement my mutation screen, I also proceeded with the 
amplification of the entire promoter sequence of UBQLN1, up to 1.3kb upstream of the 
start cordon using genomic DNA from the FHL I cell lines. No mutation was 
demonstrated in the promoter sequence by this method, however, a number of known 
variations were present in the promoter sequence of all the cell lines. Table 3.7 
summarises the variations observed in the promoter sequences. 
Table 3.7. Variations in the UBQLN1 promoter in the FHL I cell lines 
 
PP0150 PP0277 PP0231 
2523 T/C rs1333865 het 
 
2523 T/C rs1333865 het 2523 T/C rs1333865 het 
2962 C/T rs3814505 het 
 
  
3379G/C rs1056073 het 
 
  
het : heterozygous. Variation data was confirmed using the International Hapmap 
database, all known SNP’s are assigned their unique identifying numbers, with a prefix 
‘rest’, as indicated. 
3.5.5.3 RQ-PCR of UBQLN1 
 
I employed RQ-PCR analyse the relative expression of UBQLN1 in the FHL I cell lines 
in order to explore any abnormality at the level of gene expression. After validation, the 
primers were used to amplify cDNA synthesised from the FHL I cell lines PP0150, 
PP0277 and PP0231. Relative gene expression was computed by the 2 -ΔΔCT method. My 
data indicated that gene expression in PP0231 was comparable to that of the non-FHL 
cell line PP0065 but gene expression in both parental cell lines were reproducibly 
reduced. 
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Figure 3.24. Relative expression of UBQLN1 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the cell line PP0065. Individual bars 
represent two separate RQ-PCR experiments. Expression in the proband cell line 
PP0231 was almost similar to that of the control cell line. 
 
3.5.5.4 Conclusions of UBQLN1 sequencing 
 
Taking together the data obtained from sequencing of the UBQLN1 cDNA and the 
promoter sequence, as well as data from UBQLN1 expression the FHL I cell lines, I was 
able to conclude that there were no mutations in the UBQLN1 gene in the FHL I cell 
lines and that UBQLN1 was not the disease gene in FHL I. 
 
3.5.6 Mutation screening of FRMD3 
3.5.6.1 Cellular expression of FRMD3 
 
FRMD3 was strongly expressed in fetal brain as well as B cells and cord blood. CD8+ T 
and NK cell expression was low, as indicated by faint bands on agarose gel 
electrophoresis of the PCR product when cDNA was amplified using cDNA –specific 
primers for FRMD3, (see Figure 3.25). This is in keeping with published data by Ni et al 
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where the authors were unable to demonstrate FRMD3 expression in normal adult PBMC 
[338]. In all cases, cDNA was synthesised from a fixed amount of RNA (200ng) and a 
control PCR using the housekeeping gene β-actins was performed. I also tested FRMD3 
expression in PHA-activated T cells, using cDNA from normal donor T cells activated by 
PHA for various lengths of time (15 minutes to 2 hours). (See figure 3.26). Weak 
FRMD3 expression was noted in cDNA from T cells activated with PHA for 30 minutes, 
but not in any other time points. 
 
 
 
 
 
3.25. FRMD3 expression in various cells and cell lines 
 
Agarose gel showing RT-PCR amplification of FRMD3. FRMD3 is strongly expressed in 
B Cells, cord blood and fetal brain, but its expression is lower in T and NK cells. Source 
of cDNA is indicated above. Amplification control by β actins is shown in the bottom gel 
PP0065: Non-FHL B cell line, FB: Fetal brain. 
 180 
 
 
3.26. FRMD3 expression in PHA-activated T cells 
Weak expression was present at 30 minutes of activation, but in no other time points. 
Expression was present in cord blood (CB), fetal brain (FB) and NK cells 
 
 
3.5.6.2 FRMD3 genomic DNA sequencing 
 
FRMD3 has 20 exons, all of which were amplified by PCR using primers that were 
designed to amplify intron-exon boundaries as well as whole exons. Genomic DNA 
extracted from cell lines PP0150, PP0277 (both parental) and PP0231 (affected) was 
screened for mutations by this method. Table 3.8 summarises the data from direct 
genomic DNA sequencing and highlights all SNP’s that were identified in the sequences. 
Of all the single nucleotide changes observed, only one intronic change (‘A’ deletion 
14bp upstream of Exon 3) is not a published SNP but was present in all three FHL I cell 
lines. 
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Table 3.8. Summary of the genomic sequencing data of FRMD3  
 
FRMD3 
genomic 
sequencing  
PP0150 PP0277 PP0231 Comment 
Exon 1 WT 
 
rs4529536 , 
A/C het, 
exonic 
rs4529536 , 
A/C het, 
exonic; 
rs7863223 
G/C het, 
intronic, (2bp 
upstream of 
start of Exon1) 
 
 
Exon 2 rs59288178, 
G/A het, 
intronic (6bp 
upstream of 
start of Exon2) 
WT rs7853850, 
G/A hom, 
intronic (14bp 
upstream of 
start of Exon2) 
 
Exon 3 Exonic 
sequence is 
WT, But has 
intronic ‘A’ 
deletion 14bp 
upstream of 
start of Exon3 
Exonic 
sequence is 
WT, But has 
intronic ‘A’ 
deletion 14bp 
upstream of 
start of Exon3 
Exonic 
sequence is 
WT, But has 
intronic ‘A’ 
deletion 14bp 
upstream of 
start of Exon3 
‘A’ deletion is 
not a 
recognised 
intronic SNP 
Exon 4 WT WT WT  
Exon 5 WT WT WT  
Exon 6 WT WT WT  
Exon 7 WT WT WT  
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Exon 8 WT WT WT  
Exon 9 WT WT WT  
Exon 10 WT WT WT  
Exon 11 WT WT WT  
Exon 12 WT WT WT  
Exon 13 WT WT WT  
Exon 14 WT WT WT  
Exon 15 WT WT WT  
Exon 16 rs10780587 
T/C het, exonic 
rs10780587 
T/C het, exonic 
rs10780587 
T/C het, exonic 
 
Exon 17 WT WT WT  
Exon 18 WT WT WT  
Exon 19 WT WT WT  
Exon 20 rs10114696 
T/C het, exonic 
rs10114696 
T/C hom, 
exonic 
rs10114696 
T/C hom, 
exonic 
 
het: heterozygous, hom: homozygous, WT: wildtype. SNP’s that are published in public 
databases such as the hapmap database all have a unique identification number with 
the prefix ‘rs’.  
   
3.5.6.3 RQ-PCR for FRMD3 
 
As with the other genes of the FHL I locus, I analysed expression of FRMD3 in the FHL 
I cell lines by RQ-PCR. Gene expression of FRMD3 in PP0231 was higher than that of 
the parental cell lines PP0277 and PP0231 (Figure 3.27). 
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Figure 3.27. Relative expression of FRMD3 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. There is higher expression of 
FRMD3 in PP0231, the affected cell line, compared to that of the parental cell lines. 
 
3.5.6.4 Conclusions from FRMD3 sequencing 
 
FRMD3 was a candidate gene for FHL I due to the presence of a FERM domain. Other 
proteins bearing this domain play an important role in the formation and function of the 
immunological synapse (See section 3.3.4 for further details). In an earlier study by Ni et 
al, FRMD3 expression was shown to be predominantly present in normal adult ovarian 
tissue only, and hence this gene is also known as 4.1O (ovarian type) [338]. Although Ni 
et al were unable to demonstrate FRMD3 expression in PBMC; my data suggests that this 
gene is well expressed in B cells and mononuclear cells derived from cord blood. As 
FRMD3 was expressed in B cells, I was able to study its expression in the FHL I BLCL 
by RQ-PCR. I amplified and sequenced all 20 exons of FRMD3 from genomic DNA 
obtained form the FHL I cell lines but did not find any mutations. Any likelihood of a 
regulatory area mutation, potentially leading to reduced gene expression was excluded by 
the gene expression data by RQ-PCR. In summary, FRMD3 does not appear to be the 
disease gene in FHL I. 
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Chapter 4. Mutation screening of the remaining genes of the 
FHL I locus 
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4.1 Remaining genes of the FHL I locus 
Apart from the 4 candidate genes described in chapter 3, the FHL I locus also contains 11 
other protein- coding genes, of which one is a novel gene. Table 4.1 details their known 
functions. 
Table 4.1. Function and description of the non-candidate genes of the FHL I locus 
 
Name Function No of 
Splice 
variants 
Expressed in Conserved domains 
TLE1 Transcription factor 
binding 
 
17 Germinal 
Centre, CLL 
cells 
Groucho/TLE/N-
terminal Q-rich region, 
WD40 repeat region 
FLJ46321 
(FAM75B 
like 
protein) 
Not known N/A Testis Transmembrane domain, 
proline –rich domain 
FAM75B Protein coding 
 
N/A Testis Not known 
C9ORF103 ATP binding, amino 
acid biosynthesis, 
glucokinase activity 
5 Thymus, 
germinal B 
centre, brain, 
kidney 
Shikimate kinase 
domain 
GKAP1 Kinase activity, 
protein binding 
 
9 Germinal B 
cell centre, 
muscle 
Coiled coil stretch 
domain 
C9ORF64 Protein coding 
 
4 Brain, cervix, 
lung 
DUF2419 superfamily, 
no known function 
hnRNP-K RNA binding 37  Jurkat cell 
line, CML, 
Lymphoma 
K homology types 1 and 
2 domain, ROK-N 
terminal domain 
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As no mutation was identified in the 4 strong candidate genes, I proceeded to screen all 
the remaining genes in the FHL I locus for mutations. As before, my test samples were 
the parental cell lines PP0150 and PP0277 and PP0231, the sole proband with FHL I 
linkage. My mutation screening strategy employed a combination of genomic DNA and 
cDNA sequencing as well as gene expression studies by RQ-PCR. In some cases, 
ambiguous chromatograms from direct sequencing had to be reassessed at a single 
cell line etc 
RMI1 Limits DNA 
crossover, 
Associated with 
Bloom Syndrome 
10 High 
expression, 
widely 
expressed, 
Germinal 
centre B 
cells, thymus, 
etc 
Nucleic acid binding, 
OB-fold, tRNA/helicase-
type domain, domain of 
unknown function 
DUF1767 
SLC28A3 Neurotransmission, 
vascular tone, 
nucleoside binding 
 
7 Breast 
cancer, 
trachea, 
embryonic 
stem cells 
 Na+ dependent 
nucleoside 
transporter domain, 
Nucleoside 
recognition domain, Na+ 
dependent nucleoside 
transporter, C-
terminal domain 
NTRK2 Trans-membrane 
receptor protein 
tyrosine kinase,  
Protein binding 
17 Brain, 
kidney, 
tongue 
Tyrosine protein kinase 
domain, leucine-rich 
repeat, cysteine-rich 
flanking region, domain, 
I-set domain 
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molecule level by cloning into a TOPO or a pJET vector and sequencing of individual 
clones.  
 
4.1.1 Mutation screening of TLE1 
 
TLE1 (transducin-like enhancer of split) is the most centromeric gene of the FHL I locus. 
TLE1 covers 106Kb, 84198598 to 84303596 (NCBI 37, March 2009), on the reverse 
strand and has 20 exons. (See Figure 4.1).  
 
 
 
Figure 4.1. Scheme of the genomic structure of TLE1 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
 
Thirteen different splice variants are predicted, some of which contain a groucho/TLE 
domain, an N-terminal glutamine-rich region, a WD-40 repeat domain and a N-
myristoylation domain. TLE1 acts as a transcriptional co-repressor by forming complexes 
with a number of different DNA-binding proteins and associating with specific promoter 
regions. For example, TLE1 associates with the transcription factor proline-rich 
homeodomain protein (PRH/Hex) and increases its repressor activity [343]. Among other 
protein interactions of TLE1, the transcriptional repressor Runx2 has been shown to 
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associate with TLE1 and mediate its interaction with ribosomal RNA (rRNA) genes 
during mitosis.  When TLE1 is depleted, Runx2-mediated repression of rRNA gene 
transcription is removed, leading to active transcription. When TLE-dependent rRNA 
gene repression is lost, it leads to increased cell proliferation and increased protein 
synthesis [344]. Furthermore, TLE1 acts as a highly sensitive histochemical marker for 
synovial sarcomas [345] and although TLE1 staining positivity is also seen in certain 
nerve sheath tumours, it remains an important biomarker for synovial sarcomas in the 
appropriate clinical context and in conjunction with other, more conventional markers 
[346]. According to Aceview database of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), TLE1 is well expressed in a 
wide variety of tissues, such as stomach, ascites, brain, lung, eye, etc. 
4.1.1.1 TLE1 gene expression 
 
In RT-PCR experiments with cDNA from different cellular sources from normal 
individuals, TLE1 expression using cDNA-specific primers was studied. My data 
suggests that TLE is expressed in a large variety of haemopoietic cells, including T, B 
and NK cells (Figure 4.2). 
 
Figure 4.2. TLE1 mRNA expression in various cell types 
Agarose gel showing RT-PCR amplification of TLE1. TLE 1 is expressed in T, B and NK 
Cells, cord blood and fetal brain and PBMC. Source of cDNA is indicated above. 
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Amplification control by β actin is shown in the bottom gel PP0065: Non-FHL B cell line, 
FB: Fetal brain, CB: Cord blood. 
 
 
4.1.1.2 TLE1 mutation screening 
 
I amplified the entire coding sequence of TLE1 (2.3Kb) using long range RT-PCR from 
cDNA from the FHL I cell lines PP0150, P0277 and PP0231. Using internal sequencing 
primers designed to anneal at every 300bp along the length of the whole cDNA, I 
sequenced the consensus coding sequence of TLE 1 (Ensemble Transcript ID 
ENST00000376499, TLE-001). One further TLE1 transcript variant was also amplified 
along with the consensus one. This variant ((Ensemble Transcript ID 
ENST00000376464) has a 30bp insertion at the beginning of exon 7 when compared to 
the coding variant and resulted in an abnormal chromatogram when the long-range PCR 
product was sequenced with internal sequencing primer at exon 7.  However, when 
sequencing was repeated with a reverse primer situated further downstream in the 
sequence, I could demonstrate that the consensus coding variant TLE-001 was 
completely wildtype for all the FHL I cell lines. 
Two published SNP’s were identified in TLE-001 sequence- rs2228173 (G/A, exon 6) in 
homozygosity in all three cell lines and rs8782 C/T in homozygosity (C/T, exon 16) in 
PP0231 only.  
The entire coding sequence of the FHL I cell lines PP0150, P0277 and PP0231 did not 
have any mutations. 
4.1.1.3 RQ-PCR for TLE1 expression 
 
In order to exclude a regulatory area mutation, which might potentially lead to a loss of 
gene expression, I studied the relative expression of TLE1 in the FHL I cell lines by RQ-
PCR. As before, I designed and optimised primers for efficiency and employed the ΔΔCt 
method to assess gene expression in the FHL I cell lines PP0150, P0277 and PP0231 
compared to a non-FHL cell line PP0065. My data demonstrated an increase in gene 
expression in the cell line PP0150 and low gene expression in the cell lines PP0277 and 
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PP0231. The values represent mean of 5 separate experiments. I am unsure why PP0150 
expresses a significantly more amount of TLE compared to the other two cell lines. But 
as PP0231 expresses more TLE1 than PP0277, it is unlikely that a regulatory area 
mutation of TLE1 could be responsible for the diminished expression in PP0231 
(proband) compared to parent (PP0277) (Figure 4.3). 
 
 
 
Figure 4.3. Relative expression of TLE1 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the cell line PP0065. Data is 
representative of 5 experiments (mean ± s.d.). There is more expression of TLE1 in the 
parental cell line PP0150, compared to PP0277 (parent) and PP0231 (proband). 
 
Taking together the sequencing data from the cDNA sequence of TLE1 and the gene 
expression data from the cell lines, TLE1 is unlikely that TLE1 is the disease-causing 
gene in FHL I. 
 
4.1.2 Mutation screening of FLJ46321 
FLJ46321, synonym FAM75B-like protein and AL355985.1, is a novel gene in the FHL I 
locus. Its hypothetical protein structure is predicted to be a single-pass transmembrane 
phosphoprotein. It covers 6.49kb from 84603687to 84610171 (NCBI 37, March 2009), 
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on the direct strand. It has 4 exons and it transcription produces one mRNA. (See Figure 
4.4). 
 
 
 
Figure 4.4. . Scheme of the genomic structure of FLJ46321 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
FLJ46321 is predicted to contain a transmembrane domain but no experimental data 
supporting any putative gene function exists.  There are a number of pseudogenes 
flanking the genomic region of this gene, such as FLJ43950, FLJ43859, FLJ44082 and 
LOC100130636. FLJ46321 mRNA is 4.83Kb and the predicted protein has 1501 amino 
acids. According to the Aceview database of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), this gene is expressed at 
low levels only, and available data only supports expression in human testicular tissue 
(direct submission to Genbank, NCBI by Tashiro et al, Isogai Helix Research Institute, 
Genomics Laboratory, Japan.) 
The above finding supports my experimental data, as I was unable to demonstrate 
FLJ46321 expression in any human haemopoietic cells.  
Nonetheless, I proceeded to amplify and sequence the gene from genomic DNA obtained 
from the FHL I cell lines. Exons 1, 2 and 3 are 233, 46 and 70bp long respectively and 
exon 4 is 4.7kb long.  
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I amplified Exon 4 using a long range PCR and sequenced the PCR product using 15 
internal sequencing primers designed to span every 300bp along the entire sequence of 
Exon 4. There were no mutations seen in the entire exonic sequence of FLJ46321 in 
genomic DNA from any of the FHL I cell lines. 
As FLJ46321 is not expressed in B cell lines, I was unable to study gene expression in the 
FHL I cell lines. 
 
4.1.3 Mutation screening of FAM75B 
 
The next gene in the FHL I locus telomeric to FLJ46321 is FAM75B. This gene spans the 
coordinates 84675660-84677004 (NCBI 37, March 2009) on the reverse strand. (See 
figure 4.5).  
 
 
Figure 4.5. Scheme of the genomic structure of FAM75B along with sequencing 
strategy 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. For mutation screening, genomic DNA from FHL I cell lines was 
amplified and sequenced. The sequencing strategy involved amplifying and sequencing 
the entire gene in three overlapping amplicons; amplicons A, B and C. 
 
There are no recognised protein domains in this gene and gene expression data is also not 
available in the public databases. However, on its predicted protein structure, FAM75B 
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belongs to a family of FAM proteins, all of which are located in chromosome 9, see table 
4.2. Function of the FAM family of proteins is currently unknown.  
 
 
 
 
4.2 The FAM75 protein family  
 
Protein names Gene names 
Location 
Length 
(amino 
acids) 
Sequence 
homology 
with 
FAM75B 
FAM75-like protein C9orf79 C9orf79 9q22.1-q22.2 1445  
FAM75-like protein FLJ43859 - 9q21.3-22 917  
FAM75-like protein FLJ46321 - 9q21.3-22 1576  
Protein FAM75A1 FAM75A1 9p12 1347 95% 
Protein FAM75A2 FAM75A2 9p13.1 1347 95% 
Protein FAM75A3 FAM75A3 9p12 1347 95% 
Protein FAM75A4 FAM75A4 9p12 1347 95% 
Protein FAM75A5 FAM75A5 9p12 1347 95% 
Protein FAM75A6 FAM75A6 9p11.2 1343 95% 
Protein FAM75A7 FAM75A7 9q12 1347 95% 
Protein FAM75B FAM75B  9q21.32 182  
Putative FAM75-like protein 
FLJ44082 Pseudogene 
 
917 
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First, I studied the expression of FAM75B in haemopoietic cells and other cells by RT-
PCR using cDNA-specific primers. cDNA from various cell types was synthesised from 
RNA of normal individuals. My data suggests that FMA75B is well expressed in T, B 
NK cells, fetal brain and cord blood. See figure 4.6.  
 
 
Figure 4.6. FAM75B mRNA expression in various cell types 
Agarose gel showing RT-PCR amplification of FAM75B. FAM75B is expressed in T cells, 
B cell lines, NK Cells, cord blood and fetal brain. Source of cDNA is indicated above. 
Amplification control by β actin is shown in the bottom gel PP0065: Non-FHL B cell line, 
FB: Fetal brain, CB: Cord blood. 
 
 
Next, I proceeded to sequence the exons and intron-exon boundaries of FAM75B from 
genomic DNA extracted from the FHL I cell lines. For this purpose, I amplified the entire 
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gene using three sets of primers with a 150bp overlap between each amplicon. I 
arbitrarily named the three amplicons A, B and C. (See Figure 4.5). Amplicons A and B 
were entirely wildtype in PP150 and PP0231. PP0277 had one synonymous published 
SNP (Ensembl SNP ID ENSSNP4990250, C/T heterozygous) in amplicon B but was 
otherwise wildtype in amplicons A and B. However, direct PCR sequencing of amplicon 
C showed abnormal chromatograms from all three FHL I cell lines as well as 4 normal 
controls.  
In order to assess this at a single molecule level, I cloned Amplicon C (from PCR 
amplification of template genomic DNA from PP0231 and a normal blood donor) into a 
TOPO vector as well as a pJET vector. In both occasions, individual clones from both 
templates showed alignment with the other FAM75 family genes, and only two clones 
aligned to the genomic sequence of FAM75B. From the cloning data I was able to 
conclude that the abnormal chromatograms were arising as a result of sequence similarity 
of the FAM75 genes, and that FAM75B gene itself was likely to be unmutated in 
PP0231, as evident by the complete alignment of a small proportion of clones with its 
published sequence. Table 4.3 tabulates my findings from the cloning experiments. 
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 Table 4.3. FAM75B amplicon ‘C’ cloning data  
 
DNA source No of clones 
that had 
relevant 
sequences 
Exonic changes Remarks 
PP0231 8 (out of 24) 2 clones had 100% alignment 
with FAM75B sequence, one 
clone had 99% alignment with 
FAM75B sequence, with one 
nucleotide change 1507 A/G 
(not a known SNP, non- 
synonymous, His-Arg) 
Rest aligned to other FAM75 
family genes (98-99% 
alignment) 
Abnormal 
chromatograms 
was likely due to 
sequence 
alignment with 
other FAM75 
family genes, but 
the FAM75 gene 
is unmutated. 
Normal control 4 (out of 24 
clones) 
100% alignment to FAM75B 
sequence in 1 clone, 99% 
alignment to FAM75B in 1 
clone (one T/A change, non-
synonymous; Leu-His), 2 
clones had sequence 
homology with other FAM75 
family genes 
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Data is a summary of PCR cloning into TOPO as well as pJET vector. TOPO vector 
cloning was less successful and had fewer relevant sequences compared to pJET 
vector. His: histidine, Leu: Leucine, Arg: arginine. 
 
 
4.1.4 Mutation screening of C9ORF103 
 
C9ORF103 covers 21.17kb, from 86237966 to 86259038  (NCBI 37, March 2009), on 
the direct strand. (See figure 4.7). It has 7 exons and transcription is predicted to produce 
9 different mRNA’s, 5 alternatively spliced and 4 unspliced. 
 
 
Figure 4.7. Scheme of the genomic structure of C9ORF103 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
C9ORF103 has one consensus coding sequence, 426 nucleotides long, encoding a protein 
of 141 amino acids. C9ORF103 protein is predicted to be localised in the cytoplasm and 
to have a Shikimate kinase domain. In plants and microorganisms, shikimate kinases 
catalyse the biosynthesis of aromatic amino acids such as folates and ubiquinones, among 
others, and link carbohydrate metabolism and amino acid biosynthesis pathways. 
However, no such pathway exists in higher animals [347]. 
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According to the Aceview database of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), C9ORF103 is well 
expressed in a variety of human tissues, including brain, heart, pancreas, kidney and lung. 
When I amplified cDNA from various sources from normal donors, I was able to 
demonstrate good expression of C9ORF103 in cells of haemopoietic origin, such as T 
cells, B cells and NK cells. See figure 4.8. 
 
 
 
 
Figure 4.8. C9ORF103 expression in various cell types 
Agarose gel showing RT-PCR amplification of C9ORF103. 
C9ORF103 is expressed in T cells, B cell line, NK cells and cord blood. Source of cDNA 
is indicated above. Amplification control by β actin is shown in the bottom gel. 
PP0065, PP0007: Non-FHL B cell line, PP0277, PP0231: FHL I cell line, FB: Fetal brain, 
CB: Cord blood. 
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4.1.4.1 Mutation screening of C9ORF103 
I amplified and sequenced the entire coding region of C9ORF103 from cDNA 
synthesised from the FHL I cell lines PP0150, PP0277 and PP0231. I did not observe any 
changes in the sequence of this gene in any of the cell lines tested compared to the 
published sequence in NCBI and Ensembl. 
4.1.4.2 RQ-PCR of C9ORF103 
 
I tested the relative expression of C9ORF103 in the FHL I cell lines PP0150, PP0277 and 
PP0231 compared to that in a non-FHL B cell line PP0065. As before, I designed primers 
and tested them for efficiency and validity by multiple cDNA dilutions of PP0065 cells. 
My data showed no evidence of a reduction in relative gene expression in PP0231, the 
cell line from the proband compared to that of the parental cell lines (See Figure 4.9). 
 
 
 
 
 
Figure 4.9. Relative expression of C9ORF103 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
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Sequencing and RQ-PCR data for mutation screening highlights the fact that C9ORF103 
can be excluded as the disease-causing gene of FHL I. 
4.1.5 Mutation screening of GKAP1 
 
GKAP1 [synonym GKAP42; cyclic guanosine monophosphate (cGMP) dependent 
protein kinase anchoring protein of 42kDa] covers 90kb from 86354336 to 86432752 
(NCBI 37, March 2009), on the reverse strand and lies immediately centromeric to KIF27 
(See Figure 4.10). 
 
Figure 4.10.  Scheme of the genomic structure of GKAP1 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
 
GKAP1 has 18 exons and transcription is predicted to produce 10 splice variants, of 
which two isoforms, GKAP-001 and GKAP-002 are translated into proteins of 366 and 
315 amino acids respectively and form the 2 consensus coding sequences of this gene. 
(See Figure 4.10). According to the NCBI Aceview database 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), GKAP1 is well expressed 
and can be identified in several human tissue types, including lung, brain, testis and 
germinal centre B cells.  
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GKAP1 has a closely related mouse homolog, also known as Gkap1. In the mouse, 
Gkap1 protein was shown to localise in the golgi complex and physiologically interact 
with cGMP-dependent protein kinase-1α (cGK-1α), functioning as anchoring protein for 
the latter. It has been proposed that through phosphorylation of Golgi-associated proteins 
such as GKAP42, cGK-1alpha may participate in germ cell development [348]. 
I studied GKAP1 expression in various tissues from normal subjects and found that 
GKAP1 was well expressed in haemopoetic cells such as T-, B- and NK cells, as well as 
cord blood mononuclear cells. See figure 4.11. 
 
Figure 4.11. GKAP1 expression in various cell types 
Agarose gel showing RT-PCR amplification of GKAP1 which is expressed in T cells, B 
cell line, NK cells, cord blood and fetal brain. Source of cDNA is indicated above. 
Amplification control by β actin is shown in the bottom gel. 
PP0065: Non-FHL B cell line, FB: Fetal brain, CB: Cord blood. 
 
 
GKAP1 is situated immediately centromeric to KIF27 and was reported to possess 
sequence homology with the same area of segmental duplication as KIF27. Hence, in 
theory, amplification of genomic DNA would be complicated by amplification of both 
the gene as well as the duplicon. My initial mutation screening strategy was to therefore 
amplify and sequence the full-length GKAP1 cDNA using long-range PCR primers for 
amplification and internal primers for sequencing.  Using template cDNA synthesised 
from the FHL I cell lines, both isoforms GKAP-001 and GAKP-002 were amplified in 
the same PCR reaction, which were then gel extracted and sequenced separately using 
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isoform-specific internal sequencing primers. However, despite several attempts, I was 
unable to sequence some parts of the sequence of both isoforms from all three cell lines, 
despite the fact that some other parts of the long-range PCR amplicons were very easily 
sequenced using internal sequencing primers. From data obtained by cDNA PCR 
sequencing, I was able to demonstrate that about 60% of the sequence was wildtype in all 
three FHL I cell lines. 
Next, I proceeded to sequence the gene from genomic DNA. Upon further investigation 
of the published GKAP1 genomic sequence from the Ensembl and NCBI databases, it 
appeared that only the non-coding exons of GKAP 1 (Exons 1-6) had sequence homology 
with the complex inverted duplicon upstream of GKAP1 and KIF27, and that published 
sequences from the coding exons 7-18 did not align to any other area of the genome. I 
therefore proceeded to amplify and sequence exons 7-18 from template genomic DNA.  
My sequencing data revealed that Exons 7-18 was wildtype for all the FHL I cell lines.  
I also tested relative expression of GKAP1 by RQ-PCR. Despite a large degree of 
variability between two experiments, expression of GKAP1 in the affected cell line 
PP0231 in both experiments was higher than that in the parental cell lines (See Figure 
4.12) 
.  
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Figure 4.12. Relative expression of GKAP1 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
 
In summary, sequencing of GKAP1 was complicated by the inability to amplify cDNA 
sequences, which was circumvented by resorting to genomic DNA sequencing. No 
mutation has been identified in the genomic sequence of PP0231 and GKAP1 is unlikely 
to be the disease-causing gene in FHL I. 
 
 
4.1.6 Mutation screening of C9ORF64 
 
Chromosome 9 open reading frame 64 is a five-exon gene situated immediately telomeric 
to KIF27 and covers 18.74kb, from 86553226 to 86571663 (NCBI 37, March 2009), on 
the reverse strand (See Figure 4.13). 
 
 
Figure 4.13. Scheme of the genomic structure of C9ORF64 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
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C9ORF64 is predicted to have three spliced variants and its consensus coding sequence is 
translated to a protein with 341 amino acids. According to the Aceview database of NCBI 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), this gene is well expressed 
in a large number of human tissues, including brain, lung, placenta and testis. Predicted 
protein domain structure reveals the presence of an unknown domain DUF2419 
superfamily, found in plants to humans with no known function.  
I studied the expression of C9ORF64 in various normal haemopoietic tissues. My data 
suggests that this gene is well expressed in T and B cells but is not expressed in NK cells. 
(See Figure 4.14). 
 
Figure 4.14. C9ORF64 expression in various cell types 
Agarose gel showing RT-PCR amplification of C9ORF64, which is strongly expressed in 
T cells and B cell line, and weakly expressed in cord blood and fetal brain. It is not 
expressed in NK cells. Source of cDNA is indicated above. Amplification control by β 
actin is shown in the bottom gel. 
PP0065: Non-FHL B cell line, FB: Fetal brain, CB: Cord blood. 
 
Similar to my approach of mutation screening of the other genes of the FHL I locus, I 
amplified and sequenced C9ORF64 from genomic DNA extracted from the FHL I cell 
lines and studied its expression by real-time PCR. Genomic DNA PCR sequencing was 
designed to sequence exons and intron-exon boundaries. 
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Genomic DNA PCR sequencing did not reveal any mutations in all three FHL I cell lines 
studied (PP0150, PP0277 and PP0231). 
I designed RQ-PCR primers with amplicon size of 130-150bp and chose the most 
efficient primers for using with my test cDNA. As before, I tested primer efficiency by 
performing real-time PCR using several dilutions of template cDNA from the reference 
cell line PP0065.  
My data from the RQ-PCR experiments suggest that gene expression in PP0231, derived 
from the proband, was increased compared to that of the parental and control cell lines, 
thereby excluding any regulatory area mutation affecting gene expression. See figure 
4.15. 
 
 
Figure 4.15. Relative expression of C9ORF64 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
 
 
From my mutation screening of C9ORF64, I was able to conclude that it is not the gene 
responsible for FHL I. 
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4.1.7 Mutation screening of hnRNP-K 
 
hnRNP-K or heterogeneous ribonucleoprotein K , the gene immediately telomeric to 
C9ORF64 covers 13.01kb from 86582998 to 86595569 (NCBI 37, March 2009), on the 
reverse strand (See Figure 4.16).   
 
 
Figure 4.16. Scheme of the genomic structure of hnRNP-K 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
As one of at least 20 major proteins constituting the heterogeneous nuclear 
ribonucleoprotein particles, the hnRNP-K protein is unique in its ability to bind to both 
single-stranded RNA (ssRNA) and single-stranded DNA (ssDNA) [349]. For example, 
the hnRNP-K protein can specifically bind to a CT-rich element in the c-myc promoter 
[350] and also to a repetitive CU-rich sequence in the 3’UTR of the erythroid 15-
lipoxygenase mRNA, causing translational silencing of the latter [351].  
hnRNP-K binds to nucleic acids via one of its three KH (hnRNP K homology) domains, 
designated KH1, KH2 and KH3. Between the KH2 and KH3 domains, there are three 
proline-rich SH3 binding domains via which hnRNPK interacts with a large variety of 
SH3-domain containing proteins, such as Src and Vav1. See figure 4.17. 
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It has been shown that upon multiple tyrosine phosphorylation by c-Src, the hnRNP-K 
protein loses its ability to cause translational silencing of the lipo-oxygenase mRNA in 
vivo, leading to the expression of the lipo-oxygenase protein during the later stages of 
erythroid development [352]. On the other hand, serine phosphorylation of hnRNP-K by 
extracellular signal-regulated kinase (ERK) increases its cytoplasmic accumulation and 
promotes its translational repression activity in vivo by degradation of mRNA that binds 
to it [353]. In addition to the KH and SH3 domains, there is also a region that can bind to 
several transcriptional repressors such as the Zinc finger protein Zik1 [354]. 
 
Figure 4.17. Domain structure of the hnRNP-K protein 
Adapted from the Human Protein Reference database (www.hprd.org). 
 
Recently, using proteomic analysis of nuclear proteins extracted from activated T cells, 
Chan et al identified hnRNP-K protein as one of the downstream nuclear targets of ERK 
during the late phase of T cell activation and essential for IL2 production. The authors 
demonstrated that ERK signaling caused relocation of hnRNP-K from the nucleus to the 
cytoplasm, where it protected Vav1 from proteolysis by caspases, enabling Vav1 to 
enhance IL2 promoter activity [355]. They also demonstrated that while over-expression 
of Vav1 in Jurkat cells increased IL-2 promoter activity, co-transfection of Vav1 and 
short interfering RNA (siRNA) expression construct of hnRNP-K severely impaired IL2 
promoter activity.  
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The versatility of the hnRNP-K protein was further elucidated by a recent report where it 
was demonstrated that it was significantly downregulated in the presence of 
chemotherapy or UV-radiation-induced apoptosis of leukaemia cell lines. It was 
demonstrated that proteolytic activation of PKCδ caused this down regulation in a 
proteasome-dependent manner [356]. It was also demonstrated that gene silencing of 
hnRNP-K caused significant induction of apoptosis in the leukaemia cell lines, although 
the mechanism underlying this observation remains unclear. 
In summary, hnRNP-K is implicated in multiple processes of regulation of gene 
expression, biologically linking together nucleic acid function and signal transduction 
pathways.   
I studied hnRNP-K gene expression in a panel of cDNA synthesised from various 
haemopoeitic cell types of normal donors. My data demonstrated that this gene was well 
expressed in T, B as well as NK cells (See figure 4.18). 
 
 
Figure 4.18. hnRNP-K expression in various cell types 
Agarose gel showing RT-PCR amplification of hnRNP-K, which is expressed in T cells, B 
cell line, NK cells, cord blood and fetal brain. Amplicon size was 120bp. 
Source of cDNA is indicated above. Amplification control by β actin is shown in the 
bottom gel. PP0065: Non-FHL B cell line, FB: Fetal brain, CB: Cord blood. 
 
Next, I proceeded to screen hnRNP-K form mutations using genomic DNA from the FHL 
I B cell lines. I have collated my findings in Table 4.4. There were two unpublished 
SNP’s in exons 1 and 2 respectively of the parental cell line PP0277.These exons are 
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non-coding. The exonic sequence of the patient cell line was WT apart from 3 known 
SNP’s, as indicated in table 4.4. 
 
 
 
 
 
 
 
 
 
Table 4.4 Sequence analysis of hnRNP-K from genomic DNA from the FHL I cell 
lines 
 
hnRNP-K genomic 
sequencing 
PP0150 (Parent) PP0277 (Parent) PP0231 (Proband) 
Exon 1  WT One known exonic  
SNP rs296888 
C/T het, one ‘A’ 
insertion in 
homozygosity in 
position 
896595503, not a 
known SNP 
Rest WT 
One known exonic 
SNP rs296888 
C/T het, rest WT 
Exon 2 WT One known exonic 
SNP rs296887 
G/A het, one 
further exonic 
SNP A/C het in 
position 
One known exonic 
SNP rs296887 
G/A het 
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86595028, not a 
known SNP 
Exon 3 Known exonic 
SNP rs167203C/G 
het, rest WT 
Known exonic 
SNP rs167203C/G 
het, rest WT 
Known exonic 
SNP rs167203C/G 
het, rest WT 
Exon 4 (Coding 
sequence starts here) 
WT WT WT 
Exon 5 WT WT WT 
Exon 6 WT WT WT 
Exon 7 WT WT WT 
Exon 8 WT WT WT 
Exon 9 WT WT WT 
Exon 10 Not available WT WT 
Exon 11 WT WT W 
Exon 12 WT WT WT 
Exon 13 WT WT WT 
Exon 14 WT WT WT 
Exon 15 WT WT WT 
Exon 16 WT WT WT 
Exon 17 WT WT WT 
Exon 18 WT WT WT 
WT: wildtype, het: heterozygous 
 
Next, I proceeded to assess gene expression of hnRNP-K in the FHL I cell lines by RQ-
PCR (SYBR green) using the ΔΔCt method. My findings demonstrate that gene 
expression in the parental cell line PP0277 was similar to that of the cell line PP0231 
from the proband, effectively excluding the possibility of a regulatory area mutation, 
giving rise to abnormal gene transcription (See figure 4.19). 
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Figure 4.19. Relative expression of hnRNP-K in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
 
In summary, my findings demonstrate that hnRNP-K is well expressed in haemopoietic 
cells and mutation screening from genomic DNA failed to reveal any abnormalities in the 
sequences. There is comparable gene expression in all three FHL I cell lines by RQ-PCR, 
excluding a defect in gene transcription. It is therefore unlikely that hnRNP-K is the gene 
responsible for causing FHL I. 
 
 
 
 
 
 
 
 
 
 
0	  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
1.2	  
PP0150	   PP0277	   PP0231	   PP0065	  
Re
la
%v
e	  
Ge
ne
	  E
xp
re
ss
io
n	  
HN
RN
PK
	  
Experiment1	  
Experiment	  2	  
 212 
 
 
4.1.8 Mutation screening of hsa-miR-7-1 
Embedded within the genomic sequence of hnRNP-K, is the genomic sequence of hsa-
miR-7-1, one of 940 unique microRNAs in the human genome that are currently reported 
in the microRNA registry [357].  
Micro RNAs are small regulatory molecules of about 22 nucleotides that belong to the 
group of non-coding RNA genes and play important post-transcriptional regulatory roles 
in gene expression by pairing with near-complementary regions of the 3’ untranslated 
region (3’ UTR) of mRNA of genes and causing translational repression or 
transcriptional and translational cleavage [358].  
Micro RNA’s are transcribed by RNA polymerase II as pri-mRNA’s, which are then 
cleaved by the nuclear Drosha ribonuclease III enzyme, followed by further cleavage by 
the cytoplasmic Dicer ribonuclease to produce the mature microRNA product. This is 
then incorporated into a RNA-induced silencing complex (RISC), which recognize their 
target mRNAs by virtue of imperfect base pairing, leading repression of gene translation 
[359] [360]. (See figure 4.20). 
 213 
 
Figure 4.20. microRNA biogenesis 
MicroRNA’s processed from the introns of protein coding genes are transcribed by RNA 
polymerase II, giving rise to a pri-miRNA, which is then cleaved within the nucleus by the 
RNase III endonuclease Drosha, to form a 60-70bp long stem-loop miRNA precursor 
pre-miRNA. This is then transported to the cytoplasm by the receptor Exportin-5, where 
both of its strands are cut by Dicer, another RNase III endonuclease. One of this 22 bp 
miRNA duplex arms associates with the RISC which then acts in translational repression 
or mRNA cleavage. RISC: RNA-induced silencing complex, ORF: Open reading frame 
Adapted from Mraz M, MicroRNA Information Center (www.microrna.ic.cz).  
 
 
Although the majority of microRNA genes are located in intergenic regions of the 
genome and contain their own transcription regulatory units, hsa-miR-7-1, and a minority 
of other microRNA genes are located within the introns of other genes [358]. For 
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example, hsa-miR-7-1 is located in the last intron of hnRNP-K, is in the same orientation 
as the latter, and its transcriptional regulation is determined by the promoter of hnRNP-K. 
This genomic arrangement between hsa-miR-7-1 and hnRNP-K is conserved throughout 
evolution, from Drosophila to human [361].  
In a recent report, hsa-miR-7-1 was noted to be temporally regulated in the human 
embryonic pancreatic islet cells, with maximum expression between 14-18 weeks 
gestational age, at a time when pancreatic hormonal synthesis increases exponentially 
[362] leading the authors to speculate a potential role of hsa-miR-7-1 in islet cell 
differentiation.  
To date, microRNA’s have not been implicated in autosomal recessive diseases. I 
sequenced the pre-miRNA sequence and 200bp on either side of hsa-miR-7-1, which 
effectively constitutes intron 17 of the hnRNP-K gene using template genomic DNA 
from the FHL I cell lines PP0150, PP0277 and PP0231 as well as 3 normal controls. In 
all cases, I found the presence of the SNP rs296885. It was homozygous in PP0277, 
PP0231 and 2 normal controls and heterozygous in PP0150 and one normal control. 
Additionally, I found PP0231 and one normal control (blood donor) to also have an‘A’ 
insertion in heterozygosity, 139bp upstream of the pre-miRNA sequence. This variation 
has not been reported in the public variation databases (Ensembl, Hapmap). (See Figure 
4.21). 
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Figure 4.21. hsa-miR-7-1 sequencing of genomic DNA from FHL I cell lines and 
normal controls (Control A, B and C). 
Genomic DNA from normal controls was obtained from blood donors. The SNP 
rs296885 was in present in homozygosity in PP0277, PP0231 and 2 normal controls and 
heterozygous in PP0150 and one normal control. Another ‘A’ insertion in heterozygosity 
was observed in PP0231 and Control A but is not a published SNP. 
 
 
My findings suggest that in the absence of a potential pathogenic variation in the genomic 
sequence of hsa-miR-7-1, it is unlikely that this non-coding RNA plays a significant role 
in the pathogenesis of FHL I, which is an autosomal recessive condition. I have not 
studied the expression of hsa-miR-7-1 in the FHL I BLCL or performed any functional 
studies. 
4.1.9 Mutation screening of RMI1 
 
RMI1 (synonym BLAP75, RecQ mediated genome instability 1) is one of five human 
RecQ helicase genes and has been shown to play an important role in maintaining 
genomic stability. RMI1 covers 23.68 kb, from 84595637 to 86618989 (NCBI 37, March 
2009), on the direct strand and is telomeric to hnRNP-K (See Figure 4.22). 
Pre-miRNA 
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Figure 4.22. Scheme of the genomic structure of RMI1 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
According to the NCBI Aceview database 
(www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), RMI1 is widely expressed 
in human tissues, including those of haemopoietic origin. RMI1 has three exons, of which 
only exon 3 is the coding exon. It has three splice variants and one consensus coding 
sequence.  
RecQ helicases catalyse the dephosphorylation of nucleoside triphosphatases, leading to 
the unwinding of paired DNA or RNA. The RecQ family members share three regions of 
conserved protein sequences, namely, the N-terminal helicase domain, the C-terminal 
helicase-and-RNase-D C-terminal (HRDC) domain and the RecQ conserved domain in 
the middle. Other members of this family are WRN (mutations in which causes Werner 
Syndrome – a syndrome of premature ageing), BLM (mutation causes Bloom Syndrome- 
a cancer susceptibility syndrome due to increase in chromosomal breakage), RECQ4 
(mutation causes Rhothmund-Thomson's syndrome- characterized by genomic instability 
and predisposition to osteogenic sarcoma) and RECQ5 (not associated with any human 
disease so far). RMI1 was found to be closely associated with the BLM protein and 
essential in maintaining genome integrity [363]. RMI has also been shown to associate 
with topoisomerase III-α and BLM during chromosomal recombination and the three 
 217 
proteins together were integral to genome maintenance and cancer avoidance due to their 
role in limiting DNA crossover formation during meiosis [364].  
Using cDNA synthesised from mRNA treated with DNAse in order to eliminate genomic 
DNA contamination, I studied the expression pattern of RMI and demonstrated that it is 
well expressed in haemopoietic tissue such as B, T and NK cells. See figure 4.23. This 
finding is in accordance with published microarray data (www.genecards.org).   
 
Figure 4.23. RMI1 expression in various cell types 
Agarose gel showing RT-PCR amplification of RMI1, which is expressed in T cells, B cell 
line, NK cells, and fetal brain.  
Source of cDNA is indicated above. Amplification control by β actin is shown in the 
bottom gel. PP0065: Non-FHL B cell line, FB: Fetal brain. 
 
Next, I directly sequenced the entire coding region of RMI1 and 200 bp on either side 
from genomic DNA extracted from the FHL I cell lines, using long-range PCR and 
internal sequencing primers designed to align at 300bp intervals along the sequence. The 
entire sequence from the FHL cell lines PP0150, PP0277 and PP0231 was wildtype. 
I also studied RMI1 expression in the FHL I cell lines by RQ-PCR. (See Figure 4.24). My 
findings indicate that gene expression in PP0231 and PP0277 were similar, but that in 
PP0150 varied between experiments. 
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Figure 4.24. Relative expression of RMI1 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
 
Since no mutation was found the coding sequence of RMI1 and gene expression data did 
not point towards abnormal gene transcription, I concluded that RMI1 is not the disease 
gene on FHL I. 
4.1.10 Mutation screening of SLC28A3 
 
SLC28A3 [solute carrier family 28 (sodium-coupled nucleoside transporter), member 3], 
synonym CNT3 is the penultimate telomeric gene within the FHL I locus and covers 
93.25 kb from 86893092 to 86983413 (NCBI 37, March 2009), on the reverse strand (See 
Figure 4.25).  
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Figure 4.25. Scheme of the genomic structure of SLC28A3 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
 
SLC28A3 is a member of the concentrative nucleoside transporter proteins, of which 
three are known in humans. The concentrative nucleoside transporters have varying 
substrate specificities- SLC28A1 transports pyrimidines, SLC28A2 transports purines 
and uridine and SLC28A3 has a broader substrate specificity, transporting both purines 
and pyrimidines [365]. These proteins also mediate the transport of nucleoside analogues 
used as anti-cancer or anti-viral drugs [366] and recent data correlates the abundance of 
immunostaining of SLC28A3 in nucleoside analogue-treated carcinomas with improved 
survival [367]. SLC28A3 has 18 exons and encodes a 691-residue protein, which has 47 
and 48% sequence homology with SLC28A1 and SLC28A2 proteins, respectively. 
SLC28A3 transcripts have been identified in a wide variety of human tissues, such as 
pancreas, bone marrow, trachea, mammary gland, liver, prostate, intestine and heart 
[368]. Recently, an isoform of SLC28A3 was identified, which in contrast to the full-
length protein, is retained in the ER and is proposed to salvage intracellular nucleosides 
from the lumen of the ER to the cytoplasm [369]. 
 I studied the expression of SLC28A3 in various cell types using cDNA-specific primers 
and demonstrated that the gene is expressed in B cells and NK cells but not in T cells. 
(See Figure 4.26). 
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Figure 4.26. SLC28A3 expression in various cell types 
Agarose gel showing RT-PCR amplification of SLC28A3. Data shows that SLC28A3 is 
strongly expressed in B cells and weakly expressed in NK cells, but not expressed in 
resting T cells.  
 Source of cDNA is indicated above. Amplification control by β actin is shown in the 
bottom gel. PP0065: Non-FHL B cell line, FB: Fetal brain. 
 
I then proceeded to undertake mutation screening in SLC28A3. My initial strategy was to 
amplify the full-length SLC28A3 cDNA from the FHL I cell lines by long range PCR. 
However, I was unable to amplify the cDNA both from normal controls and from the 
FHL I cell lines despite numerous attempts with a number of different primer sets. I 
therefore designed primers to amplify all 19 exons and intron-exon boundaries from 
genomic DNA of the FHL I cell lines. I have tabulated my findings in Table 4.4. 
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Table 4.5. Sequence analysis of SLC28A3 from genomic DNA from the FHL I cell 
lines 
 
SLC28A3 genomic 
DNA mutation 
screening 
PP0150 (Parent, 
FHL I) 
PP0277 (Parent, 
FHL I) 
PP0231 (Proband, 
FHL I) 
Exon 1 WT WT WT 
Exon 2 WT WT WT 
Exon 3 WT WT WT 
Exon 4 WT WT WT 
Exon 5 WT WT, exonic SNP 
rs10868138 in 
heterozygosity 
WT 
Exon 6 WT WT WT 
Exon 7 WT WT WT 
Exon 8 intronic SNP 
rs41282427 in 
heterozygosity, 
exonic sequence is 
WT 
WT WT 
Exon 9 WT WT WT 
Exon 10 WT Intronic SNP 
rs10868137, exonic 
sequence WT 
WT 
Exon 11 WT WT WT 
Exon 12 WT WT WT 
Exon 13 WT WT WT 
Exon 14 WT Exonic SNP 
rs7853758 
in heterozygosity 
Exonic SNP 
rs7853758 
in heterozygosity 
Exon 15 WT WT WT 
Exon 16 WT WT WT 
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Exon 17 Double peaks on 
chromatogram 
Double peaks on 
chromatogram 
Double peaks on 
chromatogram 
Exon 18 WT WT WT 
Exon 19 WT WT SNP rs7858075 in 
heterozygosity 
61bp downstream 
of stop codon 
 
Direct sequencing of Exon 17 of SLC28A3 showed abnormal chromatograms in all the 
FHL I cell lines. Therefore, Exon 17 of SLC28A3 was PCR-amplified from genomic 
DNA from PP0231, cloned into a TA cloning vector, followed by sequencing of 
individual clones. My cloning data revealed that Exon 17 from PP0231 was entirely 
wildtype.  I was not able to amplify Exon 18 from genomic DNA despite several attempts 
and primer pairs. I therefore amplified and sequenced the area of SLC28A3  mRNA 
corresponding to Exon 18 by amplifying and sequencing from cDNA synthesised from 
all three FHL I cell lines. The cDNA amplicon spanned Exons 15-18. Direct sequencing 
of this amplicon from all three cell lines revealed an entirely wildtype sequence. By this 
method, I was also able to re-confirm my cloning data that exon 17 of SLC28A3 was 
wildtype. 
 
Next, I studied the relative gene expression of SLC28A3 in the FHL I B cell lines 
PP0150, PP0277 and PP0231 by RQ-PCR compared to that in the non-FHL I BLCL 
PP0065. I demonstrated that relative expression of the gene was in fact higher in PP0231, 
than in the parental cell lines PP0277 and PP0150, see figure 4.27. 
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Figure 4.27. Relative expression of SLC28A3 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent two separate RQ-PCR experiments. 
 
Taking together the sequencing and gene expression data, I am able to conclude that 
SLC28A3 is not the disease-causing gene in FHL I. 
 
4.1.11 Mutation screening of NTRK2 
 
NTRK2 (synonym TRKB) encodes a member of the neurotrophic tyrosine kinase 
receptor family and is the most telomeric gene in the FHL I locus. It covers 358.69kb, 
from 86473104 to 86831796 (NCBI 37, March 2009), on the direct strand (See Figure 
4.28).  
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Figure 4.28. Scheme of the genomic structure of NTRK2 
Numbers indicate coordinates in the NCBI 37 build of the human genome. Exons are 
drawn to scale. 
 
NTRK2, along with NTRK1 and NTRK3, belong to a class of neurotrophin receptors. 
Neurotrophins are regulators of nerve development, survival and function, and four such 
proteins are present in mammals, namely, NGF (nerve growth factor), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and NT-4 [370]. Neurotrophins 
directly bind and dimerise the NTRK receptors, causing activation of the tyrosine kinases 
present in their cytoplasmic domains. NT-4 and BDNF are specific ligands for NTRK2. 
NTRK2 contains two N-terminal leucine-rich domains, a central immunoglobulin C-2 
type domain (the most important site at which NTRK receptors interact with 
neurotrophins) and a C-terminal tyrosine kinase domain (See figure 4.29). 
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Figure 4.29. Domain structure of the NTRK2 protein 
Adapted from the Human Protein Reference database (www.hprd.org) 
 
 
Eleven alternatively splice variants of NTRK2 is predicted, and experimental evidence 
suggest that differential splicing results in proteins with different extracellular domains, 
leading to differences in the nature of ligand interaction [371]. NTRK receptors are also 
implicated in a wide variety of signaling pathways via adaptor protein (such as SH-2) 
docking of their cytoplasmic phosphotyrosine residues. Such interactions lead to the 
activation of Ras/ERK, PI3K/Akt kinase and PLCγ signaling cascades [370]. 
Mutation in the NTRK2 gene has been implicated in a human subject with hyperphagic 
obesity, neurocognitive impairment and recent memory loss [372], where a heterozygous 
missense mutation resulting in a Y722C substitution resulted in marked impairment of 
receptor autophosphorylation and MAPK signaling.  
NTRK2 is reported to be expressed at very high levels in brain, tongue and tracheal tissue 
and when I amplified cDNA from various normal human tissues with cDNA-specific 
primers, my data suggested that this gene is also expressed in T, B and NK cells (See 
Figure 4.30). 
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Figure 4.30. NTRK2 gene expression in various tissues 
Agarose gel showing RT-PCR amplification of NTRK2. Data shows that NTRK2 is 
expressed in T cells, B cell lines, NK cells and cord blood as well as fetal brain. 
 Source of cDNA is indicated above. Amplification control by β actin is shown in the 
bottom gel. PP0065: Non-FHL B cell line, FB: Fetal brain. 
 
 
In order to screen for underlying mutations, I initially amplified the full-length NTRK2 
cDNA from the FHL I cell lines PP0150, PP0277 and PP0231 with a view to sequencing 
the coding region of the gene. However, due to the presence of a large number of 
alternatively spliced variants with high degree of sequence homology, it was difficult to 
obtain reliable sequencing data from PCR sequencing of cDNA, particularly downstream 
of Exon 12, from where the main variants differ in their sequences. From cDNA 
sequencing form the FHL I cell lines I was able to demonstrate that no mutations existed 
in exons 1 to 12 in the NTRK2 gene. I then amplified and sequenced exons 12 -18 from 
genomic DNA using primers designed to span exons and intron-exon boundaries. My 
data from genomic DNA suggests that all three FHL I cell lines tested had completely 
normal sequences from Exons 12-18. 
Next, I tested NTRK2 gene expression in the FHL I cell lines by RQ-PCR to exclude any 
potential regulatory area mutation. My data indicates that gene expression in all three cell 
lines is lower than the reference cell line PP0065, and although expression in PP0231 
(proband) is about half of that in PP0277 (parent), not much difference exists between 
expression levels of PP0150 (parent) and PP0231 (proband) (See figure 4.31). It is 
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therefore unlikely that the difference in gene expression seen in PP0277 and PP0231 is a 
reflection of an underlying defect in gene transcription. 
 
 
Figure 4.31. Relative expression of NTRK2 in FHL I cell lines by RQ-PCR 
Gene expression is indicated relative to that of the non-FHL I cell line PP0065. Individual 
bars represent three separate RQ-PCR experiments. 
 
Taken together, my data suggests that NTRK2 is not the disease-causing gene in FHL I. 
 
 
4.1.12 Summary of mutation screening of the non-candidate genes of the FHL I 
locus 
Using a combination of PCR amplification and direct sequencing of either genomic DNA 
or cDNA from the FHL I cell lines and in some cases cloning of the PCR amplicons into 
a cloning vector and then sequencing individual clones has failed to reveal any mutation 
in the coding region of any gene in the FHL I locus. Using cDNA from the FHL I cell 
lines, I also studied gene expression of the genes in the FHL I locus in order to exclude 
abnormalities in gene transcription. However, no such abnormality was identified. The 
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FHL I-causing gene thus remains unidentified. In the next chapter, I describe the genetic 
and cellular characterisation of the new patients recruited to my study. 
 
4.2 Apoptosis in FHL I  
 
As discussed earlier, all patients assigned to FHL I had been diagnosed with FHL on 
clinical grounds but not on the basis of defective cytotoxicity, the functional hallmark of 
HLH. Since I never had primary lymphocytes to perform functional studies I was unable 
to confirm defective cytotxocity in FHL I. 
However, I was able to explore an alternative cellular phenotype in FHL I, which is 
testable in B cell lines, namely whether de-regulated apoptosis is the primary cellular 
defect accounting for HLH. This was prompted by the work of Rigaud et al who showed 
that in X-linked lymphoproliferative syndrome caused by mutations in X-linked 
inhibitor-of-apoptosis XIAP (also known as BIRC4) the prominent HLH phenotype is 
linked to a pro-apoptotic phenotype of B and T cells [246]. For this purpose, I studied the 
degree of apoptosis induced by incubating the FHL I cell lines with anti-CD95 antibodies 
mimicking Fas-FasL-induced apoptosis and compared it with other non-FHL B cell lines 
or Jurkat cells (a CD4+ T cell line known to be sensitive to FasL killing). Apoptotic cells 
were identified by flow cytometry as annexin V- positive cells. In the first instance, I 
incubated Jurkat cells and B cell lines for several time points for up to 24 hours in 
increasing concentrations of anti-CD95 and found that the most reproducible data is 
obtained at 4 hours and thus subsequent experiments were performed at 4hrs incubation. 
My data showed that as expected, Jurkat cells were very sensitive to anti-CD95 in a 
concentration-dependent manner (Figure 4.32). By contrast, all B cell lines tested, FHL I 
and non-FHL I, were rather resistant and displayed little cell death even at the highest 
concentration of anti-CD95 which resulted in 90% Annexin+ in Jurkat cells. 
Overall, there was no difference in the degree of apoptosis between the FHL I cell lines 
and at least five other non- FHL I B cell lines. It is therefore unlikely that a defect in the 
apoptotic pathway is responsible for the cellular phenotype of FHL I.  
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Figure 4.32. Apoptosis assay by flowcytometry 
The FHL I B cell lines (PP0150, PP0277 and PP0231), Jurkat cells and 5 non- FHL I cell 
lines (C1R, PP0007, PP0054, PP0065 and PP0091) were incubated with increasing 
amounts of CD95 antibodies (0- 100 ng/ml, as indicated) and apoptosis was measured 
by the percentage of Annexin V positive cells by flowcytometry. While 90% of Jurkat 
cells were apoptotic after a 4- hour incubation period, all the B cell lines tested had very 
little annexin V positive cells. There was no difference in the degree of apoptosis in the 
FHL and non-FHL I B cell lines. Data is representative of three separate experiments. 
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Chapter 5.  Cellular and genetic characterisation of new 
patients with HLH  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 231 
5.1 Mutation screening of two newly diagnosed Pakistani patients with HLH  
  
As mentioned in section 2.1.2, I recruited two newly diagnosed patients with HLH to my 
study as they both fulfilled the majority of the initial inclusion criteria, namely, clinical 
diagnosis of HLH, Pakistani ethnicity and normal perforin expression and normal granule 
release assay, effectively excluding FHL II, III, IV and V. Written consent was obtained 
prior to obtaining blood samples from the patients and parents. The patients are identified 
as AK and RS. Neither of them was consanguineous.  
5.1.1 Microsatellite marker data 
 
Using the same complement of 7 microsatellite markers with which I genotyped the FHL 
I locus in the cell lines PP0231, PP0277, PP0225 and PP0150, I amplified genomic DNA 
from AK, RS and one parent each. (AK’s father refused to participate and RS’s mother’s 
DNA was insufficient to test for the markers).  
Of all the markers tested, D9S1877 was universally homozygous and was therefore 
uninformative. The marker D9S1865 failed to amplify despite several attempts. RS was 
only homozygous in D9S1867 among the informative markers (See Figure 5.1). AK was 
homozygous in two contiguous markers D9S264 and D9S167 but her mother was also 
homozygous in those markers and hence this finding is unlikely to be significant. As I did 
not have microsatellite data from both parents in the case of AK as well as RS, I was only 
able to presume the parental source of haplotype. In Figure 5.1, the maternal haplotype is 
delineated in brown and paternal haplotype is delineated in blue. In the absence of 
homozygosity in any of the informative markers of the FHL I locus, I concluded that 
there was no linkage to the FHL I locus in AK and RS. 
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Figure 5.1. Haplotypes from new patients AK and RS recruited to my study 
Microsatellite markers covering the FHL I locus and used in the Ohadi et al study [223] 
were used. In case of RS, paternal haplotype is in blue and the inferred maternal 
haplotype is in brown. However, in case of markers D9S264 and D9S1790, it was not 
possible to assign parental haplotype source and are depicted in black. In case of AK, 
maternal haplotype is in brown inferred paternal haplotype is in blue.  
5.1.2 Mutation screening of KIF27 and RASEF of the two new families 
 
I screened genomic DNA extracted from granulocytes of patients RS and AK for 
mutations in the two strong candidate genes, KIF27 and RASEF. As with genomic 
sequencing of the FHL I cell lines, KIF27 sequencing from RS and AK was complicated 
by the presence of the complex inverted duplicon with 95-98% homology with KIF27. In 
total, 8 out of the 18 exons were wildtype in both AK and RS and the remaining 
sequences had identical changes to those observed in the FHL cell lines. Two SNP’s were 
identified (rs55654273, rs295274) in exons 15 and 16 respectively. KIF27 sequencing 
data from RS and AK is tabulated below (See Table 5.1). 
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Table 5.1. Sequence analysis of KIF27 from genomic DNA from the patients RS and 
AK 
 
KIF27 RS AK 
Exon1 Non-coding Non-coding 
 
Exon2 WT WT 
 
Exon3 WT WT 
 
Exon4a Double peaks in last 49bp 
exonic 
Double peaks in last 49bp exonic 
 
 
Exon4b WT WT 
 
Exon5 WT WT 
 
Exon6 T1851C, A1952G het exonic 
changes, 3 intronic changes, 
same as PP0150 
WT 
 
 
 
Exon7 6 heterozygous exonic changes 
as in PP0225 and PP0231 
6 heterozygous exonic changes as in 
PP0225 and PP0231 
 
Exon8 Double peaks as in FHL cell 
lines 
Double peaks as in FHL cell lines 
 
 
Exon9 Double peaks as in FHL cell 
lines 
Double peaks as in FHL cell lines 
 
 
Exon10 T2388C and A2563G het in 
exonic sequence 
5 heterozygous exonic changes: 
T2388C 
 
T2416A 
 
G2469A 
 
T2471C 
 
A2563G 
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Het: heterozygous, WT: wildtype, AA: amino acid. 
 
Genomic DNA PCR sequencing of RASEF from RS and AK did not show any mutations 
in the coding region (See table 5.2). 
 
 
 
 
 
Exon11 G2664A het in exonic 
sequence, no change in AA 
 G2595A  
G2664A  
het changes in exonic sequence, same as 
PP0150, PP0225, PP0231 and PP0180. No 
change in AA  
 
 
Exon12 
PCR conditions not found PCR conditions not found 
Exon13 WT WT 
 
Exon14 WT A3250G heterozygous (published SNP 
rs55654273) 
 
 
Exon15 A3330T homozygous 
(published SNP rs295274) 
A3330T homozygous (published SNP 
rs295274) 
 
Exon16 WT WT 
 
Exon17 C/T het C3856T homozygous, same as seen in 4 
clones of PP0231 during TA cloning of 
exon17 
 
 
Exon18a Double peaks 40bp upstream of 
5’ end similar to other test 
samples 
Double peak area coincides 
with the 3bp AGG insertion in 
the exonic sequence, as seen in 
231 and controls cloning data 
 
Double peaks 40bp upstream of 5’ end 
similar to other test samples Double peak 
area coincides with the 3bp AGG insertion 
in the exonic sequence, as seen in 231 and 
controls cloning data 
Exon18b G4326A het in exonic sequence 
and 5bp insertion in non-coding 
part 
G4326A het in exonic sequence and 5bp 
insertion in non-coding part 
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Table 5.2 Sequence analysis of RASEF from genomic DNA from the patients RS and 
AK 
RASEF RS AK 
Exon1 Not amplified Not amplified 
Exon2 WT WT 
Exon3 WT WT 
Exon4 WT WT 
Exon5 C1046T homozygous SNP 
rs4146960 
C1046T het SNP rs4146960 
Exon6 WT WT 
Exon7 WT WT 
Exon8 WT WT 
Exon9  WT exonic sequence, 5bp deletion 
intronic sequence 54 bp downstream of 
exon-intron junction 
Exon10 WT WT 
Exon11/12 WT WT 
Exon13 WT WT  
Exon14 WT WT 
Exon15 WT WT 
Exon16 WT WT 
Exon17 WT coding sequence Double peaks as PP0231 
WT: wildtype, het: heterozygous. 
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5.1.2 Polyclonal expansion of cells from RS for immunofluorescence and confocal 
microscopy 
At the time of presentation, both RS and AK had normal cytotoxic granule release upon T 
cell stimulation, thereby functionally excluding FHLIII, IV and V. I expanded PBMC’s 
from RS (taken at remission) by PHA and allogeneic stimulation in order to visualise the 
cytotoxic machinery at single-cell level. The method of polyclonal expansion of PBMC’s 
is outlined in Section 2.3.3. Briefly, I incubated 5x105 PBMC in 1 ml human T cell 
medium containing 1µg/ml PHA, 100u/ml IL-2 and 1x106 irradiated feeder cells (normal 
donor PBMC) in 48-well plates at 370C and 5% ambient CO2. IL-2 was replenished 
every 72 hours. Polyclonal expansion was observed from day 5 of cultures. On day 13, 
cells were conjugated with P815 cells at 1:1 ratio in the presence of 1µg/ml PHA or 
1µg/ml anti-CD3. Conjugated cells were then stained for γ tubulin and Lamp1, to 
visualise the MTOC and the cytotoxic granules, respectively. My data demonstrates that 
T cells from RS were able to form conjugates and displayed normal MTOC and granule 
polarisation (Figure 5.2).  
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Figure 5.2 Confocal microscopy of CD8+cell-P815 cell conjugates from patient RS 
Polyclonal T cells were expanded with PHA and allogeneic stimulation. Conjugation was 
performed at 370C for 30 minutes in 8-well slides in the presence of PHA or anti-CD3. 
Cells were methanol-fixed, blocked and stained for MTOC (γ-tubulin, red), cytotoxic 
granules (Lamp-1, green) and nucleus (DAPI, blue). Data indicate that cells from RS 
were able to conjugate with target cells and polarise their cytotoxic granules normally. 
Figure is a representative of at least 50 conjugates.  Arrow points to the immunological 
synapse where MTOC and Lamp-1 are juxtaposed.  
P815- Rat mastocytoma cell line, MTOC: Microtubule Organising Centre. 
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5.2 Cellular and genetic characterisation of cryopreserved patient samples 
with HLH 
5.2.1 Patient details 
 
I have outlined the details of the two patients with HLH whose parents were first cousins 
in section 2.1.3. Briefly, the patients were both from consanguineous Pakistani families, 
and presented with clinical HLH in 2002 (patient ‘NA’, age 2 months) and 2005 (Patient 
‘AM’, age 10 years), respectively. Neither had an affected sibling and AM had tested 
negative for a mutation in the PRF1 gene. Both patients were subsequently treated with 
HSCT, one of who succumbed to the complications of the procedure. PBMC from both 
patients were collected at the time of diagnosis, before any treatment was commenced. 
These cells were available for analysis. I did not have access to parental cells from either 
patient.  
5.2.2 Single cell culture from cryopreserved samples 
 
Because of the small number of cryopreserved PBMC available from these 2 patients and 
in order to amplify the cellular material available for both cellular and genetic studies I 
tried to generate CD4+, CD8+ and NK cell clones.  Specifically, I aimed to grow 
sufficient numbers of CD4+ T cell clones to extract genomic DNA and mRNA for 
mutation analysis and gene expression and use CD8+ T cells and NK cells for functional 
studies. I have described the technique of cellular expansion in detail in Section 2.3.4. 
Briefly, I FACS-sorted single cells with CD4+, CD8+ or CD56+ phenotype into 96-well 
plates containing irradiated feeder cells in human T cell medium containing IL-2. Cells 
were stimulated using PHA and allogeneic stimulation was repeated every fortnight. IL-2 
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was replenished every 72 hours. Expanding clones were grown and subjected to cellular 
and genetic analysis. 
Despite two attempts with cells from NA (from whom there were 3 vials of 
cryopreserved cells available), and one attempt from AM (from whom only one cryovial 
was available), I was unable to expand NK cell clones using standard protocols I 
previously used successfully to expand NK cells from normal donors. My NK cell 
cloning protocol has been detailed in section 2.3.4. I successfully expanded CD8+ and 
CD4+ T cells clones from NA and CD4+ T cells only from AM.  
 
5.2.3 Microsatellite marker data of patients ‘NA’ and ‘AM’  
 
In the first instance, I tested genomic DNA from patients NA and AM for linkage to the 
FHL I locus, as in the case with the FHL I BLCL, using the same set of microsatellite 
markers as in the Ohadi et al study [223]. (See figure 5.2).  
Majority of the markers were in heterozygosity in NA, and only two contiguous 
informative markers (D9S167 and D9S152) were in homozygosity in AM. In the 
background of consanguinity, the presence of mostly heterozygous alleles excludes 
linkage to the FHL I locus in both NA and AM. As mentioned before, marker D9S1877 
was universally homozygous, and hence uninformative. Furthermore, in the absence of 
parental material for genotyping, it was not possible to assign paternal vs. maternal 
haplotypes or to exclude potential recombination, which would have resulted in disparate 
haplotypes. 
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Figure 5.2 Haplotypes from patient NA and AM, whose cryopreserved PBMCs were 
expanded and tested for linkage to the FHL I locus. 
Microsatellite markers covering the FHL I locus and used in the Ohadi et al study [223] 
were used. Consecutive markers D9S167, D9S 152 and D9S1877 (boxed) were 
homozygous in AM. However, among these, D9S1877 is universally homozygous and 
uninformative. 
5.2.4 Genotyping of ‘NA’ and ‘AM’ for mutations in the other FHL genes 
 
At the time of presentation, patient ‘AM’ was found not to harbour any mutations in the 
PRF1 gene, thereby excluding perforin as the disease-causing gene in his case. Using 
genomic DNA obtained from CD4+ cell cultures I amplified and sequenced exons 2 and 
3 of the PRF1 gene and I have been able to demonstrate that patient ‘NA’ was also 
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negative for any PRF1 mutations. Furthermore, using long-range PCR primers and 
internal sequencing primers I amplified and sequenced exon 2 of STX11 (coding exon) 
from NA, which was normal. Finally, I amplified and sequenced exons 5, 8, 9, 10, 14, 15 
and 16 of STXBP2 (gene implicated in FHL V) and found that they were normal in both 
NA and AM, thereby excluding all known mutations. Thus, I was able to exclude FHL II, 
FHL IV and FHL V by genotyping in both NA and AM. 
5.2.5 Granule release assay  
 
Next, I proceeded to assess functionally CD8+ clones from ‘NA’. Specifically, their 
ability to degranulate upon stimulation with PHA or CD3 antibody. If found to be 
normal, it would effectively exclude any defect in the granule-release mechanism of the 
cells, thereby functionally excluding FHL III, IV and V as likely cause for HLH in ‘NA’.  
In order to get enough cell numbers to perform the assay, I pooled three CD8+ clones 
each from NA and a normal control, both of which were grown from single cell cultures. 
My data revealed that in case of CD3+CD8+ clones from ‘NA’, there was a 10% increase 
of CD107a + (degranulating) cells of upon stimulation with anti-CD3 antibodies and a 
6% increase of CD107a+ cells upon stimulation with PHA. Single cell clones from 
normal controls that were cultured at the same time as cells from NA had a net increase 
of 10% and 8% when treated with anti-CD3 and PHA, respectively (See Figure 5.3).  
My experiment suggests that cells from NA were able to degranulate effectively upon 
stimulation. This implies that the granule exocytic machinery, which involves vesicle 
polarisation, priming and docking were intact, thereby excluding FHL III, IV and V, and 
any other defect in the exocytic pathway to be responsible for causing HLH in ‘NA’.  
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Figure 5.3. Granule release assay in CD8+ clones from patient ‘NA’ grown from single 
cell cultures 
Single cell cultures of CD8+ cells from cryopreserved sample from patient NA shows 
degranulation upon stimulation by CD3 or PHA, as indicated. Data is representative of 
one experiment only. 
5.2.6 Confocal microscopy of cellular conjugates 
 
In order to visualise the cytotoxic machinery of the CD8+ clones from patient ‘NA’ at a 
single-cell level, I conjugated CD8+ cells with P815 cells in the presence of anti-CD3 
antibody in 8-well polylysine coated slides and stained them with antibodies against the 
MTOC (γ tubulin- mouse anti-human) and cytotoxic granules (Lamp-1 or CD107a rabbit 
anti-human) along with nuclear staining for DAPI. Secondary antibodies used were 
AlexaFluor-488 (donkey anti-rabbit) and AlexaFluor-546 (rat anti-mouse). There were 
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similar numbers of cell conjugates per high power field in both normal controls and NA. 
CD8+ cells from NA that were conjugated to P815 cells showed normal granule 
polarisation, indicating that the cells were able to conjugate and polarise their granules 
normally, eliminating a defect at this stage of the cytotoxic machinery (See figure 5.4). 
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Figure 5.4. Confocal microscopy of CD8+cell-P815 cell conjugates  
Cells were grown from single cell cultures. After conjugation, cells were fixed and stained 
for MTOC, cytotoxic granules and nucleus. Data indicate that cells from patient ‘NA’ 
were able to conjugate with target cells and polarise their cytotoxic granules normally, as 
compared to a normal control. DIC: Differential interference contrast. 
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5.2.7 Conclusion of study of cryopreserved primary cells  
 
I was able to obtain adequate numbers of CD8+ and CD4+ cells following single cell 
sorting and culture from one patient (NA) only. Microsatellite marker data demonstrated 
that majority of the markers were present in heterozygosity thus excluding linkage to 
FHL I locus. Mutation screening from genomic DNA obtained form the expanded CD4+ 
populations indicated that NA had normal PRF1, STX11 and STXBP1 coding sequence. 
Flow-cytometric analysis of the appearance of Lamp-1 antigen upon T cell stimulation 
with PHA or anti-CD3 antibody indicated that NA’s cells degranulated normally. When 
conjugated with P815 target cells, NA’s T cell clones were able to form stable conjugates 
and were able to polarise cytotoxic granules normally, as indicated by images obtained 
from confocal microscopy. I was unable to expand CD8+ cells from ‘AM’ satisfactorily 
to be able to do functional studies.  
In the absence of clear homozygosity in the FHL I microsatellite markers, it is unlikely 
that either NA or AM suffered from FHL I. However, absence of material from parents 
precluded me from drawing any further conclusions form the genotyping data. NA’s cells 
conjugated, polarised and released granules effectively.  
Due to lack of adequate numbers of CD8+ T cells, I was unable to perform formal 
cytotoxicity assay i.e., the assay diagnostic of HLH.  Therefore, the nature of the 
cytotoxicity defect, if any, leading to HLH in this patient remains uncharacterised.   
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5.3 Screening for linkage to FHL I locus using microsatellite markers in a 
third consanguineous Pakistani family   
 
During the course of my study I received samples from another consanguineous Pakistani 
family with HLH.  The proband was 6-month-old boy who had succumbed to HLH and 
in whom FHL II, III and IV had been excluded by genetic or functional assays. The only 
living child of the family was asymptomatic. I obtained PBMC from both parents and the 
unaffected sibling in order to investigate the possibility of linkage to the FHL I locus. I 
did not have access to DNA from the proband. My findings failed to demonstrate any 
linkage to the FHL I locus or identify a disease-linked haplotype (See Figure 5.5). 
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Figure 5.5. Haplotypes from a third family of Pakistani descent in whom one child had 
succumbed to HLH in the past.   
Microsatellite markers covering the FHL I locus and used in the Ohadi et al study [223] 
were used. Genotype of the FHL I cell line PP0231 has also been displayed alongside 
for reference. DNA from the sibling that had died from HLH was not available for study. 
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5.4 Conclusions of genetic and cellular screening of new families 
 
I was able to study two newly diagnosed patients; two cryopreserved patient samples and 
one family where a proband had died of HLH. All these patients were of Pakistani origin. 
At presentation, newly diagnosed patients RS and AK had normal perforin expression by 
flowcytometry and normal granule release upon stimulation, effectively excluding FHL 
II-V. Microsatellite data from the FHL I locus has failed to demonstrate linkage. RS and 
AK are both alive and well 2 years after withdrawal of anti-HLH therapy, and neither has 
proceeded to an allogeneic HSCT. This raises the possibility that in both cases, the HLH 
was secondary in nature. This is further supported by the fact that although of Pakistani 
origin, neither family was consanguineous. 
Patient ‘NA’ (from whom cryopreserved PBMC was obtained) had normal PRF1, STX11 
and STXBP2 genotypes, normal granule release upon stimulation, normal cellular 
conjugation with target cells and normal granule polarisation. Microsatellite markers have 
failed to demonstrate linkage to the FHL I locus.  
Patient AM had normal PRF1 genotype on diagnosis. His cells could not be expanded as 
effectively as that of NA. However, from genomic DNA obtained from expanded CD4+ 
cells from AM, microsatellite markers were amplified, which failed to demonstrate 
linkage to the FHL I locus. 
Finally, the asymptomatic surviving child of the family in which another child had 
succumbed to HLH earlier was also investigated for linkage to the FHL I locus. 
 No such linkage was demonstrated in the sibling. 
 249 
 
 
 
 
Chapter 6.  Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 250 
6.1 Homozygosity mapping 
 
My study aimed to resolve a crucial outstanding issue in the genetics of Familial 
Haemophagocytic Lymphohistiocytosis by seeking to identify the gene responsible for 
FHL I, the first FHL subtype to be assigned a genetic locus by homozygosity mapping. In 
consanguineous families where a monogenic genetic disorder is inherited and propagated 
through generations, the  chromosomal region linked to the disease is shared by several 
members through a phenomenon known as identity by descent [373].  Genome- wide 
homozygosity mapping in consanguineous families using restriction fragment length 
polymorphism (RFLP) [374] or microsatellite marker analysis [375], and more recently 
SNP arrays [376] have been invaluable tools in identifying such chromosomal intervals 
or disease loci by multipoint linkage and haplotype analysis. 
 
6.2 Linkage data of the FHL I study 
 
In their original study, Ohadi et al [223] identified the FHL I locus using linkage data 
from 6 consanguineous families, 3 of Pakistani, 2 of Middle Eastern and 1 of Turkish 
descent. Three hundred and forty-two fluorescent- labelled PCR primer pairs were 
selected in the first instance to amplify highly informative microsatellite loci from the 
Genethon human linkage map [322] that covered all the autosomal chromosomes with an 
average distance of 10cM. Of these, 310 markers provided informative data and only one 
(D9S167) was found to be homozygous in three affected individuals from three Pakistani 
pedigrees, but not in any of the unaffected siblings. A combined 2-point lod score of 3.1 
was achieved for the marker, suggesting the likelihood of linkage of the disease gene in 
these families to this marker. By haplotype analysis of microsatellite markers both 
centromeric and telomeric to D9S167, the authors were able to limit the centromeric 
boundary of the locus to D9S175 and the telomeric boundary to D9S283, 14cM and 
12cM, respectively from D9S167 (See figure 1.19).  Next, they selected nine further 
microsatellite markers between D9S175 and D9S283 in an attempt to narrow the disease 
gene interval. The presence of two recombination events in the maternal line of one of the 
kindred helped limit the disease gene interval to a 7.8cM region between and excluding 
 251 
markers D9S1867 and D9S1790 and the authors were able to compute a combined 
multipoint lod score of 4.9. Subsequently, the authors were able to analyse three further 
Pakistani families with HLH, one of whom demonstrated homozygosity between markers 
D9S167 to D9S1790, thereby increasing the lod score to 6.05. However, no haplotype 
data exists of the parents of these three newer families. No linkage to the FHL I locus was 
demonstrated in the Middle Eastern and Turkish pedigrees, suggesting genetic 
heterogeneity in FHL a fact subsequently confirmed by the identification of several other 
genes in FHL. 
6.3 Haplotype disparity in the FHL I pedigrees 
 
Although linkage analysis identified the FHL I locus in pedigrees of Pakistani descent 
alone and not in consanguineous families of other ethnicities, individual haplotypes were 
not identical in the pedigrees analysed, suggesting a lack of a founder mutation. In the 
linkage study that identified the FHL II locus [224], haplotype disparity was also present, 
but probands were derived from many ethnicities. PRF1, encoding the pore-forming 
protein perforin was identified as the disease-causing gene in FHL II [227] and 
subsequently, mutations in the PRF1 gene were shown to have ethnic specificities, such 
as the 91delCT mutation in Japanese patients and 50delT mutation in patients with 
African ancestry, implying that these were founder mutations in these ethnic groups 
[263].  
It is possible that high-density markers are required to identify a putative founder 
mutation harboured within the disease-causing chromosomal interval in FHL I, or that 
families from other ethnic backgrounds might in future demonstrate linkage to this locus. 
For example, until recently, although FHL IV was identified in Kurdish populations only, 
there were a number of different mutations in the STX11 gene causing the disease within 
this population, suggesting the lack of a founder effect [288]. More recently however, a 
novel STX11 gene mutation was identified in three unrelated Argentinean patients with 
FHL III, suggesting a founder effect within this population [312].  
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6.4 Candidate gene approach to mutation screening 
 
The FHL I locus spans 5Mb in the physical map of the human genome, comprising 13 
known and 1 novel gene, 1 microRNA gene, as outlined in Table 3.1, and several 
pseudogenes and processed transcripts. All the other FHL genes described so far have 
experimentally and functionally validated roles in the lymphocyte cytotoxicity pathway, 
and although the Ohadi study [223] did not provide functional data, it was reasonable to 
presume that the FHL I gene mutation would also disrupt this pathway. Four genes out of 
14 had domain structures and predicted functions that could have putative roles in the 
lymphocyte cytotoxicity pathway and were strong candidates to harbour the pathological 
mutation of FHL I. I have described these genes and their candidacy in detail in section 
3.3. 
To date, a vast number of disease-linked genes have been identified using a positional 
candidate gene approach where a functional readout and linkage data identifying a 
disease carrying chromosomal interval are available [377]. Conversely, despite having 
robust pedigree data and modern mutational screening strategies such as high density 
SNP array genotyping, a number of gene-finding studies have failed to identify a disease 
gene [378] [379] [380].  
 
6.5 The putative FHL I gene 
 
Despite extensive and exhaustive attempts at mutation screening of the FHL I locus, the 
disease- causing gene for FHL I remains unidentified. In the first instance, I screened the 
4 strong candidates, namely KIF27, RASEF, FRMD3 AND UBQLN1 for the presence of 
a pathological mutation. Using a combination of PCR amplification and direct 
sequencing of genomic DNA or of the full-length cDNA and gene expression using RQ-
PCR, no such mutation could be identified. I then proceeded to screen the remaining 
genes o the FHL I locus using a similar strategy, but I could not identify a pathological 
mutation in any of the known or novel genes in the FHL I locus. 
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6.5.1 Challenges encountered in mutation screening of KIF27 
 
Mutation analysis of KIF27 was complicated by the presence of an area of genomic 
duplication and the presence of the pseudogene RP11-213G2.2 with over 95% homology 
with the genomic sequence of KIF27. This resulted in a number of abnormal 
chromatograms when I directly sequenced PCR-amplified products from genomic DNA 
from the FHL I cell lines. The same abnormalities were noted in genomic DNA from a 
number of normal controls. When analysed at a single-molecule level with the help of TA 
cloning, I was able to establish that the exonic sequences of KIF27 from the FHL I cell 
lines were wildtype. This was also corroborated by a wildtype sequence of the full-length 
cDNA from the affected FHL I cell line PP0231. Apart from a heterozygous ‘G’ insertion 
232bp upstream from the start of Exon 1 in PP0231, not present in parental cell lines and 
10 normal controls, no other abnormalities were identified in the promoter of KIF27. I 
also studied KIF27 protein by western blotting and immunofluorescence microscopy. In 
both cases, protein expression was comparable to that of normal controls.  
My KIF27 mutation screening strategy mainly focussed on the exonic regions and the 
promoter area of the gene. It is possible that a distant regulatory region, not covered by 
my screening or a critical intronic region is mutated, leading to a loss of function of the 
putative protein. However, the fact that protein levels of KIF27 in the patient B cell line 
was similar to controls makes this possibility unlikely: a regulatory area mutation would 
result in reduced transcription and protein production while an intronic mutation might 
alter splicing resulting to a frameshift and reduced protein levels.  
In a recent report, Sun et al performed copy-number analysis with the Affymetrix 
Genome-Wide Human SNP Array and identified genomic microdeletions of different 
sizes and with different breakpoints in chromosome 17q24.2-q24.3 in three Han Chinese 
families with autosomal dominant hypertrichosis [381]. It is possible that copy number 
variations in the KIF27 gene might be responsible for the disease in FHL I. I have not 
experimentally explored this possibility. 
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6.5.2 Other issues in the mutation screening of the genes in the FHL I locus 
RASEF, one of the strong candidates in the locus was not found to be consistently 
expressed in cells of haemopoietic origin (apart from cord blood) and hence gene 
expression in the FHL I B Cell lines could not be studied. Mutation screening of 
FAM75B was complicated by sequence homology of the FAM75 family genes, all 
located in chromosome 9, and was resolved by PCR cloning and sequencing. Like KIF27, 
the non-coding exons of GKAP1 also had sequence similarity with the same complex 
inverted duplicon and were not included in mutation screening. The presence of two 
isoforms of GKAP1 in mRNA from BLCL made cDNA sequencing technically difficult, 
and genomic DNA sequencing of the coding exons revealed that GKAP was wildtype in 
the FHL I cell lines.  
6.6 Genetic material available for study 
 
During the course of my project, only two newly diagnosed patients, RS and AK were 
accrued to my study. Both were of Pakistani origin, had no family history of HLH and 
neither was consanguineous. Both responded to chemotherapy only and did not require 
HSCT to obtain remission. To date, no cases of FHL have survived in the absence of 
HSCT [59] and it is likely that both were suffering from secondary HLH at the time of 
diagnosis. Neither demonstrated linkage to the FHL I locus.  
I also had access to cryopreserved cells from 2 Pakistani patients who fulfilled the 
inclusion criteria of my study. Out of these, I was able to successfully expand and 
functionally analyse cells from one patient only (NA). Neither demonstrated linkage to 
the FHL I locus. Functional studies demonstrated that NA’s CD8+ cells had normal 
granule release upon stimulation and normal granule polarisation when conjugated to 
appropriate target cells, functionally excluding FHL II-V. Due to the lack of adequate cell 
numbers, I was unable to perform cytotoxicity studies on NA’s cells. Thus, the only 
genetic material linked to FHL I I studied during the course of my project was BLCL 
derived from the Ohadi et al study. I therefore had no access to primary cytotoxic 
lymphocytes from patients with FHL I, which has precluded functional studies to be 
undertaken. I was able to exclude defects in apoptosis of these BLCL using a FACS-
based assay.  
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PP0231, the sole proband in my project also harbours the A91V polymorphism in her 
PRF1 gene. As detailed in section 1.8.3, the A91V-PRF polymorphism, although on its 
own is not pathogenic, when inherited in compound heterozygosity with a second 
perforin allele with ‘null’ activity, could be disease causing. In principle, PP0231 could 
harbour a putative FHL I mutation with ‘null’ activity in heterozygosity and could present 
in compound heterozygosity with A91V-PRF and lead to clinical FHL. However, 
compound heterozygosity of the A91V-PRF polymorphism with mutations in other FHL 
genes has not been reported making very unlikely that the -233G insertion in the 
promoter of KIF27 in patient PP0231 is pathogenic. 
 
6.7 Future work 
 
In the absence of a pathological mutation in the exonic region of the FHL I locus, a high 
throughput sequencing strategy, covering the entire 5Mb region of the locus could be 
employed to screen for potential mutations. This could be undertaken using the 
commercially available ‘Sequence Capture’ technology for high throughput sequencing 
of the 5Mb region of interest using genomic DNA from patient cell lines. ‘Sequence 
Capture’ technology is a process that enables the selective enrichment of up to 5Mb of 
selected genomic regions from human or mouse genomic DNA in a single enrichment 
step [382]. The process utilizes high-density, long-oligo arrays for the targeted 
hybridization and elution of only the specified genomic region. In this technique, only 
unique genomic regions are enriched and repetitive regions are removed using a ‘repeat-
masking’ method.  Following enrichment, samples could then be subject to high-
throughput sequencing by an appropriate sequencing machine such as the 454 GS FLX 
sequencer. 
Alternatively, the recently- described exome sequencing strategy could be employed to 
obtain a more comprehensive, genome-wide mutation screening data. Exome sequencing 
and homozygosity mapping have been employed to identify rare Mendelian disorders 
[383] in recent reports. Next- generation sequencing strategies continue to remain 
expensive and require bioinformatics support that was beyond the scope of this project. 
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To date, no new families have demonstrated linkage to FHL I since the Ohadi et al study. 
Should such families present in the future, material from parent-proband trios could be 
subjected to high-density SNP arrays to both confirm linkage to 9q21.3-22 as well as 
potentially narrow the disease interval. Primary cells could be used in various functional 
studies, some of which I was able to establish during the course of my project but unable 
to use, due to lack of sufficient patient material.  
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Appendix Table 1. Genomic primers KIF27 
Name Sequence  Amplicon 
length 
(bp) 
Annealing 
temp 
(0C) 
KIF27Ex2F  
KIF27Ex2R 
CAAGACAGGCTTACTCTTTGT 
ATGCTAAACACCTACCATGTGTC 
643 57 
KIF27Ex3F 
KIF27Ex3R 
ATTTGGGGTTGTAGCTTTGCT 
CTGTTTGCTAATGAAGGCAACTG 
308 57 
KIF27Ex4aF 
KIF27Ex4aR 
GGGACTATCTTGGCCAGGCTG 
CTTCTCGATTGATCTGGGTAGTTTG 
758 55.5 
KIF27Ex4bF 
KIF27Ex4bR 
CCTCCTCCTCGAATTTTGATG 
TATTTTGGGGGTACATGTGTTAACA 
585 56 
KIF27Ex5F 
KIF27Ex5R 
TGTGGTGAATGTCACTTGTGC 
CAGGTGCCTATGTTCAGAACTC 
314 56 
KIF27Ex6F 
KIF27Ex6R 
CACCAGAGAGCTAGTCTCTGGA 
CACTGTGATATTACACATGGCT 
423 57 
KIF27Ex7F 
KIF27Ex7R 
GGGAGCATTTTCCAGTGATTGGCT 
CCTACACTTCTATATTTATTGCAGCA 
376 57 
KIF27Ex8F 
KIF27Ex8R 
TCGGGGAAACTAATTTGAGGGCAG 
CTGGTCTTTGAGAATTCCTGGA 
278 57 
KIF27Ex9F 
KIF27Ex9R 
TTTGTCTCTTCCACTGCCAC 
CACCTTGTTACACCAATCCAA 
345 55 
KIF27Ex10F 
KIF27Ex10R 
AATAGTATCACTGCCTGGCTGGAT 
CAGTACAAGAATCCTCAGAAGCA 
380 56 
KIF27Ex11F 
KIF27Ex11R 
GTTGAGGATTGTGAGAGATTCAGT 
GTGAATAAGGACAGCAGTGAAGG 
390 56 
KIF27Ex13F 
KIF27Ex13R 
TAGGATCTCAGACGGCTACCT 
TTATAGCCATCCTAGTGGGGAGTA 
397 56 
KIF27Ex14F GTAACTGTTTTTGAGGTGGCTGG 304 57 
 282 
KIF27Ex14R AAGTGATCCATCATACAGCACC 
KIF27Ex15F 
KIF27Ex15R 
GCTTAGGAGGATCTGAGTATATG 
TAGGATGTAAGCATCTTGACCCA 
346 57 
KIF27Ex16F 
KIF27Ex16R 
CAAAGCATTTGCCTAAGGACC 
AGTACCCACACCTACACATCAACC 
401 57 
KIF27Ex17F 
KIF27Ex17R 
GGAGCTTACAGTGAGCCGAGC 
CCCAGTCAATTGGTAAAGGCT 
410 56 
KIF27Ex18aF 
KIF27Ex18aR 
TATGCATATTGGGTGATAATAATG 
CTGGAACGTCGCAATGATAGT 
491 55.5 
KIF27Ex18bF 
KIF27Ex18bR 
CAGGTTGTGGGAAATGTGGGAC 
GTGACTCCCTCTGACAAAAGC 
 
635 57 
 
 
Appendix Table 2. Genomic primers KIF27 promoter region (including Exon 1) 
Name Sequence  Amplicon 
length (bp) 
Annealing 
temp 
(0C) 
KIF 
Promoter 
‘A’ 
CTGAGCAAAGGCAAGAGAAATATTG 
TATGGGGGCGTCCGAGGGGTC 
736 61 
KIF 
Promoter 
‘B’ 
ACGAGACGAACACAGGGTGCG 
GTTGGTGGGACACAACTCGGA 
647 61 
KIF 
Promoter 
‘C’ 
GCGTCTTTTGTTGTCGCGAGT 
CTTGAAAACATTAAGCAAAAG 
AAGCTAG 
632 61 
 283 
The 1.6Kb area was divided into three overlapping regions arbitrarily designated A, B 
and C for amplification and sequencing purposes 
 
Appendix Table 3. KIF27 RT-PCR primers for amplification of the full length cDNA 
and internal sequencing primers 
Name  Sequence  Amplicon 
length 
(bp) 
Annealing 
temp 
(0C) 
KIF27LTPCRF 
 
 
ATGGAAGAAATACCAGTAAAAGTTGC 4.3Kb 59 
KIF27Internal 
3F 
GCATCTCTGAACATCCTAGCATT 
 
  
KIF27Internal 
4F 
GAGAGAGCTTAAGAAATGCCAG 
 
  
KIF27Internal 
4R 
GAAAGAGTAACCAAAACGGGGAAT 
 
  
KIF27Internal 
7F 
GAAGAACAAGATAAGGTCC 
 
  
KIF27Internal 
8R 
GTA TCA CTC AAT TCA ACA AGG G 
 
  
KIF27Internal 
9R 
AGCTTCAGTAAGTATGCGTTCTG 
 
  
KIF27Internal 
12F 
CTTGAAAAGGAGAAAAGGTTCGTTTG 
 
  
KIF27Internal 
13R 
GAGGAGCTGGAAGCAGACTTAAAG 
 
  
KIF27Internal 
16-17F 
TTTCAAAGAACAAGATGGAGAAGGCA   
 284 
KIF27Internal 
17R 
CGGGATCATAAGAAGAAACTTAAGGA   
KIF27LTPCR 
R 
CTAAGTTTTTAAGTCCCTTGGTTTC 
 
4.3 Kb  
I amplified the full- length cDNA (4.3Kb) by the LTPCR primers. Internal primers were used for 
sequencing. 
Appendix Table 4. RASEF Genomic DNA PCR primers 
Name Sequence  Amplico
n length 
(bp) 
Annealing 
temperatur
e (oC) 
RASEFEx1F 
RASEFEx1R 
GCTCTACCTGAGCAGCGCTTACGCC 
CAGAGAGTCAGCGTTTGGGGAGAA
AG 
1122 59 
RASEFEx2F 
RASEFEx 2R 
GTGCATTTTCACTGTCCTCGCA 
CTAGACTCCTCAGGCTCAGGAA 
492 
 
 
57 
RASEFEx 3F 
RASEFEx 3R 
ACACCAAAATGGTCGAATTGC 
AAAATTCCTTTGCTGGGAGACTC 
412 55 
RASEFEx 4F 
RASEFEx 4R 
TGTGGGATCCTGCTCTTCTT 
GAATCATTTGAATCCAGGAGGC 
  
RASEFEx 5F 
RASEFEx 5R 
AAGGCTTTTCAGCTGTTTCCA 
AGGACTTTTTCTAACTACAGTATT 
450 56 
RASEFEx 6F 
RASEFEx 6R 
TGAACACTGAGAGTTGTGGAAG  
ATTAAGCCCTGCACTAGCCAA 
476 55 
RASEFEx 7F 
RASEFEx 7R 
GGATGTGAGTGTGTTTGTGGAGT  
AGAAACACCCACTGACCTGCA 
405 55 
RASEFEx 8F 
RASEFEx 8R 
CAGCATAGACAGTTGATTCCTGCA  
ATAAGGACTTACTTGAGGCTCT 
301 55 
RASEFEx 9F 
RASEFEx 9R 
GAATATGCAGTAGGGTTTGGACG 
TAGAGATGAGGTAATGATGAG 
582 55 
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RASEFEx 10F 
RASEFEx 
10R 
GCTGCATAGAATGAACTGATGGTG 
ACTATGCTTTACATCTATGACCT 
539 55 
RASEFEx 11F 
RASEFEx 
12R 
CATAGATTGCCATTCAGTGTCAC 
TCCTAAAAGCAGGCCTTGGCCA 
805 55 
RASEFEx 13F 
RASEFEx 
13R 
AAATCATTCCCCAAGTCAGCCA  
TGAAGAACATCAAGTGGCCTGCA  
384 55 
RASEFEx 14F 
RASEFEx 
14R 
TTCTAAGTCGGTCACCCAGAT 
CTTCAGGGAAATGTGCCCAAATCC 
515 55 
RASEFEx 15F 
RASEFEx 
15R 
TTAGTTTGGATCCAGGCCCTG 
TAAAAGAGGTGGGAGTCATGGCAG 
542 56 
RASEFEx 16F 
RASEFEx 
16R 
CCTCCAACTAGGAACTTTTCCTG 
ATTTCTCCCACCATGACTGACAG 
420 55 
RASEFEx 17F 
RASEFEx17R 
TTCCTCACATACAAAATGGGGCA  
CAGATGAAGAAACAGATCCGAC 
819 55 
 
Appendix Table 5. RASEF cDNA primers for gene expression 
Name Sequence  Amplicon 
length (bp) 
Annealing 
temperature 
(oC) 
RASEFEx5F 
RASEFEx 6R 
GTCAAAAGGAAGATGTGGCTG 
CTTTTCAAAGCATCTAACTCACT 
136  60 
RASEFEx11F 
RASEFEx12R 
GACATAAGGGATGAAGAGACATTTG  
AATTCATTCTTGCAAAGTCTCATG 
 
130 60 
 286 
 
Appendix Table 6. FRMD3 genomic primers 
Name Sequence  Amplicon 
length 
(bp) 
Annealing 
temperature 
(oC) 
FRMD3Ex1F 
FRMD3Ex1R 
TGCGACTGAGCAGGCCACCA 
GTTCTCGCATGCCCACCGCAA 
643 62 
FRMD3Ex2F 
FRMD3Ex 2R 
AGAACCTTCCTGGTAGGATCA 
CGGAACCAAAAGGACCCCAAA 
228 58 
FRMD3Ex 3F 
FRMD3Ex 3R 
AGAACATAGACCCATGGTGGT 
ATCACTAGGGCTTTGAGAGGAA 
288 
 
58 
FRMD3Ex 4F 
FRMD3Ex 4R 
CGAGGCTGTACTTTGGAATTC 
CTGGCAGGAGAAAGTTTGTCA 
225  58 
FRMD3Ex 5F 
FRMD3Ex 5R 
CTTTCCCGTGTGTGTTTGAGG 
TAGCCTGCAAGACCAAAGAGAT 
222 59 
FRMD3Ex 6F 
FRMD3Ex 6R 
AAAGGGCTGGGCATGTCTAAG 
AGAAGGGAGGCTTGAAACAGC 
310 59 
FRMD3Ex 7F 
FRMD3Ex 7R 
CTCCATATGCACCCTGCTCAT 
CTGCCACGCAAAACAGCCTA 
324 59 
FRMD3Ex 8F 
FRMD3Ex 8R 
CTCAGGGAAGTCAGAAACTTG 
CTATTAGTCAATGAGTTGTGAGG 
252 58 
FRMD3Ex 9F 
FRMD3Ex 9R 
CAGGAATCACCAAACACTTAAG 
TAGCAGCCTGTTCTCAGCTC 
192 57 
FRMD3Ex 10F 
FRMD3Ex 10R 
CCTTGTGGTGAGAAATAATGATC 
CATTATATGGTGACCTGCTGTG 
290 58 
FRMD3Ex 11F 
FRMD3Ex 11R 
TTAACCTAGGGTGAGGATGAATA 
AGGCAAGGAAATGGATACCAG 
306 58 
 
FRMD3Ex 12F 
FRMD3Ex 12R 
AGTCAGATTCCTATGGGAAACC 
ACTCCTGAATCTCTCTCATGC 
210 58 
FRMD3Ex 13F GGAGATAGGATACAAAGTAAACA 280 54 
 287 
FRMD3Ex 13R TTAAAAGAAATAAATATGCAGCCA 
FRMD3Ex 14F 
FRMD3Ex 14R 
CATCACCACACCTCTATAGCA 
TAGAAATGGAAGACTCAAACAGA 
273 57 
FRMD3Ex 15F 
FRMD3Ex 15R 
GTGCATATCCCTCCCATTCTT 
CACTACACAAAGGGATGTTATAG 
215 58 
FRMD3Ex 16F 
FRMD3Ex 16R 
AAGTGTGGCTAAGCCAGCCT 
AGGACCTTGGATAAATGACTTAAC 
483 58 
FRMD3Ex 17F 
FRMD3Ex17R 
GTTCCCTGTAGACACAAAATGG 
AACATAGTTTATGGCCCACTCC 
356 58 
FRMD3Ex 18F 
FRMD3Ex 18R 
TCATTCCAGGGCTGGTTCTAA 
TACTTCCTAGGACACTTGACTG 
206 58 
FRMD3Ex 19F 
FRMD3Ex 19R 
CTTTCATTGTTTGTTAGAGGGGT 
CGCACACTTCAGGAACAGGA 
403 57 
FRMD3Ex 20F 
FRMD3Ex 20R 
FRMD3Ex20Intseq 
CAACTTAGGATACCACAGAATAAT 
ATCAATTATGAGTAAGGAACACC 
TGCTTTGTCGTGGAGCTATG 
852  
 
 
Appendix Table 7a. UBQLN1 primers-long template PCR for full- length cDNA 
 
Primer Sequence Leng
th 
(bp) 
Annealing 
temp (oC) 
UBQLNLTPCR_Ex1F 
UBQLNLTPCR_Ex11
R 
ATGGCCGAGAGTGGTGAAAGC 
CAGCTATTGGAAGGTTACTGGG
C 
1701 61 
 
 288 
 
 
Appendix Table 7b. UBQLN1 cDNA internal sequencing primers 
 
Primer Sequence 
UBQLNInternal 
Ex4F 
GGACTTGCAGGTCTGAGTAGC 
UBQLNInternal 
Ex4/5R 
AATGAGACAAACGTTGGAACTTGC 
UBQLNInternal 
Ex6/7F 
TGGAGTAGGAGCTAGTATGTTC 
UBQLNInternal 
Ex8/9R 
CATCCCAGGGTTTACTCCTGG 
UBQLNInternal 
Ex10/11F 
GAACCACTGAACCTGGACATCA 
Appendix Table 7c. UBQLN1 Promoter primers (genomic DNA) 
 
Primer Sequence 
 
UBQLNAF GTACATTCCTTGCAAGTCATC 
UBQLNAR AGCTGGGCATGAGGTAAGGT 
UBQLNBF TGACTGATCGTCTGACCAAAC 
UBQLNBR TTTAGTCCTTCACACTGGCTTC 
UBQLNCF TACGACCCCTCCAAATATCAAA 
UBQLNCR TGCTCTGCATTCTTCGCTGTC 
UBQLNDF TGAACACACGGCGGCTGCC 
UBQLNDR AGCTCCGTCCAGCAGGTGA 
The promoter sequence was divided into 4 overlapping segments and PCR-amplified in 4 overlapping 
amplicons. 
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Appendix Table 8a. TLE1 primers-long template PCR for full- length cDNA 
 
Primer Sequence Leng
th 
(bp) 
Annealing 
temp (oC) 
TLE1LTPCR_Ex1F 
TLE1LTPCR_Ex20R 
ATGTTCCCGCAGAGCCGGCAC 
CTGGCTCGGGGGACAAGAAGG 
2313 63 
 
Appendix Table 8b. TLE1 cDNA internal sequencing primers 
 
Primer Sequence 
TLE1Internal Ex5F TGTGCACAAGTCATCC CATTTC 
TLE1Ex7F TAGTGCTCTGAGTGGGCAGTCT 
TLE1Internal Ex9R AAGTAATTCCCTCCTGGTCCCA 
TLE1Internal Ex11R ATGGAATCGACAAAAATCGC 
TLE1Internal Ex12R CATGAAAAAGCCAGCACGCCTGTT 
TLE1Internal 
Ex12/13F 
TC GTTAACCAAGCGGCAGCTG 
TLE1Internal 
Ex15/16R 
CTGAACAGAGACAATTATATCCGT 
TLE1Internal 
Ex16/17F 
CTAGTGAGGCAATTCCAGGGC 
 
Appendix Table 8c. TLE1 genomic primers for Exon1 
Primer Sequence Leng
th 
(bp) 
Annealing 
temp (oC) 
TLE1Ex1F 
TLE1Ex1R 
ACTAATGTGGCCCTGAGGGCC 
AGACTGGTGGCTTCTGAGGCC 
341 63 
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Appendix Table 9. FAM75B genomic primers 
Primer Sequence 
 
Annealing 
temp (oC) 
Length 
(bp) 
FAM75BAF 
FAM75BAR 
TAATTTGATCTTGTCTGTCCCAG 
AAACATACACTCAGCCTCCTGT 
58 578 
FAM75BBF 
FAM75BBR 
GAATGACAAAGCCCTGTCCTC 
TTATCTACCTGTTAGCTTCCCCA 
58 700 
FAM75BCF 
FAM75BCR 
CTTGTAGAGAGTGCCCGAGA 
TTGCTCAGCTCTGATGGCCA 
58 1000 
FAM75BC 
Internal 
Sequencing 
AAGGTGACTTTGGTCAGCTCT   
The sequence was divided into 3 overlapping segments and PCR-amplified in 3 overlapping amplicons 
Appendix Table 10a. C9ORF103 primers for amplification of full length cDNA 
 
Primer Sequence 
 
Annealing 
temp (oC) 
Length 
(bp) 
C9ORF103 
cDNA 1F 
C9ORF103 
cDNA 5R 
 
GCATACCGCTCAATGACCAGGACCGG 
 
ACAAATAAATGAAACTTCGCTGTC 
60 750 
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Appendix Table 10b. C9ORF103 internal sequencing primers for cDNA 
 
Primer Sequence 
 
C9ORF103Internal Ex 2F ATTCCATGGCTCTGTAACTTG 
C9ORF103Internal Ex 3R ATCTGAGCGGGTCGTTTGAG 
C9ORF103Internal Ex 3F AGGAAAAGATGGTGTAGCTCTG 
C9ORF103Internal Ex 4R CTTGCCCATACTAGATTCTAAA 
C9ORF103Internal Ex 5R ACAAATAAATGAAACTTCGCTGTC 
 
Appendix Table 10c. C9ORF103 genomic primers for Exon1 
Primer Sequence Leng
th 
(bp) 
Annealing 
temp (oC) 
C9ORF103Ex1F 
C9ORF103Ex1R 
CTACACCTGCCTGTTAGTAATC 
ATGAGCTCGCTACAGCACTTG 
244 58 
 
Appendix Table 11. GKAP1 genomic primers  
 
Primer Sequence  Annealing temp Length 
 
 
 
GKAP1Ex 7F CTCTGTTTGTTTACCCATCTGC 57 387 
 292 
GKAP1Ex 7R 
 
TACTATCTTGTTCCCCTGTGTAT 
GKAP1Ex 8F 
GKAP1Ex 8R 
 
GTATCCCAGGATTGGTAA 
CACATGGCAGTGCCTCTGAAT 
57 276 
GKAP1Ex 9F 
GKAP1Ex 9R 
 
GGTTCTTCATACTCTTTAACTGAT 
AGTGCCTGCTATTTCCTCTTT 
56 197 
GKAP1Ex 10F 
GKAP1Ex 10R 
 
CAATTATTCTGTAACACCTGGCAT 
GAAGTTTAAGTGGTGAGAGGTT 
56 658 
GKAP1Ex 11F 
GKAP1Ex 11R 
 
CATATTACCTGTTGGTGAGTTTA 
CTACATCTGTTTTATACTTCAGTT 
55 262 
GKAP1Ex 12F 
GKAP1Ex 12R 
 
TCCTTCAATAAAGTTTCATCTTTG 
CACTGATGATTTTAAGAATAATAC 
55 124 
GKAP1Ex 13F 
GKAP1Ex 13R 
  
ATATCCCTTCTTGTGGTTGACT 
AACAAGTAAGCAGTAGAATCAAAT 
56 327 
GKAP1Ex 14F 
GKAP1Ex 14R 
  
GGTCAGAATTTTTCCTCTTAAAC 
TTCATGGGAATAGTCATTCTGTTT 
56 317 
GKAP1Ex 15F 
GKAP1Ex 15R 
GKAP1Ex 15 
Internal seq 
  
AGTGATACAGAGAGTGTTATAAGA 
AGTGTTTGATAGCACAATAGGG 
TATATTGCCAGACAGTACTGCTT 
 
58 –using 
LTPCR protocol 
1025 
GKAP1Ex 16F 
GKAP1Ex 16R 
 
CTATGTCTTAGTTCCCTGAAGT 
AGCTGTCTTTAGTCTTGAATTATT 
56 215 
 293 
GKAP1Ex 17F 
GKAP1Ex 17R 
  
ATGTTAAGAATTGAGTATTTGCCA 
TGTGTGAGAATAAATGCAGTATTT 
55 229 
GKAP1Ex 18F 
GKAP1Ex 18R 
  
TTGCTTCCTTCTCATACCCCAA 
CCCTGCAGGACATGCAAGAT 
59 582 
 
Appendix Table 12. HNRNPK genomic primers  
 
Primer Sequence  Annealing 
temp 
Length 
 
 
 
HNRNPKEx 1F 
HNRNPKEx 2R 
GGCAGTTGTTAGATCTCGCGA 
CATTTCCCTGAGCGTGTATCC 
59 702 
HNRNPKEx 3F 
HNRNPKEx 4R 
ATGAAACCAGGCTCCCTTGAATT 
GCCTTAGGAGTGTGTGGTGAA 
59 539 
HNRNPKEx 5F 
HNRNPKEx 5R 
GTGGCAGTATTTTGTGTTTGGTG 
CTAAACAGACTTGAAGGCTCTG 
58 560 
HNRNPKEx 6F 
HNRNPKEx 6R 
CTAGTCCTCACAGCACTTAGAA 
CAAAAGCCCAGATTGAGCAGG 
58 436 
HNRNPKEx7F 
HNRNPKEx 7R 
GTTCCTCTTGATTACTGTAAACTG 
CCCCTTTAGACGGTGTATTGTTT 
59 862 
HNRNPKEx 8F 
HNRNPKEx 8R 
TCTCTGTCTCTCTGCAAGTCT 
CAATGGATATGACAGTTTGTAGCA 
58 410 
HNRNPKEx 9F 
HNRNPKEx 9R 
GTAGTAGCTTTACCAATATATGCG 
GATACATGAATGGTCTTACAACTC 
58 291 
HNRNPKEx 10F 
HNRNPKEx 11F 
HNRNPKEx 11R 
TATAGCAGATAAGTGTGTATTGGG 
AGTTCCCTCCAAAGATTGCTTAT 
CCCTAGCAATTTTCTATCACCTG 
58 762 
500 
 294 
HNRNPKEx 12F 
HNRNPKEx 13R 
TGTTAGAAGGATTGGTATGAAGCA 
GTGTGTTGGGTATGTGAGGGTTG 
59 640 
HNRNPKEx 14F 
HNRNPKEx 14R 
CTGTTATTTGCTGCTGGAGGATT 
CTCACTCATAATCCCAACTACAAA 
59 471 
HNRNPKEx 15F 
HNRNPKEx 16R 
CTTGAGCCCGAGAGTTTGAGA 
TGGGCTTTAGTGAGCTGGGTT 
58 467 
HNRNPKEx 17F 
HNRNPKEx 17R 
GAGCGTTAGATCATCAGTTAAGAT 
AGCCATGGTGTCTCAACCTTTT 
58 402 
HNRNPKEx 18aF 
HNRNPKEx 18aR 
HNRNPKEx 18bF 
HNRNPKEx 18bR 
HNRNPKEx 18cF 
HNRNPKEx 18cR 
CTCTTCTAATTGTAATGGACGTGT 
AACAATAGTCCACATGTCCCTG 
GGGCGTGCAAAAACTAACATTGA 
CTTGCCCCTACTTTTCAACAATTT 
GTTCTGGTGATTTCTTGATGGTTT 
GGTGGTAGTTGGGCTCATAATTA 
58 1570 
Ex 18 was divided into 3 overlapping amplicons 
Appendix Table 13. hsa-miR-7a genomic primers  
 
Primer Sequence  Annealing 
temp 
Length 
 
 
 
hsa-miR-7a F 
hsa-miR-7a R 
GTCTCAACCTTTTGGGGACCTA 
TGAACTCTTCTAATTGTAATGGA
CG 
58 527 
 
 
 
Appendix Table 14a. RMI long template PCR genomic primers  
 
 295 
Primer Sequence  
 
Annealing 
temp 
Length 
 
 
 
RMILTPCR-
F 
RMILTPCR-
R 
TGTCTGTGCATTGTAGAGAATTAC 
GCCTTAGCCTCTTGAGTTGCT 
58 2300 
 
 
Appendix Table 14b. RMI internal sequencing primers for genomic DNA long-
template PCR 
Primer Sequence 
 
RMIInternal Ex 3aR ATAGTGATCTTCCTCCAGGTAC 
RMIInternal Ex 3bF TCCTTGGTTGATGTAAGTCAGC 
RMIInternal Ex 3bR CCGATCGAAGTATAGAGAGATTTT 
RMIInternal Ex 3cF ATTCCCAGAGTTACAGATGTTCT 
RMIInternal Ex 3cR CAAAGGAAGTTACAACAGTGAAAG 
RMIInternal Ex 3dF TTTCAGTTCATTGTAATGTACCC 
RMIInternal Ex 3dR CACCTTGAGAATCTAAAGAAGCG 
 
 
Appendix Table 15. C9ORF64 genomic primers 
Primer Sequence  
 
Annealing 
temp 
Length 
 
 
 
C9ORF64Ex 1F TTGTTTAGGCCCTGTGATCGC 58 547 
 296 
C9ORF64Ex 1R AGCGGGTTGGGAGATGGAATA 
C9ORF64Ex 2F 
C9ORF64Ex 2R 
GGTGCATTCCTATACCACTCA 
TTTGCTCTTGTTGCGCAGGCT 
58 588 
C9ORF64Ex 3F 
C9ORF64Ex 3R 
CCTAGACGAGACAGAATTAGAC 
TAAAAATTAGCCGGGTGTGGTG 
58 422 
C9ORF64Ex 4F 
C9ORF64Ex 4R 
GCCCGGCCAATCTATAAATTCT 
GAATTGTTGGATCTCGGTTTAGT 
57 395 
C9ORF64Ex 5F 
C9ORF64Ex 5R 
CCCTGTCTTTGTGGAATTTAAC 
TGGTTTATGCCTGTAATCCCAG 
58 615 
 
 
Appendix Table 16. SLC28A3 genomic primers 
Primer Sequence  
 
Ann
ealin
g 
temp 
Length 
 
 
 
SLC28A3Ex 1F 
SLC28A3Ex 1R 
CAGGTGTCAGCCCTAGTCATT 
GCAGGGAGATTATCAGGACAAT 
58 336 
SLC28A3Ex 2F 
SLC28A3Ex 2R 
CCTCCAAATTCCTCTAGGTATTT 
CAGAGGAACAGATTAAGTGGTAA 
57 310 
SLC28A3Ex 3F 
SLC28A3Ex 3R 
GTTTGGCCTCGTGGAATTATAG 
AATGGGATGGGTCAGAGATATC 
58 372 
SLC28A3Ex 4F 
SLC28A3Ex 4R 
CGAGTTCTGAGCAATGAAACC 
CCTCCCGTTTGGTTTTATTACTT 
57 225 
SLC28A3Ex 5F 
SLC28A3Ex 5R 
AATCTAGCCTCACCATGCAGTT 
GGTTAGGGATACCACTGTCTTT 
58 205 
SLC28A3Ex 6F 
SLC28A3Ex 6R 
GTTAGTGATGTTCAGTGTCTGTT 
AAGAGAGATAGTAGTCCTTTCC 
57 282 
SLC28A3Ex 7F 
SLC28A3Ex 7R 
CCTGATTATGATTCTCAAGTTAG 
CTTGATGGGATATTTAACGTGA 
56 343 
 297 
SLC28A3Ex 8F 
SLC28A3Ex 8R 
ACGGCCTGCATTAATTTTCCTA 
TTTTAACATTGGAGGTAATCCTC 
56 230 
SLC28A3Ex 9F 
SLC28A3Ex 9R 
CATTCCTGTGCACTGTCTAATTT 
GCGGCTTCTGTCTTTGTAGA 
56 211 
SLC28A3Ex 10F 
SLC28A3Ex 10R 
TATAAAACCTGCTGGTGCAGC 
CAAGGCCTTTTATGCAGGTATTT 
57 237 
SLC28A3Ex 11F 
SLC28A3Ex 11R 
GCCCTCAATATTTTACACCAGTT 
CACAATGTTCTTTTAGTGTAGAG 
56 282 
SLC28A3Ex 12F 
SLC28A3Ex 12R 
AGGAATCTGGTCACCCTTCTT 
GGAGGCCAAGAGAGTGTCTTT 
58 266 
SLC28A3Ex 13F 
SLC28A3Ex 13R 
AAGCTAATCCCAGGTTTGCCTT 
CCAGGAGTCAATGTACAGCAAA 
58 262 
SLC28A3Ex 14F 
SLC28A3Ex 14R 
TTATGCTACTTCTGCACCAATG 
CTCTGTTTTGTTTCTGCCTATC 
56 298 
SLC28A3Ex 15F 
SLC28A3Ex 15R 
TGTTGTCACTGAGGAGGCAA 
ACCTGGGATAGATTAGAGAGC 
56 388 
SLC28A3Ex 16F 
SLC28A3Ex 16R 
AAGCCAGCTCAGATTGTGTATA 
TGTGCCATAGACATACTTGGAT 
56 193 
SLC28A3Ex 17F 
SLC28A3Ex 17R 
CCCAGCCTCAGAACAATTTTCAG 
TTTCAGGACAGGCAGTGCCT 
58 264 
SLC28A3Ex 18F 
SLC28A3Ex 18R 
GGTTGCAGTGAGCAGAGATCA 
CAATCAAATCACACCTAAATATCC 
56 305 
SLC28A3Ex 19F 
SLC28A3Ex 19R 
AGCTTCCTGCCCTGAACTATT 
AAGAAGCTATTGTCCACAGATTGA 
 
58 320 
 
 
Appendix Table 17a. NTRK2 long template PCR primers for full length cDNA 
 
Primer Sequence  
 
Annea
ling 
Length 
 
 298 
temp  
 
NTRK2 LTPCR 2F 
 
NTRK2 LTPCR 19R 
ATGTCGTCCTGGATAAGGTGGC 
 
TTGGCCAAGGCATCTCCGGT 
61 2520 
 
 
Appendix Table 17b. NTRK2 internal sequencing primers for long template PCR of 
full length cDNA 
Primer Sequence  
 
NTRK2 Internal Ex4/5 F CTGCAGCACATCAATTTTACCCG 
NTRK2 Internal Ex6R AGACACTCAGGATTTGTACTGCC 
NTRK2 Internal Ex8F GCCACACACAGGGCTCCTTA 
NTRK2 Internal Ex9F GCTGGCCTGGAATTGACGATG 
NTRK2 Internal Ex12R GTCTATGCTGTGGTGGTGATTGC 
NTRK2 Internal Ex15/16F TGGTGGCAGTGAAGACCCTG 
NTRK2 Internal Ex16/17R GACCTCAACAAGTTCCTCAGGG 
NTRK2 Internal Ex18F TCGGTGGCCACACAATGCTG 
 
 
Appendix Table 17c. NTRK2 genomic primers 
Primer Sequence  
 
Annealing 
temp 
Length 
 
 
 
NTRK2 Ex1F 
NTRK2 Ex1R 
AATTAGTGGTGTTGGGGGTCC 
CCACGTCCTGCAAATGCAGT 
59 543 
NTRK2 Ex11F 
NTRK2 Ex11R 
TGAGTTGGTGTACATAAGGCTG 
GGAAGTGGCTAGATTTATGATG 
58 357 
 299 
NTRK2 Ex12F 
NTRK2 Ex12R 
GGGAGTTTGTTGCATTATTTGAC 
ATGCTTAGACCCTCTTTACATTC 
57 233 
NTRK2 Ex13F 
NTRK2 Ex13R 
AGTGAGTGCTAACTGGGTGAT 
GTGCAGTGAAATGTTTGAGGATT 
57 488 
NTRK2 Ex14F 
NTRK2 Ex14R 
CTGAGTTCTGGAGAAAAAGGTG 
GTGGCCAATGCAGGAGTAAATT 
58 441 
NTRK2 Ex15F 
NTRK2 Ex15R 
CCTTAGGAACTAGGCTGTTTTC 
CCTTTCTCGAAGCATCTTATTTG 
57 408 
NTRK2 Ex16F 
NTRK2 Ex16R 
TTTGTCTCCTCTTCATGCTAAGT 
AAGTCCAAGCTCAAGGTGTGA 
57 568 
NTRK2 Ex17F 
NTRK2 Ex17R 
GTGCAAATAAGGAAAGCAAACAG 
CGATCTTATGGGCTTTGTTGGT 
57 379 
NTRK2 Ex18F 
NTRK2 Ex18R 
CAAAACCAAGAGTGGGCTTCTT 
CATCTTTTAACTGCCGCTGGA 
58 400 
NTRK2 Exons 11 to 18 were amplified from genomic DNA due to difficulty in sequencing from cDNA due 
to the presence of several isoforms 
 
 
Appendix Table 18.   RQ-PCR Primers (SYBR Green) 
Name  Sequence  Amplicon 
length 
(bp) 
Annealing 
temp 
(0C) 
KIF27 
(4F/5R) 
GAGAGAGCTTAAGAAATGCCAG 
TTTCAAAGATACAGCATGCCC 
130 60 
FRMD3 
(5F/6R) 
TACCTGGGTGCCTGTATTGTT 
TTCCAGCTTCTGTGACTGCTT 
115 60 
UBQLN1  
(4F/4_5R) 
AGAGCATGCTCTCAAATCCTGAC 
AATGAGACAAACGTTGGAACTTGC 
145 60 
TLE1 TAGTGCTCTGAGTGGGCAGTCT 123 60 
 300 
(7F/9R) CCTCCTGGTCCCAGACAGTCT 
C9ORF103  
(2F/3R) 
ATTCCATGGCTCTGTAACTTG 
AGGAAAAGATGGTGTAGCTCTG 
135 60 
GKAP1 
(3F/4R) 
TGAAGCAGATCTTGAGAAGGCA 
GAATCATCAGGGAAAAGACAGACC 
152 58 
HNRNPK 
(11F/12R) 
TATGACAGAAGAGGGAGACCT 
TTATGAACCACAGGGTGGCTC 
134 60 
RMI  
(Single-Ex 
gene) 
TCCTTGGTTGATGTAAGTCAGC 
AACCTTGGGAAGCAAAGCCTT 
126 59 
C9ORF103 
(1F/2R) 
GTGACAGACACGCTCAACTTC 
GACGAAGGGATACCAATAACTAG 
136 60 
SLC28A3 
(9F/10R) 
CTACCTGGGACTGATGCAGTG 
CGACCATATTTACCTTACATCACC 
163 60 
NTRK2 
(9F/11R) 
GCTGGCCTGGAATTGACGATG  
GACACCACGAACAGAAGTAATG 
 
108 60 
 
 
 
Appendix Table 19. Perforin genomic primers 
 
Name  Sequence  Amplicon 
length 
(bp) 
Annealing 
temp 
(0C) 
Perforin 2F 
Perforin 2R 
CCTGATAATCTGTGGCTGTGG 
CAGAGTCCTCCAATCAAACTTG 
765 59 
Perforin 3F 
Perforin 3R 
CTTACATGTGACCTTGAGCAGT 
AGGACCAGTAGCTTGGACTG 
 
1264 59 
 301 
 
 
Appendix Table 20a. Syntaxin 11 long template PCR primers for Ex 2 (coding Ex)-
genomic DNA 
Name  Sequence  Amplicon 
length 
(bp) 
Annealing 
temp 
(0C) 
STX11 Ex2 
LTPCR F 
STX11 Ex2 
LTPCR R 
TGCCCACACCGAGGAATACAA 
 
GTTTGCCCCTTCCTAGTCC 
1800 62 
 
 
 
Appendix Table 20b. Syntaxin 11 internal sequencing primers for long template PCR 
Name  Sequence  
 
STX11 2-2F AGAACGCCCGCTTCCTCACGTCC 
STX11 2-2R CTCAACGAGATCGAGAGCCGCCA 
STX11 2-3F ACCAGATCGAGGACATGTTCGAG 
STX11 2-3R GACGCACCAAAGCCGGGAGCTCT 
STX11 2-4F CGTCATCGAGCTCAACGTACAA 
STX11 2-4R CAAGGAGGAAGTCAATTGGGCA 
Appendix Table 21. Syntaxin Binding Protein 2 (STXBP2) genomic primers 
 
Name  Sequence  Amplicon 
length (bp) 
Annealing 
temp 
(0C) 
 302 
STXBP2 Ex5F 
STXBP2 Ex 5R 
GTCCGTCCATGTTTGCACATG 
AGCCCCTGTTCAGTGAGCTA 
309 59 
STXBP2 8F 
STXBP2 Ex10R 
TTAACCTCTCTTGTGACCCCA 
ACTGGCCTCCAATTTCACCC 
746 58 
STXBP2 Ex14F 
STXBP2 Ex14R 
AAATGTCCTCTTGCCGAGGAT 
ACAGCTCTCCTTGGGTCATTT 
341 58 
STXBP2 Ex15F 
STXBP2 Ex15R 
TGCAAGGTTCTCTCATCAGAGT 
TTCCTGGCGTGGTGTGGTTG 
342 59 
STXBP2 Ex16F 
STXBP2 Ex16R 
TGTTCCACTTCCCCATCTTTG 
ATTCCCTTGGCACCGATCTG 
353 58 
Mutations have been described in Exons 5,8,9,10,14,15 and 16 
 
Appendix Table 22. Microsatellite primers in the FHL I locus (9q21.3-22) 
 
Name Sequence Amplicon length 
 
D9S1867 GTGAACTGCATCAGCCG 
ATCAGCCAGGGTTTCAACA 
172-210 
D9S264 
TGTTTCCCATATTTTGGCTA 
TTCCATTGCTGGTGAGA 
153-171 
D9S167 
TCCTCCAGTTCAATCCATGC 
GTATAAGATCAAACAATCCCACTCC 260-286 
D9S152 
CCAGTTTTTTACTCTCTTCTCTCTC 
GTTATGTTAGCTTTCTAAATGGCTG 
120-136 
D9S1877 GATAGGGGCTTTGGGC 
ATGTACTTGCAGTCTTTAGAATGG 
103-125 
D9S1865 
TGCAGCAAAACCAGTAAT 
ATGTCCAGTAATTTTCAGCC 
142-159 
D9S1790 
AAAAATAAAGTTGGCCTTGAAACC 
CCATTTAGTAGGGTACAACCCAC 
176-194 
 303 
 
